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Phosphatases and microRNAs: 
Investigations in the Context of DNA Damage 
 
Abstract 
 
 Integrity of the cellular genome is constantly threatened by various 
sources of DNA damage that cause a variety of lesions including double strand 
breaks. Cells respond to such insults by upregulating the DNA damage response, 
a carefully orchestrated set of molecular events that leads to transcriptional 
changes, cell cycle arrest and/or apoptosis.  In this dissertation we provide 
evidence supporting a role for phosphatases and microRNAs (miRNAs) in the 
cellular response to DNA damage.  
 53BP1 (tumor suppressor p53 binding protein 1) is a critical mediator of 
DNA repair signaling and its activity is regulated by several post-translational 
modifications. Here we show that 53BP1 is phosphorylated during mitosis on two 
residues, T1609 and S1618, located in the ubiquitination-dependent recruitment 
motif. These residues are dephosphorylated in late mitosis/early G1 by the 
PP4C/R3! phosphatase complex, which is required for 53BP1 accumulation at 
DNA breaks. We discovered that R3! preferentially interacts with 53BP1 in 
stalled mitosis and determined that this interaction is dependent on the 
phosphorylation of R3! residue S840 by the cyclin-dependent kinase family 
member CDK5. We also found that 53BP1 is deliberately excluded from 
 iv 
chromatin during mitosis to prevent genomic instability. Ectopic reactivation of 
53BP1 in mitosis causes increased micronuclei and lagging chromosome 
formation, which can be partially reversed by inhibiting the non-homologous end-
joining pathway.   
 In a more clinical scenario, accidental radiation exposure can cause DNA 
damage that manifests itself in complex malignancies including bone marrow 
failure and cancer. In order to accurately predict radiation exposure for better 
management of radiation accidents, we identified serum microRNA (miRNA) 
signatures capable of indicating the long-term impact of total body irradiation in 
animals. Using different doses of radiation we systematically studied the impact 
of TBI on the hematopoietic system and then identified three miRNA signatures 
that effectively distinguished between animals exposed to control, sublethal, and 
lethal radiation. Furthermore, we used radioprotective and radiomitigating agents 
to show that serum miRNAs can predict not only the dose of radiation but also its 
impact on animal health. Finally, to investigate the relevance of these miRNAs in 
humans, we validated our findings in a humanized mouse model. 
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CHAPTER 1 
Introduction 
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The cellular genome is constantly exposed to exogenous and endogenous 
sources of DNA damage that cause a variety of toxic lesions. If left unrepaired, 
these lesions get incorporated in the genome during subsequent cell division 
cycles in the form of mutations or chromosomal rearrangements. Cells respond 
to DNA damage by upregulating the DNA damage response (DDR), a highly 
orchestrated series of events that lead to transcriptional changes, cell cycle 
arrest, repair of damaged DNA, and/or apoptosis (Chapman et al., 2012b; 
Goldstein and Kastan, 2015; Lee and Chowdhury, 2011; Lord and Ashworth, 
2012). A number of DNA repair pathways have evolved to counteract the various 
types of lesions that occur (Fig. 1.1). These include mismatch repair, base 
excision repair, nucleotide excision repair, intra-strand crosslink repair and single 
strand break repair pathways (Ciccia and Elledge, 2010; Iyama and Wilson, 
2013; Moldovan and D'Andrea, 2009). Double strand breaks (DSBs) are a 
particularly lethal form of DNA damage because their persistence can lead to 
genomic instability and cancer. DSBs are repaired by two major pathways, 
homologous recombination (HR) and non-homologous end joining (NHEJ) 
(Lieber et al., 2010; San Filippo et al., 2008; West, 2003). The evolution of 
several repair pathways with diverse yet specific functions in counteracting 
various types of damage underscores the importance of DNA repair in the 
survival of an organism. In this dissertation, we mainly focus on the molecular 
mechanisms involved in the repair of DSBs.  
 
DNA Damage Sensors Activate DDR 
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Figure 1.1: DNA repair pathways have evolved to counteract DNA damage 
caused by endogenous and exogenous sources. The specific pathway 
employed for repair depends on a type of lesion as well as the stage of the cell 
cycle (Lord and Ashworth, 2012). 
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The DDR is highly conserved from yeast to humans and many of the 
important players in the damage response have been identified. These players 
can be classified into damage sensors, mediators, transducers and effectors 
(FitzGerald et al., 2009). One of the earliest events involved in sensing of DNA 
damage is the activation of the phosphoinositide 3-kinase-like kinases (PIKKs). 
Three major PIKKs characterized, ATM (ataxia-telangiectasia, mutated), ATR 
(ATM and Rad3 related), and DNA-PK (DNA-dependent protein kinase), are 
activated by different types of DNA damage (Cimprich and Cortez, 2008; Shiloh 
and Ziv, 2013; Smith and Jackson, 1999). ATM and DNA-PK are activated by 
DNA damaging agents that cause DSBs such as IR or X-rays, while ATR is 
activated by RPA (replication protein A)-coated ssDNA or DSBs resulting from 
replication stress. Other sensor proteins such as PARP1 (poly-ADP ribose 
polymerase 1) and PARP2 may also be activated by SSBs and DSBs (Ciccia and 
Elledge, 2010). 
While DNA-PK has a specific role in regulating proteins involved in end 
joining pathways, ATM/ATR regulate a plethora of substrates that further 
orchestrate the downstream response to DNA damage (Bennetzen et al., 2010; 
Bensimon et al., 2010; Matsuoka et al., 2007). These include the mediator 
proteins MDC1 (mediator of DNA damage checkpoint protein 1), 53BP1, and 
BRCA1 (breast cancer 1, early onset), which upon phosphorylation by ATM/ATR 
localize to damage sites. Apart from the E3 ubiquitin ligase activity of BRCA1, 
mediator proteins have no apparent enzymatic activity, but may be thought of as 
recruitment platforms for other DDR proteins involved in repair (FitzGerald et al., 
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2009). The damage signal amplified by sensors and mediators is then 
transmitted to transducers, namely CHK1 (checkpoint kinase 1) (Liu et al., 2000; 
Zhao and Piwnica-Worms, 2001) and CHK2 (checkpoint kinase 2) (Ahn et al., 
2000; Buscemi et al., 2006) (Matsuoka et al., 2000).  
             In addition to activating factors after DNA damage that constitute the 
DDR, cells also employ various mechanisms to slow down cell cycle progression. 
These mechanisms, collectively known as the checkpoint response, provide 
extra time to allow cells to repair their DNA before cell division thereby inhibiting 
the transmission of mutations to daughter cells (Li and Zou, 2005) (Lukas et al., 
2004).  There are three major checkpoints that can be activated in response to 
DNA damage: the G1/S checkpoint (primarily mediated by p53 halting 
progression from G1 to S phase), the intra-S checkpoint (activated by stalled 
replication forks leading to inhibition of DNA replication), and the G2/M 
checkpoint (activated by negative regulation of CDK1 and suppresses entry into 
mitosis). By employing checkpoints at different stages during the cell cycle, the 
cell ensures that the genetic information passed on to daughter cells is accurate.   
 
Double Strand Break Repair Pathways  
As mentioned earlier, DSBs can be lethal if left unrepaired. Therefore, it is 
not surprising that cells have evolved two major pathways to repair double strand 
breaks, namely HR and NHEJ, although alternative NHEJ (alt-NHEJ) and single-
strand annealing (SSA) pathways may be used to repair DSBs in specific 
scenarios (Hartlerode and Scully, 2009; Lieber, 2010; San Filippo et al., 2008). 
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The choice of pathway employed to repair DNA is largely dependent on the cell 
cycle and whether the DNA ends need to be resected (Fig. 1.2).  
NHEJ is an error-prone repair pathway and is initiated by the recruitment 
of the Ku70-Ku80 heterodimer and the DNA-PK catalytic subunit (DNA-PKcs) to 
the break site (Lieber et al., 2010). DNA-PKcs mediates several phosphorylation 
reactions that protect the DNA ends from getting resected (Meek et al., 2008). 
Successful NHEJ requires that the DSB ends be protected from resection by 
factors such as CTIP (C-terminal binding protein-interacting protein), and EXO1 
(exonuclease 1). Recent data suggests that resection is prevented during NHEJ 
by ATM-dependent phosphorylation of the histone variant H2AX (known as !-
H2AX) (Helmink et al., 2011) and 53BP1 recruitment to damage sites (Bunting et 
al., 2010; Chapman et al., 2012a). Following binding to DSBs, DNA-PKcs is 
involved in autophosphorylating itself, which leads to destabilization of its 
interaction with DNA. This allows end-processing enzymes such as ARTEMIS, 
and ligases XRCC4 (X-ray repair complementing defective repair in Chinese 
hamster cells 4), LIG4 (ligase 4), and XLF (XRCC4-like factor 1) to join DNA 
ends and complete repair (Ciccia and Elledge, 2010; Lieber, 2010).   
 HR or homology directed repair (HDR) is an error-proof pathway that 
relies on the availability of a repair template and therefore is more likely to occur 
during the S and G2 phases of the cell cycle (Heyer et al., 2010; San Filippo et 
al., 2008). DSBs are recognized by the sensor proteins MRE11-Rad50-Nbs1 
(MRN complex) leading to ATM/ATR activation. These proteins orchestrate the  
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Figure 1.2: Mammalian cells respond to lethal double strand breaks using 
two major pathways: non-homologous end joining and homologous 
recombination. Schematic gives an overview of the major molecular players in 
each pathway (Chowdhury et al., 2013). 
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subsequent steps of DSB identification and repair by phosphorylating a plethora 
of DNA repair substrates such as CTIP (You and Bailis, 2010), BRCA1 (Huen et 
al., 2010), EXO1 and BLM (blooms syndrome RecQ helicase-like) (Bolderson et 
al., 2010). Single stranded DNA generated as a result of resection is coated with 
RPA and then replaced with RAD51 in the presence of BRCA2. RAD51 
nucleofilaments are involved in invasion of sister chromatid arms in search of 
homology to form D-loops. The D-loop is then resolved by anti-recombinases and 
resolvases such as RTEL1 (regulator of telomere length protein 1), MUS81 
(ultraviolet-sensitive 81), GEN1 (Gen homologue 1), and EME1 (essential meiotic 
endonuclease 1) (West et al., 2015). 
 
53BP1 
53BP1 has emerged as an important player in DNA damage signaling 
following DSBs. It was first identified in 1994 using yeast two-hybrid assays as a 
binding partner of the tumor suppressor p53 and was postulated to be involved in 
suppressing cellular transformation (Iwabuchi et al., 1994). 53BP1 is a large 
protein of 1972 amino acids and its domain structure has been well 
characterized. Among its many structural elements include an ATM-dependent 
S/T-Q motif (serine or threonine residues followed by a glutamine) at the N-
terminus, an oligomeraization domain, a GAR (glycine-arginine rich) domain, a 
tandem Tudor domain that binds to H4K20me2 (dimethylated lysine 20 of histone 
4), a UDR (ubiquitylation- dependent recruitment) motif that interacts with 
H2AK15ub (ubiquitylated H2A at lysine 15), and a BRCT (BRCA-1 C-terminal) 
!! 9 
domain (Fradet-Turcotte et al., 2013; Huyen et al., 2004; Panier and Boulton, 
2014; Zgheib et al., 2009) (Figure 1.3). The yeast counterparts of 53BP1, Rad9 
in Saccharomyces cerevisiae and Crb2 (Rhp9) in Schizosaccharomyces pombe, 
lack sequence homology with mammalian 53BP1, yet both mammalian and yeast 
53BP1 are capable of activating checkpoint kinases following DNA damage by 
stimulation of ATM activity (Harrison and Haber, 2006).  This occurs through 
interaction of the 53BP1 BRCT domain with the RAD50 component of the MRN 
complex, one of the first sensors of DNA damage (Lee et al., 2010b).  
In addition to being involved in stimulating ATM activity, mammalian 
53BP1 plays a much broader role in coordinating the DSB response.  It has a 
pivotal role in the joining of DSBs during the process of class switch 
recombination (CSR) (Manis et al., 2004; Ward et al., 2004). The process of CSR 
takes place in the germinal centers of lymph nodes wherein antigen-stimulated B 
cells replace the constant regions of their surface IgM molecules with the 
constant region of a different antibody isotype. While the generation of these 
breaks depends on the activity of AID (activation-induced cytidine deaminase) 
(Muramatsu et al., 2000; Revy et al., 2000), the repair of these breaks is  
mediated by NHEJ and particularly sensitive to the presence of 53BP1. For 
example, in the absence of 53BP1, there is ~90% decrease in the efficiency of 
CSR.  
Furthermore, 53BP1 also plays a pivotal role in the regulation of NHEJ 
versus HR pathway choice and has also been implicated in the joining of 
deprotected telomeres (Dimitrova et al., 2008). When components of the 
!! 10 
 
 
 
Figure 1.3: 53BP1 domain architecture. This 1972 amino-acid protein contains 
N terminal PI3-like kinase sites, an oligomerization domain, a tandem Tudor 
domain, a UDR domain, and a BRCT domain. The minimal region required for 
53BP1 focus formation on chromatin is indicated. Figure also shows evolutionary 
conservation of residues in the Tudor-UDR region of 53BP1 necessary for its 
recruitment to chromatin following DNA damage (Lee et al., 2014). 
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protective shelterin complex around telomeres are removed, the deprotected 
telomeres are exposed as broken DSB ends. This activates the ATM/ATR 
kinases, which in turn recruit 53BP1 to repair the DSBs by NHEJ. This process 
typically results in the formation of detrimental chromosome fusions 
(Zimmermann and de Lange, 2014). 
 
53BP1 and Pathway Choice 
53BP1 along with BRCA1 has been shown to be one of the key drivers of 
DSB repair pathway choice. As mentioned earlier, the cell repairs DSBs using 
two major pathways, HR and NHEJ. Employing the appropriate pathway in a 
given cell cycle stage is critical to the fidelity of DNA repair and has a direct 
impact on genomic stability. In a normal cellular context, the choice of which 
pathway to employ is tightly controlled by allowing the majority of NHEJ to occur 
in the G1 phase while restricting HR-based repair to S and G2 phases of the cell 
cycle when a sister chromatid template becomes available (Chapman et al., 
2012b; Symington and Gautier, 2011). However, how the choice between NHEJ 
and HR is regulated at a molecular level was a mystery for a long time. Recent 
landmark studies discussed below have begun to paint a clearer picture of 
pathway choice from a molecular standpoint.  
While BRCA1 has long been acknowledged as a core factor in the HR 
machinery, 53BP1’s pro-NHEJ role has only recently been recognized 
(Bouwman et al., 2010; Bunting et al., 2010; Iwabuchi et al., 2006; Nakamura et 
al., 2006b). In these studies, the observation that loss of 53BP1 in a Brca1-null 
!! 12 
background rescues HR and allows cells to become resistant to PARP inhibitors, 
first implicated 53BP1 in pathway choice. Further evidence came from the 
discovery of two factors, namely RIF1 (RAP-1 interacting factor) and PTIP (Pax-
transactivation domain- interacting protein) that through distinct phospho-protein 
interactions, mediated 53BP1’s function in inhibiting DNA resection (Callen et al., 
2013; Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Diaz et al., 2013).  
 Following DNA damage, RIF1 interacts with 53BP1 by binding to its N-
terminal ATM-dependent S/T-Q sites. Mutating 28 of these S/T-Q residues in 
53BP1 to alanine generated the 53BP128A mutant that abolished interaction 
between 53BP1 and RIF1 in addition to abrogating recruitment of RIF1 to 
chromatin (Di Virgilio et al., 2013).  Furthermore, when it was observed that 
depletion of the Rif1 gene specifically in B cells resulted in a CSR defect similar 
to the ablation of 53BP1, it became clear that RIF1 acts as a functional effector of 
53BP1.   Another effector of 53BP1 recently discovered is PTIP. This protein has 
a known function in regulating transcription initiation by binding with H3K4me3 
methyltransferases MLL3 (mixed lineage leukemia 3) and MLL4. However, a 
separate pool of PTIP also plays a role in DDR and has been linked to both HR 
and NHEJ (Callen et al., 2013; Munoz et al., 2007). In the same experimental 
vein as RIF1, replacing endogenous 53BP1 with the 53BP128A mutant 
compromised PTIP recruitment to DSB foci. Moreover, mutating the first 8 S/T-Q 
sites in 53BP1 to generate 53BP18A inhibited PTIP localization to DSB sites but 
not RIF1, suggesting that 53BP1 interacts with RIF1 and PTIP through distinct 
phosphor-protein interactions. These findings suggest that 53BP1 tips the 
!! 13 
balance towards NHEJ in the G1 phase by specifically recruiting effector proteins 
such as RIF1 that suppress resection and inhibit HR (Fig. 1.4).   
It has been proposed that the genomic instability in Brca1-deficient cells 
results from failure to inhibit 53BP1 from suppressing resection in S phase 
(Bouwman et al., 2010; Bunting et al., 2010). Consistent with this model, 
presence of BRCA1 in S phase may then allow exclusion of pro-NHEJ factors 
such as 53BP1 and RIF1 from DSBs thereby favoring end resection.  Indeed 
recent data using super-resolution microscopy have showed that while 53BP1 
can localize to DSB foci in G1, S, and G2 phases it is excluded from the core S 
phase foci in a BRCA1-dependent manner (Chapman et al., 2012a). Such cell 
cycle phase dependent temporal control of 53BP1 localization appears to allow 
the cell to choose HR over NHEJ.  
The observation that the BRCA1 S1655A mutant failed to inhibit RIF1 
recruitment to DSB foci in S/G2 provided an important clue towards identifying an 
effector of BRCA1 (Escribano-Diaz et al., 2013; Feng et al., 2013).  This mutant 
compromises the BRCT-dependent interaction of BRCA1 with its binding 
partners, FANCJ (Fanconi anemia group J protein), CTIP, and ABRA1. However, 
only depletion of CTIP reproduced the S1655A phenotype suggesting that CTIP 
is the BRCA1 effector protein that limits RIF1 localization to S phase foci thereby 
promoting end resection. 
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Figure 1.4: Regulation of DNA repair pathway choice by antagonism 
between mediator-effector pairs 53BP1-RIF1 and BRCA1-CTIP. In G1, the 
53BP1-RIF1 complex inhibits BRCA1-mediated resection, thus promoting NHEJ. 
In S/G2, CDK-phosphorylation of CTIP causes it to interact with BRCA1. BRCA1-
bound CTIP prevents chromatin binding of 53BP1-RIF1 thereby promoting HR 
(Zimmermann and de Lange, 2014).                
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Recruitment of 53BP1 to Sites of DNA Damage 
The kinetics of accumulation of 53BP1 (and many other repair proteins) at 
DSBs after DNA damage can be visualized by microscopy. Damage response 
factors form distinct sub-nuclear foci that may be defined as collections of 
proteins actively involved in the repair process. The existence of these foci can 
be followed over the course of the cell cycle allowing one to study DNA damage 
in both time and space.  The molecular cascade leading to 53BP1 localization to 
damage foci is complex and involves the following major events: 1) sensing of 
the damage by the MRN complex, 2) ATM-phosphorylation of the H2A variant 
H2AX at Ser139 forming !-H2AX, 3) Recruitment and phosphorylation of MDC1, 
and finally 4) Recruitment of RNF8 and RNF168 that modify damaged chromatin.  
 In addition to the sequential recruitment of upstream DDR factors, distinct 
epigenetic chromatin modifications are required for 53BP1 localization to DNA 
damage foci and these findings are recently coming to light (Fig. 1.5). An early 
insight regarding the mechanism of 53BP1 focus formation came from 
experiments showing that 53BP1 binding to chromatin required an intact Tudor 
domain capable of recognizing H4K20me2 (Botuyan et al., 2006). Point 
mutations in this domain caused a drastic impairment in focal recruitment of 
53BP1. Moreover, X-ray crystal structure and nuclear magnetic resonance 
analysis showed the existence of a five residue 53BP1 binding cage, also 
conserved in yeast Crb2, that specifically accommodated a di-methyl lysine but 
excluded a tri-methyl lysine, thus explaining the affinity of 53BP1 to H4K20me or 
H4K20me2 but not H4K20me3 (Botuyan et al., 2006).  
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 It is intriguing however that H4K20me2 is widely present on chromatin 
even in the absence of DNA damage. One report suggests that over 80% of 
nucleosomes in asynchronous cells contain H4K20me2 (Pesavento et al., 2008). 
Even more intriguing is the observation that a significant fraction of the cellular 
53BP1 pool is constitutively associated with methylated H4K20 in the absence of 
DNA damage (Bekker-Jensen et al., 2005; Santos et al., 2010). How then is 
recruitment and retention of 53BP1 to chromatin regulated in the presence of 
DNA damage? The answer to this question came from a recent study, which 
elegantly showed that successful 53BP1 localization to damaged chromatin 
requires RNF168-dependent ubiquitylation of histone H2A (H2AK15ub) in 
addition to H4K20me2 (Fradet-Turcotte et al., 2013).  
 While the Tudor domains of 53BP1 mediate interaction with H4K20me2, 
association with H2AK15ub is dependent on the newly characterized UDR motif 
located adjacent to the Tudor domain (Fig. 1.3). Fradet-Turcotte and colleagues 
performed binding assays with RNF168-modified nucleosome core particles and 
Tudor-UDR fragments and found strong evidence for a direct interaction between 
the UDR motif and H2AK15ub. Interestingly, point mutations in the UDR motif 
compromised interaction of 53BP1 with H2AK15ub but did not affect binding with 
H4K20me2, suggesting that 53BP1 binds to H4K20me2 independent of the 
H2AK15ub.  Furthermore, it was shown that the UDR motif is also necessary for 
53BP1 function as point mutations in this domain significantly decreased the 
accumulation of RIF1 at damage sites and abrogated CSR from IgM to IgG1.  
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Figure 1.5: Model depicting two major chromatin modifications required for 
53BP1 localization to chromatin- H4K20me2 and H2AK15ub (Fradet-Turcotte 
et al., 2013).  
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Phosphatases 
 One of the best-studied DNA-damage induced post-translational protein 
modifications is phosphorylation. Kinase-dependent phosphorylation events 
during DNA damage have been well documented and until recently were thought 
to be the sole drivers of the DDR response. However, recent work highlights the 
importance of dephosphorylation (in addition to phosphorylation) in the initiation 
and maintenance of a robust DDR (Bennetzen et al., 2010; Bensimon et al., 
2010). A third of the captured phosphopeptides in the above studies were 
dephosphorylated after DNA damage and a fraction of these proteins showed 
dephosphorylation very early during the DDR response. These global proteomics 
studies suggest that phosphatases actively participate in the cellular response to 
DNA damage and are critical for the fidelity of the process (Lee and Chowdhury, 
2011) (Zheng et al., 2015). 
 Serine/Threonine (Ser/Thr) phosphatases can be classified based on 
sequence, structure, and biochemical properties such as dependence on metal 
ions. So far only a few phosphatases have been implicated in DDR and involve 
members of the phosphoprotein phosphatase (PPP) family (PP1, PP2A-like, and 
PP4) and the Mg2+/Mn2+-dependent phosphatase (PPM) family member, WIP1 
(wild-type p53 induced phosphatase 1, also known as PPM1D). Specific 
examples of the involvement of Ser/Thr phosphatases in DDR are found in many 
current studies. Recently, it was shown that PP2A-mediated dephosphorylation 
of the histone H2A variant (H2AX) is important for removal of phosphorylated 
H2AX from chromatin. An inability to remove !-H2AX results in an impaired DSB 
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response and hypersensitivity to DNA damage (Chowdhury et al., 2005). In 
addition, PP2A also regulates the activity of the major kinases involved in 
sensing DNA damage, namely ATM (Goodarzi et al., 2004), ATR (Li et al., 2007), 
and DNA-PK (Douglas et al., 2001).  
 
PP4 Phosphatase 
 The PP2A phosphatase is relatively well studied (Van Hoof and Goris, 
2003). However, less is known about other members of the PP2A-like 
phosphatase family, which comprise PP4 and PP6. PP4 is ubiquitously 
expressed in mammals and is responsible for a number of essential cellular 
functions ranging from organelle assembly and apoptosis signaling to recovery 
from the DNA damage checkpoint (Cohen et al., 2005; Gingras et al., 2005; 
Hastie et al., 2006). PP4C, the catalytic subunit of PP4 phosphatase, shares 
65% homology to the PP2AC catalytic subunit and it functions in complex with 
five known regulatory subunits, PP4 R1, R2, R3", and R3", R4 (Fig. 1.6) (Chen 
et al., 2008a; Mourtada-Maarabouni and Williams, 2008, 2009; Zhang et al., 
2005). Many current reports strongly suggest involvement of PP4 in regulating 
DDR proteins. Removal of !-H2AX generated during DNA replication has been 
shown to require the activity of PP4 (Chowdhury et al., 2008; Nakada et al., 
2008). This role is distinct from the role of PP2A in dephosphorylating !-H2AX 
during repair of exogenous DNA damage. Furthermore, PP4-mediated 
dephosphorylation of RPA2 is essential for the efficiency of homologous 
recombination and the regulation of the G2/M checkpoint (Lee et al., 2010a). PP4 
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is also necessary for dephosphorylation of the transcriptional repressor KAP-1 
thereby facilitating cell-cycle progress after repair of DNA damage (Lee et al., 
2012).  
 
Rewiring of DDR in Mitosis  
 As has been discussed earlier, following DNA damage the DDR 
machinery activates cell cycle checkpoints to halt the cell cycle and resolve DNA 
breaks before proceeding through the rest of the phases. This response ensures 
that the integrity of the genome is protected and deleterious mutations are not 
passed on to daughter cells. Recent advancements in our understanding of DNA 
repair suggest that while the cell cycle signaling network is a target of the DDR 
machinery, it can also act as a regulator of DDR by enforcing molecular 
constraints on which repair pathway can be used during a given phase or 
whether DNA can be repaired at all (Heijink et al., 2013). 
 Back in 1953, Zirkle and Bloom made the striking observation that cells 
traversing through mitosis were oblivious to microbeam-radiation and continued 
to complete mitosis without repairing broken chromosomes (Zirkle and Bloom, 
1953). It was subsequently noted that while cells passed uninterrupted through 
mitosis even in the presence of damaged chromosomes, the chromosomes 
stained positive for !-H2AX. This observation suggested that DNA damage was 
still detected in mitotic cells, but the subsequent activation of downstream 
signaling components was inhibited. We now know that this occurs primarily due  
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Figure 1.6: Subunits of PP4 Phosphatase. The PP4C catalytic subunit can pair 
with either of the substrate-specific regulatory subunits leading to possible 
dephosphorylation of a large number of substrates (Gingras et al., 2005).  
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to the activation of mitotic kinases such as CDK1 and PLK1 that dampen the 
DDR response in mitosis. 
In mitotic cells the MRN complex is capable of sensing damage, ATM can 
be activated, and H2AX is phosphorylated (Kato et al., 2009; Nakamura et al., 
2006a). Recruitment of MDC1, which is based on H2AX phosphorylation and 
ATM activation, is also observed in mitosis (Giunta et al., 2010). However, 
activation of the downstream factors RNF8 and RNF168 cannot occur until cells 
reach anaphase. Since 53BP1 recruitment requires the ubiquitylation of histone 
H2A surrounding DNA breaks, the absence of RNF8/RNF168 ultimately inhibits 
DNA 53BP1 from localizing to DNA breaks (Giunta et al., 2010; Giunta and 
Jackson, 2011).  
CHK1 and CHK2 are also suppressed in mitosis by the action of PLK1, 
which mediates degradation of the CHK1 cofactor Claspin during mitosis and 
interferes with ATM-dependent activation of CHK2 (Mailand et al., 2006; 
Peschiaroli et al., 2006; van Vugt et al., 2010). In addition, CHK2 activation is 
dependent on 53BP1 (Wang et al., 2002), which also does not localize to mitotic 
chromosomes (Giunta et al., 2010; Nelson et al., 2009). In this way while DNA 
breaks are marked during mitotic progression, the breaks are not actively 
repaired demonstrated by the dampening of downstream effector responses. 
 
Potential Role of Phosphatases in the Regulation of DDR in Mitosis 
It is conceivable that like kinases, protein phosphatases play a role in 
regulating cell cycle-specific activation or repression of DDR factors. Previously 
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discussed examples suggest that Ser/Thr phosphatases either reset DDR factors 
to their inactive state after completion of DNA repair or remove inhibitory 
phosphorylation from DDR factors to allow their participation in the DDR 
response.  In this dissertation, we present a striking example of phosphatase-
mediated activation of the key DDR factor 53BP1. In late G2/mitosis, mitotic 
kinases phosphorylate two conserved residues located in the UDR motif of 
53BP1, T1609 and S1618. These modifications block 53BP1 from localizing to 
DSBs. However, at the end of mitosis/ in early G1, 53BP1 is actively 
dephosphorylated at T1609 and S1618 by a PP4/R3# complex, which primes 
53BP1 to repair damaged DNA in G1. Furthermore, our data supports the claim 
that reactivation of 53BP1 to DSBs in mitosis is deleterious and leads to mitotic 
defects that can be reversed by blocking NHEJ.  
We further investigate the cell cycle specific activation of PP4/R3# 
complex in dephosphorylating 53BP1 and identify a key residue S840 in the 
regulatory subunit R3#. Increasing evidence suggests that this residue may be 
phosphorylated by the action of the cyclin-dependent kinase family member 
CDK5 in mitosis, thereby activating the 53BP1-specific activity of PP4. Ectopic 
expression of phosphomimic S840D in the absence of CDK5 partly rescued 
53BP1 recruitment to DSB foci in G1 suggesting a potential role for CDK5 in 
regulating 53BP1 activity.  
 
Acute Radiation Syndrome  
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In addition to upregulating the DDR, ionizing radiation-induced DNA 
damage can also cause a number of systemic effects when assessed at the 
organismal level. These system-level changes in physiology are defined as the 
acute radiation syndrome (ARS), which consists of hematopoietic, 
cerebrovascular, and gastrointestinal components (Dainiak et al., 2003; 
Waselenko et al., 2004). The hematopoietic system is the most vulnerable to the 
damaging effects of total body irradiation (TBI) and can be affected by exposure 
of at least 1 Gy at a relatively high dose-rate. Low to moderate radiation 
exposure causes a rapid decrease in blood cell counts primarily characterized by 
lymphopenia and loss of hematopoietic progenitors (Greenberger and Epperly, 
2009). After a moderate TBI dose of 2-6 Gy, mitotically active hematopoietic 
progenitors may be able to support hematopoietic recovery. However, this occurs 
at the cost of decreased self-renewal. At doses higher than 6 Gy, non-
recoverable bone marrow damage can result from myelosuppression, loss of 
marrow repopulating ability and senescence or complete loss of hematopoietic 
stem cells (HSC) (Mauch et al., 1995; Simonnet et al., 2009; Wang et al., 2006). 
At this stage, survival is questionable without cytokine therapies or bone marrow 
transplants (Dainiak et al., 2003; Waselenko et al., 2004). In a radiation disaster 
scenario caused by industrial accidents, terrorist attacks, or use of nuclear 
weapons, identifying the dose of radiation sustained by each exposed individual 
presents a significant challenge to medical responders. This has led to the 
development of a number of biodosimetry techniques to screen and triage 
patients exposed to different doses of radiation.  
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Current Biodosimetry Methods 
Biodosimetry is the measurement of biological response as a surrogate to 
assess the dose of radiation. A number of hematological, cytogenetic, and DNA 
damage-based biodosimetry techniques exist for dose estimation (Sullivan et al., 
2013). However, most still have notable limitations and only a few have been 
standardized for use in patient triage. For example, the lymphocyte depletion 
kinetics (LDK) assay can be used to estimate the dose of radiation by taking 
three to four lymphocyte counts to generate an LDK curve (Parker and Parker, 
2007) (Goans et al., 1997). The kinetics of depletion has been shown to correlate 
directly with the absorbed dose. One of the strengths of this assay is the ability to 
perform this analysis outside a specialized laboratory. However, since a number 
of measurements are needed to get a dose estimate, this technique may be 
impractical to use in a mass casualty scenario.  
Another technique known as the chromosome dicentrics assay (DCA) is 
currently considered the “gold standard” for estimation of radiation dose and has 
been used to assess exposure in a number of exposed and suspected 
individuals (Lloyd et al., 2000; Pinto et al., 2010; Prasanna et al., 2010). The 
assay involves taking a blood sample and incubating cells in the presence of a 
mitogen to generate metaphase spreads that can be scored for the presence of 
dicentric chromosomes. Dicentrics are formed by the fusion of two centromere-
containing chromosome fragments, which occur at very low levels in unexposed 
cells making this assay highly sensitive. However, the DCA has a relatively low 
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dose range of upto 5 Gy, tedious scoring methods, and requires a long 
processing time. 
One DNA damage-based assay is based on the scoring of !-H2AX 
subnuclear foci after radiation exposure. However, the peak of !-H2AX foci 
occurs between 30 min- 2 h after exposure and declines rapidly after 24 h 
(Andrievski and Wilkins, 2009; Riecke et al., 2010). Therefore, although this 
assay is sensitive, it may allow accurate dose determination during a small time 
window. Other DNA damage-based assays such as the cytokinesis block 
micronucleus assay (CBMN) rely on the scoring of micronuclei formed by 
chromosome mis-segregation during mitosis (Vral et al., 2011). Efforts are 
underway to automate sample processing, which will allow application at a 
population level (Willems et al., 2010).   
 
MicroRNA Biomarkers  
An analysis of existing biodosimetry techniques thus suggests that they do 
not accurately predict the severity of radiation injury to various organs and 
systems thereby complicating effective radiation countermeasures (Sullivan et 
al., 2013). Therefore, there exists a need for the development of radiation-
specific biomarkers that can predict acute and delayed damage at the organismal 
level, to facilitate precise and timely medical intervention.  MicroRNA (miRNAs) 
are short, non-coding nucleic acids that were discovered in the early 1990s and 
have since been implicated in multiple physiological and pathological states from 
organogenesis and development to immune disease and cancer (Mendell and 
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Olson, 2012; Ryan et al., 2010). These molecules repress gene expression by 
binding to the 3’ untranslated regions of mRNA molecules thereby triggering 
either translational repression or target mRNA degradation.  
 In addition to their intracellular role in gene regulation, miRNAs have also 
been detected in a cell-free form in multiple body fluids including serum and 
plasma. The physiological role of these circulating miRNAs is yet to be 
investigated but many groups have reported disease and stress-dependent 
changes in their patterns of expression (Chen et al., 2008b; Chim et al., 2008; 
Lawrie et al., 2008; Mitchell et al., 2008; Park et al., 2011). Most of these studies 
were done with the goal of providing an early diagnostic tool for cancer detection. 
However, several studies (including one from our group) have correlated 
changes in their levels in response to ionizing radiation (Acharya et al., 2015; Cui 
et al., 2011; Templin et al., 2011). The inherent stability of miRNAs under harsh 
conditions and reproducible levels in individuals of the same species make 
circulating miRNAs attractive candidates for use as biomarkers (Mitchell et al., 
2008; Schwarzenbach et al., 2014) 
 In this dissertation, in addition to studying the molecular interplay between 
DNA damage factors, we also examined a potential role for serum miRNAs as 
biomarkers for total body radiation-induced hematopoietic injury. We studied the 
effect of ionizing radiation on the bone marrow using two animal models and then 
correlated the extent of injury with changes in the expression of specific miRNAs. 
We were thus able to identify miRNA signatures that distinguished between low, 
sublethal, and high doses of radiation. Importantly, these miRNA changes could 
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predict the extent of hematopoietic injury within the first 24 hours after radiation 
exposure whereas symptoms of radiation sickness can typically take weeks or 
even months to appear.  Furthermore, we were also able to correlate changes in 
the expression of specific miRNAs to animal survival, suggesting that miRNAs 
may be used to predict the impact of radiation on animal health in addition to the 
dose.  
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ABSTRACT 
 Excluding 53BP1 from chromatin is required to attenuate the DNA damage 
response during mitosis, yet the functional relevance and regulation of this 
exclusion is unclear.  Here we show that 53BP1 is phosphorylated during mitosis 
on two residues, T1609 and S1618, located in its well-conserved ubiquitination-
dependent recruitment (UDR) motif. Ectopic recruitment of 53BP1- 
T1609A/S1618A to mitotic DNA lesions was associated with significant mitotic 
defects that could be reversed by inhibiting non-homologous end joining. We also 
reveal that protein phosphatase complex, PP4C/R3!  dephosphorylates T1609 
and S1618 to allow the recruitment of 53BP1 to chromatin in G1 phase. Our 
results identify key sites of 53BP1 phosphorylation during mitosis, identify the 
counteracting phosphatase complex that restores the potential for DDR during 
interphase, and establish the physiological importance of this regulation.  
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INTRODUCTION 
 53BP1 (p53 binding protein 1) is a multi-domain protein with a complex and 
unique role in the repair of double-strand DNA breaks (DSBs). Recruitment of 
53BP1 to DSB sites is essential for its function in the DNA damage response 
(DDR), and the minimal region (residues 1220 to 1711) required for its 
recruitment includes the oligomerization domain, a tandem Tudor domain and a 
carboxy terminal extension termed the ubiquitination dependent recruitment 
(UDR) motif (Fradet-Turcotte et al., 2013; Huyen et al., 2004; Iwabuchi et al., 
2003; Zgheib et al., 2009). At the chromatin end, dimethylated lysine 20 of 
histone H4 (Botuyan et al., 2006; Pei et al., 2011), and ubiquitinated lysine 15 of 
histone H2A (Fradet-Turcotte et al., 2013) are necessary for the recruitment of 
53BP1 to chromatin. Recent studies suggest that 53BP1 plays a critical role in 
choice of DSB repair pathway by promoting non-homologous end joining (NHEJ) 
mediated repair of a DSB and specifically countering the function of the 
homologous-recombination (HR) repair protein BRCA1 at a DSB (Bouwman et 
al., 2010; Bunting et al., 2010; Chapman et al., 2012). This is evident as loss of 
53BP1 in a BRCA1-deficient cell restores HR-mediated DSB repair. 
 Function of 53BP1 in DDR is regulated in the course of the cell cycle (Giunta 
and Jackson, 2011). 53BP1 is hyperphosphorylated during mitosis and this 
correlates with its exclusion from chromatin and DNA lesions (Giunta et al., 2010; 
Nelson et al., 2009; van Vugt et al., 2010). The phosphorylation of 53BP1 
dissipates as cells move into the G1-phase and participation of 53BP1 in DSB 
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repair is completely restored. We hypothesized that dephosphorylation of 53BP1 
is necessary for its role in DSB repair in G1 cells.  
 We and others have shown that protein phosphatase, PP4C, a PP2A-like 
phosphatase, regulates the activity of critical DNA repair factors, H2AX, RPA2 
and KAP-1 (Chowdhury et al., 2008; Lee et al., 2012; Lee et al., 2010a; Liu et al., 
2012; Nakada et al., 2008). To systematically identify proteins dephosphorylated 
by, PP4C, we recently conducted a quantitative phosphoproteomic screen based 
on the rationale that sites hyperphosphorylated in the absence of PP4C are 
putative substrates (Lee et al., 2012). We identified two phosphoresidues of 
53BP1, threonine 1609 (T1609) and serine 1618 (S1618) that were 
hyperphosphorylated in the absence of PP4C.  Here we demonstrate that the 
residues T1609 and S1618 are phosphorylated during mitosis to prevent the 
recruitment of 53BP1 to DNA lesions. These residues get dephosphorylated by a 
PP4C/R3! complex as cells transit to the G1 phase, and this dephosphorylation 
event is necessary for the participation of 53BP1 in the DDR. Furthermore, 
allowing the recruitment of 53BP1 to DNA breaks in mitosis via mutations of 
T1609 and S1618 leads to defective chromosome segregation.  
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MATERIALS AND METHODS 
Cell Culture, antibodies, and reagents 
U2OS, HeLa, and RPE1-Fucci, 53BP1-/- MEFs cells were grown in DMEM 
supplemented with 10% (v/v) FBS. 53BP1-/- MEFs were gifts from Penelope A. 
Jeggo (University of Sussex). U2OS cells stably expressing GFP-RNF168, kindly 
gifted by Daniel Durocher (University of Toronto) was grown in McCoy 5A 
supplemented with 10% (v/v) FBS. BRCA1-mutant ovarian line, UWB1.289 was 
obtained from ATCC and grown in RPMI-1640 supplemented with 50% MEGM 
(Mammary Epithelial Growth Medium) from Clonetics/Lonza and 3% (v/v) FBS. 
Antibodies used were against PP4 R1 (Bethyl), R2 (Bethyl), R3! (Bethyl), R3" 
(Bethyl), PP4C (Bethyl), Phospho-histone H3 (Cell Signaling), 53BP1 (Cell 
Signaling), pS1618-53BP1 (Cell Signaling), #-H2AX (Cell Signaling), #-H2AX 
(Mouse, Millipore), FLAG (Sigma) and Tubulin (Sigma). Rabbit polyclonal anti-
pT1609/S1618-53BP1 antibody was produced by Antagene (Sunnyvale, CA) with 
a peptide, Cys -NRLREQYGLGPYEAV(p)TPLTKAADI(p)SLDN.  SB203580 and 
SB202190 (p38 MAPK inhibitors), MK-2206 (AKT inhibitor), BI2536 (PLK1 
inhibitor) and NU7441 (DNA-PK inhibitor) were obtained from Selleckchem. 
Nocodazole, thymidine and aphidicolin were obtained from Sigma-Aldrich. 
 
siRNAs and plasmid transfection 
siRNA duplexes (Invitrogen) were transfected using RNAiMAX (Invitrogen). 
The PP4 siRNAs were described previously (Lee et al., 2010a).  
The following 53BP1 siRNA was used: 5´-AGGAGACGGUAAUAGUGGG-3’.  
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The siRNA-resistant 53BP1 expression vector has been previously described 
(Noon et al., 2010) and obtained from Penelope A. Jeggo in University of Sussex. 
53BP1 cDNA was subcloned into pOZ-N-FH or pLVX-AcGFP1-C1 vector. We 
constructed phospho-mutants of 53BP1 (T1609A/S1618A, T1609E/S1618D) by 
QuickChange II XL site-directed mutagenesis kit (Stratagene) according to the 
manufacturer’s instructions. To replace endogenous 53BP1 with WT or phospho-
mutants, HeLa and UWB1.289 cells were reverse transfected with 53BP1 siRNA 
by RNAiMAX and after 30 h, transfected with siRNA-resistant 53BP1 plasmids 
using Lipofectamine 2000 (Invitrogen).  
 
In vitro dephosphorylation assay 
The in vitro dephosphorylation assay was performed as described (Lee et 
al., 2012; Lee et al., 2010a). PP4C WT and D82A mutant proteins were purified 
using the Bac-to-Bac Baculovirus Expression System (Invitrogen) according to 
the manufacturer's manual. For the dephosphorylation assay, phosphorylated 
FH-53BP1 was prepared by immunoprecipitation of 53BP1 from nocodazole-
arrested mitotic cells with anti-FLAG antibody conjugated agarose. Phosphatase 
reactions with phosphorylated FH-53BP1 were performed in 20 mM Tris-HCl, pH 
7.4, 50 mM NaCl, 0.2 mM EDTA, 0.2% "-mercaptoethanol for 30 min at 30°C. 
Reactions were resolved on 12% (v/v) SDS-PAGE and relative phosphatase 
activity was determined by loss of phospho-FH-53BP1 immunoreactivity as 
determined by p1618 and p(1609-1618) antibody staining.  
 
Co-immunoprecipitation and immunoblotting  
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These techniques were performed as previously described in (Lee et al., 
2012; Lee et al., 2010a). Briefly, cell lysates from U2OS cells, expressing 53BP1 
WT or phosphomutants, were incubated with anti–Flag agarose (Sigma) at 4 °C 
for 16 h and immunoprecipitated proteins were resolved by SDS-PAGE and 
analyzed by immunoblot. Immunoblots were visualized using the Odyssey 
Infrared Imaging System. After primary antibody incubation, blots were incubated 
with goat anti–mouse IR Dye 800CW or goat anti–rabbit IR Dye 680 (LI-COR) 
and scanned using the LI-COR scanner. Images were visualized and quantified 
by Odyssey V3.0 software (http://biosupport.licor.com). Chromatin fractionation 
was performed as described previously (Lee et al, 2010). Quantification of 
fractions for equal loading was done using NanoDrop 1000 (Thermo Scientific).  
 
Immunofluorescence 
Immunofluorescence was performed as previously described (Lee et al., 
2010a). Briefly, U2OS, RPE1-Fucci, 53BP1-/- MEF cells were plated on glass 
slides, fixed, permeablized and incubated with primary and secondary antibodies  
prior to being mounted using DapiFuoromount-G (SouthernBiotech). Secondary 
Alexa Fluor IgG antibodies used were: 488 goat anti-rabbit, 488 goat anti-mouse, 
594 goat anti-rabbit, 594 goat anti-mouse, 647 donkey anti-goat, goat anti-rabbit 
568, and goat anti-human 660 (Invitrogen). A stack of images for each sample 
was collected with 100X objective (1.35 N.A.) using Olympus FV1000 confocal 
microscope and presented as maximum intensity projection.  
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Live-cell imaging 
MPL-induced DNA Damage and Fluorescence Image acquisition. A Mai 
Tai@ Ultrafast Ti:Sapphire Laser (Spectra-Physics, Santa Clara, CA, USA, 100 
fs pulse, 80 MHz repetition rate) was aligned into a Nikon Ti microscope (Nikon, 
Melville, NY, USA) via a custom-built open beam optical path. The laser was 
expanded to overfill the back aperture of a 60X1.4 numerical aperture objective 
(Nikon). A 675 nm low pass dichroic mirror (Chroma Technology Corp., Bellows 
Falls, VT, USA) was mounted in the microscope to reflect the laser into the 
objective. An average power level of 25 mW at 780 nm was used for all DNA 
damage experiments. The power was measured in the optical path outside of the 
microscope and is approximately three times higher than the power at the 
sample. Focus formation was monitored by accumulation of a GFP-tagged full--
length 53BP1 wild type or AA and ED mutant via epifluorescence excitation. 
Cells were incubated in a HEPES Leibovitz-15 based live cell media to permit a 
pH buffered environment for imaging on the CCD camera (The 
PhotometricsCoolSNAPHQ Monochrome camera). Each set of data collection 
began with the capture of four fluorescence images prior to DNA damage 
followed by exposure to the laser for five seconds. A time-lapse movie was 
collected for 10 min after DNA damage induction with a frame interval of 10 
seconds for the first 5 minutes and 30 seconds for the second 5 minutes. Data 
movies were analyzed in MATLAB@ (The MathWorks, Natick, MA, USA) with a 
custom algorithm to follow focus movement, quantify intensity and generate a 
plot of fluorescence accumulation over time. 
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Clonogenic assay 
HeLa (0.3X106 cells/well) cells were reverse transfected with 30 nM of 
scrambled control siRNA or 53BP1 siRNA, followed by transfection with FH-
53BP1 WT or phospho-mutants. After 2 days, 1000 cells were seeded in 6-well 
plates in quadruplicate and incubated overnight. Cell were irradiated at indicated 
doses on the following day and allowed to form colonies for 2 weeks before being 
stained by 0.1% crystal violet solution. Surviving colonies of greater than 1mm 
diameter were counted.  
 
Colorimetric assay 
BRCA1-mutant ovarian line, UWB1.289 (0.3X106 cells/well) were 
transfected with 30 nM of scrambled control siRNA or 53BP1 siRNA, followed by 
transfection with 2$g of FH-53BP1 WT or phospho-mutants. After 2 days, 2000 
cells were seeded in 96-well plates in six replicates and incubated overnight. 
PARP inhibitor [ABT888, (purchased from ChemieTek)] was added to the growth 
media at indicated concentrations. Cells were allowed to form colonies for 5 days 
before being quantified by CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega).  
 
Mitotic 53BP1 imaging  
U2OS cells expressing RFP-H2B were transfected with wildtype or mutant 
GFP-53BP1 constructs. For aphidicolin experiments, transfected cells were 
treated with 0.2µM aphidicolin for 12 hrs and released to regular medium prior to 
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imaging. For irradiation experiments, transfected cells were arrested in mitosis 
with 100 ng/ml of nocodazole (Noc) for 6 hrs and released to regular medium 
prior to imaging. Live-cell imaging was performed using a TE2000-E2 inverted 
Nikon microscope equipped with the Nikon Perfect Focus system enclosed within 
a temperature- and CO2-controlled environment. In parallel, Noc-arrested 
irradiated cells were fixed and stained for #-H2AX (1:300). For consistency, only 
cells with comparable and moderate level 53BP1 were subjected for the 
quantitation by gauging fluorescent intensity of 53BP1. Time from anaphase 
onset to the first appearance of discrete 53BP1 foci was quantified.  
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RESULTS 
53BP1 is a novel substrate of PP4C/R3! 
 A recent phosphoproteomic screen performed in the lab to identify substrates 
of PP4 phosphatase showed hyperphosphorylation of two essential 53BP1 
residues T1609 and S1618 in the absence of PP4. Interestingly, these two 
residues are located in the UDR motif, which is essential for 53BP1 recruitment 
to DSB sites (Fradet-Turcotte et al., 2013). These residues have also been 
shown to be phosphorylated during mitosis (Dephoure et al., 2008), 
(Grosstessner-Hain et al., 2011). We independently verified the phosphorylation 
of these residues by using isotopically-encoded synthetic phosphopeptide 
analogs for pT1609 and pS1618 (Fig. 2.1). These experiments were done in 
collaboration with Jarod Marto’s laboratory, Dana-Farber Cancer Institute. The 
MS/MS spectra of tryptic peptide derived from immunoprecipitated endogenous 
53BP1 (Fig. 2.1 upper spectra) and of isotope-encoded synthetic analog (Fig. 2.1 
lower spectra) illustrate the alignment of the major b-type (blue) and y-type (red) 
fragment ions containing the original peptide N- and C- termini, respectively, for 
both phosphorylated peptides. Peptide sequences above each spectra are 
annotated to show phosphorylated residues (green), isotope-encoded amino-acid 
(boxed) and sequence-specific fragments detected in each MS/MS spectrum 
(with blue and red underlines). Hyperphosphorylation of 53BP1 during mitosis is 
detected by a mobility shift during gel electrophoresis (Giunta et al., 2010; van 
Vugt et al., 2010) therefore we silenced the subunits of PP4 and evaluated the 
mobility of 53BP1 during the transition from mitosis to G1 (Gingras et al., 2005).    
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Figure 2.1: MS/MS spectra to verify 53BP1 phosphorylation.  
Isotope-encoded synthetic phosphopeptide analogs to verify sequence 
assignment and localization of the phosphorylated residues for pT1609 (top 
panel) and pS1618 (bottom panel). (Data generated in collaboration with Jarod 
Marto’s laboratory at Dana-Farber Cancer Institute.) 
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 There is one catalytic subunit (PP4C) are several regulatory subunits of PP4, 
namely R1, R2, R3", R3!, and R4. We transfected HeLa cells with siRNAs 
against the major regulatory and catalytic subunit of PP4 and synchronized cells 
in mitosis using nocodazole (a microtubule polymerization inhibitor). We then 
assessed 53BP1 mobility during the mitosis to G1 transition by harvesting cells at 
different time points after G1 release. Only silencing PP4C and R3!, led to a shift 
in 53BP1 mobility in G1 cells (Fig. 2.2A) while silencing other PP4 regulatory 
subunits (R2, R1 and R3") did not impact the mobility of 53BP1. Immunoblot 
presented in Fig. 2.2B shows the knockdown efficiency of siRNAs used against 
PP4 catalytic and regulatory subunits. Since we found that depletion of PP4C 
and R3! affected 53BP1 mobility, we asked if these subunits interacted with 
53BP1. We stably transduced U2OS cells with Flag- HA (FH) tagged 53BP1 and 
synchronized cells in mitosis for 8h using nocodazole. Consistent with previous 
results, only PP4C and R3! interact with 53BP1 and this association was 
significantly enhanced in cells synchronized in mitosis (Fig. 2.2C).   
 Next we generated a phospho-specific antibody to confirm that the residues 
T1609 and S1618 are indeed phosphorylated in mitosis and that their 
phosphorylation status is influenced by a PP4C/R3! complex. Using HeLa cells 
expressing FH-53BP1 wild-type (WT) or mutants T1609A or T1609A, we 
confirmed that the phospho-antibody recognized the combination of 
phosphorylated T1609 and phosphorylated S1618. When either of these 
residues were mutated, the antibody signal was significantly reduced. (Fig. 2.3A).  
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Figure 2.2: Impact of PP4C and R3! silencing on 53BP1 phosphorylation. 
(A) HeLa cells were transfected with siRNAs against PP4C or the indicated PP4 
regulatory subunits and synchronized in mitosis with 100 ng/ml nocodazole for 8h. 
Cells were released from mitosis and harvested at the indicated time points in G1 
phase. 53BP1 mobility shift was assessed by gel electrophoresis. Mitotic exit was 
monitored using phospho-histone H3 (pHistoneH3) antibody. Tubulin was used 
as a loading control. The 250 kDa marker is shown as a reference. (B) Cells 
harvested to assess 53BP1 mobility shift were also analyzed in parallel by 
immunoblot for knockdown of PP4C and the indicated PP4 regulatory subunits. 
(C) Interaction of 53BP1 with PP4C and R3". U2OS cells, stably expressing FH-
Empty vector (FH-c) or FH-53BP1 were harvested after 8h synchronization in 
mitosis (M) using nocodazole or left in an asynchronous state (Asyn). Whole cell 
extracts were immunoprecipitated with anti-FLAG agarose beads and analyzed 
by immunoblotting using indicated antibodies.  
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 After validating the phospho-antibody, we used it in combination with a 
commercially available phospho-S1618 antibody to study the dynamics of T1609 
and S1618 phosphorylation in mitosis and G1. In control siRNA treated cells, 
T1609 and S1618 were phosphorylated in mitosis. However, their 
phosphorylation dissipated as cells entered into G1. But when PP4C or R3! was 
silenced in these cells, a detectable increase in phospho-T1609 and phospho-
S1618 signal was observed in the G1 phase (Fig. 2.3C). To ascertain that cells 
transfected with PP4C or R3! and released into G1 were not stuck in mitosis, we 
performed propidium iodide (PI) staining (Fig. 2.3B), which showed that PP4C or 
R3! silenced cells entered G1 phase as expected.  
 To further validate these results we monitored the kinetics of 
dephosphorylation as cells transit from mitosis to G1 and observed that depletion 
of PP4C or R3! blocked the dephosphorylation of T1609 and S1618 at various 
time-points in G1 (Fig. 2.4A). While phosphorylation of T1609/S1618 gradually 
decreased by 3h in control cells, the phospho signal remained strong in cells 
depleted of PP4C or R3! upto 7h after mitotic release.  
  A recent phosphoproteomic study (Grosstessner-Hain et al., 2011) reported 
that S1618 is phosphorylated by PLK1. We were able to confirm these results 
using the pS1618 specific phospho-antibody and the PLK-1 inhibitor, BI2536 (Fig. 
2.5A). HeLa cells were treated with nocodazole for 6h and BI-2536 was added at 
0.5, 3, and 6h during the 6h nocodazole incubation. Decrease in the 
phosphorylation signal of S1618 correlated with the amount of BI2536 exposure 
suggesting that inhibition of PLK1 blocked S1618 phosphorylation. Similarly,  
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Figure 2.3: Analysis of 53BP1 phosphorylation using phospho-53BP1 
antibody.   
(A) Phospho-53BP1 antibody specificity. The phospho-antibody against 
pT1609/pS1618-53BP1 is specific for the combination of pT1609/pS1618 and 
does not recognize individual phospho-residues. HeLa cells expressing FH-
53BP1 WT or indicated phospho-mutants were synchronized in mitosis and 
harvested by mitotic shake-off. Anti-FLAG agarose beads were used to 
immunopreciptate WT 53BP1 or indicated phospho-mutants. The 
immunopreciptate was analyzed by immunoblotting using antibodies against 
53BP1, 53BP1-p1618, and 53BP1 p(1609/1618). (B) FACS plots of propidium 
iodide (PI) staining of HeLa cells transfected with the indicated siRNAs. At 60h 
after siRNA transfection, cells were incubated in nocodazole for 8h. Resulting 
mitotic cells were released into media without drug and harvested at 0 and 1h. 
Peaks for G1, S, and G2/M phases are indicated in addition to percent cells in 
each phase. By 1h after release 80-85% of cells exit mitosis and enter G1. (C) 
Impact of PP4C and R3" silencing on 53BP1 phosphorylation as measured by 
the phospho-53BP1 antibody. HeLa cells were transfected with indicated siRNAs 
against PP4 subunits for 60h and synchronized in mitosis with 100 ng/ml 
nocodazole for 8h. Cells were released by mitotic shake-off into media without 
drug and harvested after 5h (G1 phase). Whole-cell lysates were probed  
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Figure 2.3 (Continued):  
with 53BP1 phospho-1618 (p1618) and 53BP1 phospho-1609/1618 (p1609-1618) 
antibodies. Total 53BP1 and tubulin were used as loading controls. Phospho-
Ser10-histone H3 (pS10-H3) was used to indicate mitotic (M) cells. Cells were 
probed in parallel with antibodies against PP4R1, PP4R2, R3!, R3", and PP4C 
to determine knockdown efficiency and specificity. 
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while T1609 has also been reported to be phosphorylated during mitosis 
(Dephoure et al., 2008), the kinase phosphorylating T1609 has not been 
identified.  Based on the prediction algorithm of the Group-based Prediction 
System (GPS 2.1.2) (Xue et al., 2008), we predicted that several isoforms of the 
p38 mitogen-activated protein kinase (MAPK) potentially phosphorylate T1609 
(Fig. 2.5B). We have previously shown that p38 MAPK is active during mitosis 
and has been implicated in mitotic checkpoints (Lee et al., 2010b).  Similar to the 
PLK1 inhibitor strategy used to confirm S1618 phosphorylation, we used two 
different inhibitors of p38 MAPK, SB203580 and SB202190, to demonstrate that 
phosphorylation of T1609 is likely to be mediated by p38 MAPK (Fig. 2.5C). The 
phosphorylation of S1618 is not affected by the inhibitors of p38 MAPK as 
evident from stable pS1618 signal in the presence of these inhibitors. Since the 
in-house phospho- antibody detected phosphorylation at both T1609 and S1618 
and the commercial antibody only detected S1618 phosphorylation, loss of signal 
with the in-house but not the commercial antibody was indicative of T1609 
phosphorylation. However sequence based predictions have limited accuracy, 
and chemical inhibitors may have ‘off-target’ effects, therefore we cannot formally 
rule out that other kinases, such as CDK1 or NEK2, are also involved in the 
phosphorylation of T1609.   
 We reasoned that the elevated levels of phospho-T1609 and phospho-S1618 
in PP4C/R3! silenced G1 cells could be due to ectopic activation of PLK1 and 
p38 MAPK. In this scenario continued PLK1 and p38 MAPK activity would be 
necessary for maintaining the pT1609/pS1618 signal in the G1 phase of PP4-
  57 
deficient cells. To evaluate this possibility, we inhibited PLK1 and the p38 MAPK 
immediately after mitotic exit. In control siRNA treated cells, addition of the 
inhibitors for PLK1 and p38 MAPK led to a complete loss of pT1609/pS1618 
signal within 3 hours of G1 release (Fig. 2.4B). However, depletion of PP4C or 
R3!, caused persistence of phospho-T1609 and phospho-S1618 in G1 cells 
even in the presence of inhibitors for PLK1 and the p38 MAPK (Fig. 2.4B) for up 
to 7 hours. This result suggested that elevated level of phospho-T1609 and 
phospho-S1618 in PP4C/R3! depleted cells was due to the lack of 
dephosphorylation, and not ectopic reactivation of kinases that would lead to 
phosphorylation of these residues. 
Finally, we wanted to determine whether phospho-T1609 and phospho-S1618 
are directly targeted by PP4C. To this end, we immunopurified endogenous 
phospho-53BP1 from mitotic cells and performed dephosphorylation assays. We 
found that PP4C dephosphorylated both phospho-T1609 and phospho-S1618 in 
a dose-dependent manner (Fig. 2.4C). To confirm that the phosphorylation was 
indeed due to the catalytic activity of PP4C, we used a catalytically inactive 
PP4C mutant D82A, which failed to dephosphorylate 53BP1 even at high 
concentrations. Incubation of mitotic extracts with l-protein phosphatase (PP) 
served as a positive control. Together these results strongly suggested to us that 
PP4C directly dephosphorylates phosphoresidues, T1609 and S1618 of 53BP1. 
 
Dephosphorylation of 53BP1 is necessary for recruitment to DSBs  
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Figure 2.4: Kinetics of 53BP1 phosphorylation in mitosis/ G1. 
(A) Kinetics of 53BP1 hyperphosphorylation in PP4C/R3" silenced cells during 
transition from mitosis to G1 phase. Upper panel: Schematic to study kinetics of 
53BP1 hyperphosphorylation. Lower panel: HeLa cells transfected with control, 
PP4C or R3" siRNAs, synchronized in mitosis with nocodazole, released by 
mitotic shake-off, and harvested at indicated time points for western blot analysis. 
Cell lysates were probed with indicated antibodies.(B) Inhibition of kinases PLK-1 
and p38-MAPK in PP4C/R3" silenced cells does not affect hyperphosphorylation 
of 53BP1 at T1609 and S1618. Upper panel: Schematic to study PLK-1 and p38-
MAPK inhibition in PP4C/R3" silenced cells. Lower panel: HeLa cells were 
transfected with indicated siRNAs  and treated with nocodazole. Kinase inhibitors 
against PLK-1 (BI2536, 20nM) and p38-MAPK (SB202190, 10µM) were added to 
the cells 1h following release from mitosis. Cells were harvested at various time-
points after mitotic release and lysates were probed with indicated antibodies. (C) 
Recombinant PP4C incubated with mitotic extracts shows a dose-dependent 
decrease in phosphorylation at T1609 and S1618 whereas the catalytically  
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Figure 2.4 (Continued):  
inactive PP4C D82A mutant protein fails to dephosphorylate even at high 
concentrations. Extract was also incubated with l-protein phosphatase (PP) as a 
positive control.  
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Figure 2.5: 53BP1 S1618 is phosphorylated by PLK-1 and T1609 likely 
phosphorylated by p38-MAPK. 
(A) S1618 of 53BP1 is phosphorylated by PLK-1. HeLa cells were treated with 
PLK-1 inhibitor (BI-2536, 20nM) at various time points during 6h incubation with 
nocodazole. Mitotic cells were harvested and lysates were used for 
immunoblotting with antibodies against p1618-53BP1 and 53BP1. (B) T1609 is 
likely phosphorylated by p38-MAPK. Group-based Prediction System (GPS 2.1.2) 
was employed to predict kinase(s) that phosphorylate T1609 of 53BP1. (C) 
Upper panel: Experimental scheme for inhibiting p38 MAPK in mitotic cells. 
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Figure 2.5 (Continued): 
HeLa cells were synchronized in mitosis by a thymidine block followed by 
nocodazole treatment for 6 hr.  During the 6hr nocodazole treatment to arrest 
cells in mitosis, SB203580/SB202190 (0.5 µM, p38 kinase inhibitors) or MK-2206 
(0.5 µM, Akt inhibitor) were added at three different time points. MK-2206 was 
used as a negative control. Lower panel: Immunoblot of cells treated with the 
indicated kinase inhibitors during nocodazole arrest. Antibodies against 53BP1 
(p1618), 53BP1 p(1609/1618) and 53BP1 were used for immunoblotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  62 
 After DNA damage, 53BP1 and other DDR proteins form distinct sub-nuclear 
foci that consist of collections of DDR proteins (Panier and Boulton, 2014). By 
tracking both the formation and dissolution of these foci using microscopy, we 
can study the kinetics of the repair process as DDR proteins are sequentially 
recruited to break sites and then removed after successful repair of damaged 
DNA. Since 53BP1 can be detected at these foci after DNA damage, we 
hypothesized that PP4C/R3! mediated dephosphorylation of 53BP1 is necessary 
for its localization to DSB in G1 cells. To test this idea we evaluated the 
localization of 53BP1 in the G1 phase of synchronized HeLa cells at various time 
points after ionizing radiation (IR), in the presence and absence of PP4C and 
R3!. We depleted PP4C and R3! and synchronized cells in mitosis. Cells were 
released into G1, irradiated at 10 Gy, and then fixed at different time-points in G1. 
When 53BP1 localization was studied using immunofluorescence (IF), we 
observed a striking reduction of 53BP1 foci in PP4C and R3! silenced cells (Fig. 
2.6A). To further confirm the cell cycle phase specificity of this phenotype we 
utilized the Fucci system (Sakaue-Sawano et al., 2008) to visualize the G1 phase 
in RPE-1 cells. Cells engineered with the Fucci system allow dual-color imaging 
to distinguish cells in the G1 phase from those in S/G2/M phases. Cells in G1 
phase emit red florescence owing to the expression of mKO2-hCDT1 and those 
in S/G2/M emit green florescence owing to mAG-hGem. As anticipated, absence 
of PP4C and R3! causes a significant reduction in 53BP1 foci in G1 cells (Fig. 
2.6B). DSBs were marked by staining for #$H2AX.  
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 To evaluate the precise impact of dephosphorylating 53BP1, the two 
residues T1609 and S1618 that are hyperphosphorylated in the absence of 
PP4C were altered to phosphonull (T1609A and S1618A) and phosphomimetic 
mutants (T1609E and S1618D). These mutations were introduced individually 
and in combination (53BP1-AA and 53BP1-ED) in FH- tagged full-length 53BP1. 
Using the FLAG antibody the recruitment of these mutants to DSB sites was 
monitored in HeLa cells. None of the individual mutants have a significant impact 
on localization of 53BP1 to DSB sites (Fig. 2.7). Quantitation of more than 100 
cells per condition showed that the percentage of 53BP1 foci positive cells in G1 
were comparable for all single mutants. The 53BP1-AA double mutant was also 
recruited to DNA repair foci at similar levels compared to wild-type. However, we 
observed almost a complete block in the localization of the 53BP1-ED mutant to 
DSBs (Fig 2.7).  
 To assess the recruitment pattern of 53BP1-WT, 53BP1-AA or 53BP1-ED to 
DSBs, we released cells transfected with FH-tagged proteins from nocodazole 
block, irradiated them following G1 entry, and followed 53BP1 foci formation at 
different time points. 53BP1 foci measured by the FLAG antibody were 
detectable as early as 0.5h after radiation. The kinetics of 53BP1 foci formation 
was similar for both 53BP1-WT and 53BP1-AA mutant. However, when 
recruitment of 53BP1-ED was monitored, we saw complete absence of 53BP1 
foci even at 10h after radiation (Fig. 2.8A).  
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Figure 2.6: PP4C/R3! depletion abrogates 53BP1 foci in G1 cells. 
(A, B) Schematic shows protocol for assessing 53BP1 activity in G1 cells 
irradiated immediately after mitotic shake-off. PP4C or R3" was depleted by 
siRNA transfection of HeLa cells (A) or Fucci-RPE1 cells (B). Mitotic cells were 
collected after 8h nocodazole treatment, irradiated immediately after release (10 
Gy), fixed and co-stained with antibodies for 53BP1 (A, B) and #-H2AX (A) at 
indicated times in G1 phase. CDT1/RFP is an internal Fucci cell marker that 
illuminates cells in G1 phase. Quantitation shows percent 53BP1 positive cells in 
G1. Cells displaying % 10 foci were counted as positive. The data are expressed 
as mean ± S.D; n = 3. More than 100 cells were quantified per condition. 
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Figure 2.7:  Individually mutating T1609 and S1618 has no impact on 53BP1 
foci formation. 
Upper panel:  HeLa cells expressing FH-53BP1 WT or the indicated single or 
double phospho-mutants were treated with nocodazole, exposed to IR (10 Gy) 
and processed for immunofluorescence. Lower panel: Quantitation of 53BP1 foci 
positive cells (>100 cells were quantified per condition.) #-H2AX staining was 
used to visualize DSBs. Cells with >10 foci were counted as positive. 
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 So far, we have described that the phosphorylation of 53BP1 at T1609 and 
S1618 correlates with the loss of 53BP1 foci. This can be a result of defective 
recruitment of 53BP1 to DSB sites or impaired retention of 53BP1 at DSB sites. 
To address this issue and rigorously quantify the kinetics of 53BP1 recruitment to 
DSBs we utilized a multi-photon laser (MPL) system that induces DSBs in 
defined subfemtoliter volumes of the nucleus (Botvinick and Shah, 2007; 
Hartlerode et al., 2012). These experiments were done in collaboration with 
Jagesh Shah’s lab at Harvard Medical School. To assess the kinetics of 
recruitment by the MPL-based live cell imaging, we fused GFP to full-length 
53BP1 and stably expressed WT and mutant constructs in U2OS cells. As before, 
cells synchronized in the G1-phase were utilized for these assays. Consistent 
with previous data, 53BP1 WT and 53BP1-AA were recruited with in a few 
minutes to laser induced DSBs. However, there was virtually no recruitment of 
the 53BP1-ED mutant (Fig.2.8B). This result indicates that constitutive 
phosphorylation of 53BP1 at T1609 and S1618 blocks its recruitment to DNA 
lesions. These experiments suggested that diminished 53BP1 recruitment to 
DSBs in case of the 53BP1-ED mutant was due to a fundamental defect in 
53BP1 accumulation and not due to impaired retention at damage-induced foci. 
Since these experiments were conducted in cells expressing endogenous 53BP1 
we further confirmed our results by expressing the FH-53BP1 WT, and the 
53BP1 phosphomutants (AA and ED) in 53BP1-deficient mouse embryonic 
fibroblasts (Fig. 2.9A).  
  67 
 It is also likely that the impaired recruitment of 53BP1 to DSBs is due to a 
defect in the localization of upstream DDR factors. To negate this possibility, we 
studied the localization of RNF-168, which ubiquitylates histone H2A around 
DSBs at K15 prior to accumulation of 53BP1 (also refer to Chapter 1). We 
observed that absence of PP4C and R3! had no impact on the localization of 
RNF-168, indicating that depletion of phosphatase subunits specifically affected 
53BP1 localization (Fig. 2.9B).   
 We have shown that depletion of PP4C/R3" has an impact on 53BP1 foci 
formation in G1 cells that was comparable to the phenotype induced by the 
expression of phosphomimetic 53BP1-ED mutant (Fig. 2.6A and Fig. 2.8A). 
Taking these findings into consideration, we reasoned that if indeed the impact of 
R3" on 53BP1 recruitment was due to the dephosphorylation of S1618 and 
T1609, then the effect of silencing R3" would be reversed by expressing the 
53BP1 phosphonull (53BP1-AA) mutant. Consistent with this notion, localization 
of 53BP1 to DSB sites in R3"-silenced cells was restored by the 53BP1-AA 
mutant, but not in 53BP1-WT or the 53BP1-ED expressing cells (Fig. 2.10). This 
result strongly suggested that PP4C/R3!-mediated dephosphorylation of 53BP1 
at T1609 and S1618 is necessary for its localization to DSBs in G1 cells.  
 
Functional relevance of dephosphorylating 53BP1 at T1609 and S1618 
 Distinct nuclear bodies visible in G1 cells represent endogenous DNA 
damage that occurs during DNA replication and are carried through mitosis  
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Figure 2.8: Analysis of 53BP1 phospho-mutant recruitment to DNA lesions.  
(A) Phosphomimetic 53BP1 mutant is not recruited to DSBs. Upper panel: 
Schematic to study 53BP1 focal recruitment. Lower left panel: HeLa cells stably 
expressing full-length FH-53BP1 (WT, AA, or ED) were prepared for 
immunofluorescence after mitotic shake-off and 10Gy IR. 53BP1 foci were 
visualized using anti-FLAG antibody. #-H2AX was stained to mark sites of DNA 
damage. Lower right panel: Quantitation shows percent 53BP1 positive cells in 
G1 for WT and phospho-mutants. Cells displaying % 10 foci were counted as 
positive. The data is expressed as mean ± S.D; n = 3; > 100 cells quantified per 
mutant. Lower right panel inset: Immunoblot showing equal expression levels of 
different FH-53BP1 constructs (WT, AA, and ED). Irradiated cells released into 
G1 were analyzed in parallel for expression using anti-FLAG antibody. Tubulin 
was used as a loading control.(B) Kinetics of 53BP1 recruitment to DNA lesions. 
To quantify the kinetics of 53BP1 recruitment to DSBs, a multi-photon laser (MPL) 
system was used. U2OS cells stably expressing full-length GFP-53BP1 (WT, AA, 
or ED) were treated with nocodazole for 6h and released into G1. Left panels: 
Representative freeze-frame images from live-cell movies for each sample. A 
total of 10 cells were monitored per condition for 53BP1 recruitment to DSBs.             
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Figure 2.8 (Continued): 
Right panel: Quantitation of 53BP1 recruitment was done by comparison of 
average signal intensity at 8 min in individual cells represented by a single dot; 
mean ± S.D; n = 3. (Experiments performed in collaboration with Jagesh Shah’s 
laboratory, Harvard Medical School.) 
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Figure 2.9: 53BP1 foci in 53BP1 -/- MEFs and RNF168 recruitment in the 
absence of PP4C and R3!. 
(A) 53BP1-WT and AA but not 53BP1-ED forms foci in 53BP1-/- MEFs. FH-
53BP1 WT and the indicated phospho-mutants were expressed in 53BP1-
deficient mouse embryonic fibroblasts (MEFs) and exposed to 10 Gy IR. FH-c 
(Empty vector) was transfected as a control. Cells were fixed and stained with 
anti-FLAG antibody. #-H2AX was used to visualize DSBs. (B) RNF168 foci 
formation is not affected by silencing PP4C and R3". Left panel: U2OS cells 
expressing GFP-RNF168 were transfected with siRNAs against PP4C or  
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Figure 2.9 (Continued): 
R3". Cells were synchronized in mitosis, exposed to 10 Gy IR immediately  
following release, and fixed for immunofluorescence. Representative images are 
shown. Right panel: Quantitation of RNF168 foci positive cells (>100 cells were 
quantified per condition.) Data are expressed as mean ±S.D. #-H2AX staining 
was used to visualize DSBs. 
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(Harrigan et al., 2011; Lukas et al., 2011). Low doses of aphidicolin increases the 
frequency of nuclear bodies in cells without triggering the cellular 
checkpoints.53BP1 is recruited to nuclear bodies in G1 cells and plays a role in 
the resolution of these DNA lesions (Lukas et al., 2011).  We transfected U2OS 
cells with GFP-tagged wild-type 53BP1 and the 53BP1 phospho-mutants (AA 
and ED), treated the cells with aphidicolin and stained them with cyclin A to 
distinguish G2/M cells (Fig. 2.11). Consistent with their exclusion from DNA 
lesions, 53BP1-ED phosphomimetic mutants are not recruited to nuclear bodies 
whereas the 53BP1-AA phosphonull mutants are localized at nuclear bodies at 
levels comparable to wild-type 53BP1. Together these results suggest that 
recruitment of 53BP1 to endogenous and exogenous DNA lesions is 
compromised by constitutive phosphorylation of the T1609 and the S1618 
residue. 
 Based on these results we hypothesized that 53BP1 constitutively 
phosphorylated at T1609 and S1618 is functionally equivalent to the loss of 
53BP1. 53BP1-deficient cells have increased radiosensitivity and loss of 53BP1 
in BRCA1-deficent tumors induces resistance to PARP inhibitors. Therefore we 
assessed the radiosensitivity of HeLa cells where endogenous 53BP1 was 
replaced with the phosphomutants (AA and ED).  Cells expressing the 53BP1-ED 
mutant are significantly more radiosensitive than cells expressing the wild-type 
53BP1 and the 53BP1-AA mutant (Fig. 2.12A).  Similarly, the BRCA1-mutant 
ovarian line UWB1.289 was manipulated to replace endogenous 53BP1 with the 
phosphomutants, (AA and ED) and used to assess sensitivity to clinical grade  
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Figure 2.10: The failure of 53BP1 to form foci in R3! silenced cells is 
rescued by expressing the 53BP1 AA mutant. Left panel: HeLa cells 
expressing FH-53BP1 WT or indicated phosphor-mutants were transfected with 
control siRNA or siRNA against R3" and prepared for immunofluorescence. Anti-
FLAG antibody was used to visualize 53BP1. #-H2AX was stained to mark sites 
of DNA damage. Right panel: Quantitation shows percent 53BP1 positive cells in 
G1 for WT and phospho-mutants. Cells displaying % 10 foci were counted as 
positive. The data is expressed as mean ± S.D; n = 3; > 100 cells quantified per 
mutant. 
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Figure 2.11: Constitutive phosphorylation of 53BP1 at T1609 and S1618 
alters 53BP1 recruitment to nuclear bodies. Recruitment of 53BP1 to 
replication stress induced nuclear bodies in G1. U2OS cells, stably expressing 
full-length GFP-53BP1 (WT, AA or ED) were exposed to low dose of aphidicolin 
(0.2 µM) for 12 h and stained with anti-Cyclin A, which illuminates S/G2 cells. 
Representative images and quantitation of 53BP1 accumulation in nuclear 
bodies are shown; >100 Cyclin A negative cells were quantified; mean ± S.D; n = 
3. 
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PARP inhibitor, ABT-888. As anticipated the expression of the 53BP1-ED mutant 
confers resistance to ABT-888 whereas cells expressing the wildtype 53BP1 or 
the 53BP1-AA mutant remain sensitive to ABT-888 (Fig. 2.12B). Together these 
results highlight the importance of T1609 and S1618 in regulating 53BP1 activity 
and suggest that the phosphorylation status of the UDR motif in 53BP1 may have 
relevance in cancer. Therefore, to identify any mutations and deletions in the 
UDR motif we scanned The Cancer Genome Atlas (TCGA) 2012 (Cancer 
Genome Atlas, 2012). Sequencing of 482 invasive breast carcinomas revealed 
three sporadic missense mutations in 53BP1, and one of the mutations was the 
conversion of the isoleucine (Ile) residue at 1617 (I1617) to serine (I1617S) (Fig. 
2.13A). The I1617S mutation has a significant impact on recruitment of 53BP1 to 
DSBs (Fig. 2.13B) and cells expressing the I1617S-53BP1 mutant have 
increased sensitivity to IR (Fig. 2.14A).  Furthermore, the BRCA1-mutant ovarian 
line UWB1.289 expressing the I1617S-53BP1 mutant is relatively resistant to 
ABT-888 (Fig. 2.14B).  
 
Ectopic recruitment of 53BP1 to chromatin in mitosis causes mitotic 
defects 
 Dephosphorylation of T1609 and S1618 in G1 is necessary for the 
recruitment of 53BP1 to chromatin and specifically to DSBs. A key question is 
whether the loss of phosphorylation at these two residues is sufficient to allow 
the recruitment of 53BP1 to DNA lesions in mitosis. 53BP1 and upstream factors  
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Figure 2.12: Radiosensitivity and PARP inhibitor sensitivity of 53BP1 
phospho-mutants. 
(A) Radiosensitivity of 53BP1 phosphomutants. Endogenous 53BP1 was 
silenced in HeLa cells with siRNA and replaced with siRNA-resistant 53BP1 
constructs (WT, AA, or ED). At 72 h after siRNA transfection, cells were 
irradiated at the indicated doses and viability was evaluated by clonogenic 
survival. Immunoblots performed to confirm siRNA efficiency and expression of 
siRNA-resistant constructs are shown. Data are expressed as mean ± S.D. n =3.    
(B) Phosphomimetic 53BP1 mutant rescues PARP inhibitor sensitivity in BRCA1-
deficient cells. Endogenous 53BP1 was replaced with siRNA-resistant 53BP1  
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Figure 2.12 (Continued): 
constructs (WT, AA, or ED) in the BRCA1-deficient ovarian cancer line 
UWB1.289, and sensitivity to clinical-grade PARP inhibitor ABT888 was 
assessed by CellTiter-Glo colorimetric viability assay. Immunoblots performed to 
confirm siRNA efficiency and expression of siRNA-resistant constructs are shown. 
Data are expressed as mean ± S.D. n =3.  
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Figure 2.13: Characterization of breast cancer mutation 53BP1 I1617S. 
(A) Oncoprint from cBioPortal (http://www.cbioportal.org/public-portal) showing  
occurrence of the missense mutation I1617S. (B) Left panels: Impaired 
recruitment of 53BP1 I1617S mutant to DSB repair foci. FH- WT or 53BP1 
I1617S mutant was introduced into HeLa cells and 53BP1 foci were visualized 
using anti-Flag antibody in G1. Representative images of 53BP1 foci and #-H2AX 
staining are shown. Right panel: Quantitation of percent 53BP1 foci in G1 phase 
in cells expressing 53BP1 WT or I1617S.  
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Figure 2.14: Radiosensitivity and PARP inhibitor sensitivity of 53BP1-
I1617S. 
(A) Radiosensitivity of 53BP1-I1617S. Endogenous 53BP1 was silenced in HeLa 
cells with siRNA and replaced with siRNA-resistant 53BP1 constructs (WT or 
I1617S). At 72 h after siRNA transfection, cells were irradiated at the indicated 
doses and viability was evaluated by clonogenic survival. Immunoblots 
performed to confirm siRNA efficiency and expression of siRNA-resistant 
constructs are shown. Data are expressed as mean ± S.D. n =3.  (B) Replacing 
endogenous 53BP1 with I1617S causes resistance to PARP inhibition in ovarian  
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Figure 2.14 (Continued): 
cancer line UWB1.289.Endogenous 53BP1 was replaced with siRNA-resistant 
53BP1 constructs (WT or I1617S) in the BRCA1-deficient ovarian cancer line 
UWB1.289, and sensitivity to clinical-grade PARP inhibitor ABT888 was 
assessed by CellTiter-Glo colorimetric viability assay. Immunoblots performed to 
confirm siRNA efficiency and expression of siRNA-resistant constructs are shown. 
Data are expressed as mean ± S.D. n =3. 
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(RNF8 and RNF168) are excluded from DSBs during early and mid-mitosis.  In 
late-mitosis (anaphase/telophase) RNF8 and RNF168 are recruited to DSBs 
while 53BP1 continues to be excluded (Giunta et al., 2010; Giunta and Jackson, 
2011). A possible interpretation of this result is that RNF168-mediated 
ubiquitylation of H2A at DNA lesions in late mitosis is not sufficient to recruit 
53BP1. We hypothesized that the phosphorylation of 53BP1 at T1609 and S1618 
prevents its recruitment to DNA lesions in late mitosis. To test our hypothesis we 
utilized U2OS cells expressing RFP-H2B (to visualize chromatin) and GFP-
tagged 53BP1 WT or 53BP1 phospho-mutants (AA and ED). These experiments 
were done in collaboration with David Pellman’s laboratory at Dana-Farber 
Cancer Institute.  Cells were treated with low doses of aphidicolin to induce 
replication-induced DNA lesions and time-lapse imaging was conducted to 
monitor the sub-cellular localization of 53BP1 during mitosis. Consistent with 
previous studies wildtype 53BP1 is not recruited to chromatin during mitosis, and 
the 53BP1 foci become visible in G1 cells. As anticipated the 53BP1-ED mutant 
remains excluded from chromatin both in mitosis and G1 cells. However, the 
53BP1-AA mutant formed distinct foci during late mitosis, (transition of 
anaphase/telophase), (Fig. 2.15A).  Quantification of the time required for 53BP1 
to form foci after anaphase onset showed that the 53BP1-AA mutant was forming 
foci significantly faster than wildtype 53BP1 (Fig. 2.15A). Interestingly, in some 
cells the 53BP1-AA mutant is recruited to chromatin as early as 10-20 minutes 
after anaphase onset when the chromosomes remain condensed (Fig. 2.15, 20’ 
time point).  
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 To examine the functional consequences of 53BP1 recruitment to DNA 
lesions in mitosis we synchronized cells in metaphase and exposed them to low 
dose of IR (0.5 Gy) prior to release. Surprisingly cells expressing 53BP1-AA 
mutant exposed to IR had a significant increase in mitotic errors manifested as 
increases in lagging chromosomes and micronuclei (Fig. 2.15B). Micronuclei (MN) 
formed by whole chromosome mis-segregation contain kinetochores (Fenech, 
2010), therefore we evaluated the presence of kinetochores in MN generated by 
IR in cells expressing 53BP1-AA mutant. In cells expressing the wildtype 53BP1 
the proportion of kinetochore-positive and kinetochore-negative MN were 
comparable. In contrast cells expressing the 53BP1-AA mutant had a striking 
increase in kinetochore-positive MN (Fig. 2.16).  53BP1 promotes aberrant NHEJ 
at uncapped telomeres leading to genomic instability (Dimitrova et al., 2008). 
Interestingly, blocking NHEJ by incubation with the DNA-PK inhibitor ‘rescued’  
the mitotic defects induced by the 53BP1-AA mutant (Fig. 2.16). These results 
suggest that phosphorylation of 53BP1 at T1609 and S1618 during mitosis is 
necessary and sufficient to prevent its recruitment to DNA lesions in late mitosis.  
Furthermore, inappropriate recruitment of 53BP1 to mitotic DNA lesions impairs 
chromosome segregation. 
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Figure 2.15: Loss of T1609 and S1618 phosphorylation allows 53BP1 to 
localize to DNA breaks in mitosis and promotes genomic instability. 
(A) Premature recruitment of 53BP1-AA mutant to DNA lesions during mitosis. 
To examine the kinetics of 53BP1 foci formation, U2OS cells expressing RFP-
H2B were transfected with different GFP-53BP1 constructs (WT, AA, ED), 
treated with 0.2µM aphidicolin for 12 h and released prior to live cell imaging.                         
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Figure 2.15 (Continued):                                                                           
Left panels: Representative time-lapse still images of cells expressing RFP-H2B 
and GFP tagged 53BP1-WT (top panels) or 53BP1-AA (middle panels) or 
53BP1-ED (bottom panels) during G2, mitosis (early and late) and the 
following G1 phase. Time is shown in minutes (t=0, anaphase onset). Upper right 
panels: late mitotic cells (red box region) with premature 53BP1-AA foci 
formation are illustrated in overlaid images along with high magnification images 
(boxes 1 and 2). GFP-53BP1 and RFP-H2B are shown in green and red, 
respectively. Bottom right panels: Corresponding quantitation of the timing 
of 53BP1 foci formation (p <0.0001, non-parametric t-test). Averages are shown 
in red bars. (B) Premature mitotic 53BP1-AA foci formation is accompanied by 
increased mitotic defects. U2OS cells expressing RFP-H2B were transfected with 
different GFP-53BP1 constructs (WT, AA) and exposed to 0.5Gy IR during 
mitosis prior to live cell imaging. Overlaid images with GFP-53BP1 (green) and 
RFP-H2B (red, also shown at the bottom with RFP-H2B only). Cells containing 
premature mitotic 53BP1-AA foci progress through cell cycle with increased 
mitotic defects, such as lagging chromosomes (dashed boxes) and micronuclei 
(MN, boxes). (C) Corresponding mitotic defects that persist as MN in G1. Note 
that some MN contain 53BP1-AA (Box, 130 min, GFP in primary nuclei is 
overexposed to accentuate 53BP1 signal in MN).  Upper right panel: 
Corresponding quantification for the timing of 53BP1 foci formation in indicated 
conditions (p <0.0001, non-parametric t-test). Lower right panel: percentage of 
cells that display lagging chromosomes and MN in indicated conditions. Only 
newly arising defects in cells exiting mitosis were scored (p <0.0001, non-
parametric t-test). Errors bars indicate S.E.M. 
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Figure 2.16: Ectopic recruitment of 53BP1-AA causes an increase in 
CREST+ MN.            
U2OS cells expressing different GFP-53BP1 constructs (WT or AA) were treated 
with nocodazole for 6h. Resulting mitotic cells were irradiated at low-dose (0.5 
Gy) and released into normal media. At 6h following release, cells were fixed and 
co-stained with antibodies for #-H2AX and CREST (kinetochore marker) to 
visualize kinetochore-positive (CREST+) MN. Where indicated, transfected cells 
were pretreated with DNA-PK inhibitor (DNA-PKi) (NU7441, 10µM) 1h prior to 
irradiation.  Quantification of CREST– and CREST+ MN in cells expressing WT or 
AA GFP-53BP1 with or without DNA-PKi is shown. The data are expressed as 
mean ± S.D; n = 3 (> 100 cells were quantified).  
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DISCUSSION 
 Phosphorylation of 53BP1 has been comprehensively investigated 
(Jowsey et al., 2007), and recent studies demonstrate that generating 
phosphonull mutants of  a combination of  28 phosphosites (PI3-like kinase; 
S/TPQ motifs) in the N-terminus of 53BP1 disrupts interaction with critical factors 
such as Rif1 (Callen et al., 2013; Chapman et al., 2013; Di Virgilio et al., 2013; 
Escribano-Diaz et al., 2013; Zimmermann et al., 2013) and abrogates its function 
in class-switch recombination and DNA repair (Bothmer et al., 2011; Di Virgilio et 
al., 2013; Ward et al., 2006).   However there is no understanding of how 
dephosphorylation may directly regulate 53BP1 activity.  
 Large scale phosphoproteomic studies have revealed that a significant 
number of the DDR factors are constitutively phosphorylated in the course of the 
cell cycle (Dephoure et al., 2008; Grosstessner-Hain et al., 2011; Hegemann et 
al., 2011) and over one-third of observed phosphorylation sites are down-
regulated within minutes of DNA damage (Bennetzen et al., 2010; Bensimon et 
al., 2010). How the constitutive phosphorylation and potential dephosphorylation 
of the DDR proteins impact their function remains unclear. Studies on the role of 
phosphatases in the DDR, including ones from our group, have been limited to 
demonstrating their significance in later stages of the DDR, largely in relieving 
the cell cycle checkpoint and restoring the cell to its ‘pre-DNA damage’ state (Lee 
and Chowdhury, 2011; Peng and Maller, 2010). Our results on the PP4C/R3! 
complex mediated dephosphorylation of 53BP1 counter the existing paradigm 
regarding the role of phosphatases in DSB repair. Here we provide an example 
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where a phosphatase by regulating the critical step of 53BP1 recruitment to DSB 
sites, influences the process of DNA repair, and the choice of DSB repair 
pathway. 
 Mitotic cells are distinct from inter-phase cells in their ability to tolerate the 
presence of DSBs as cells progress through the mitotic phase without triggering 
a checkpoint response (Heijink et al., 2013). More recent studies have 
demonstrated that the ‘sensors’ of the DSBs such as the MRN complex and the 
Ku complex (Gomez-Godinez et al., 2010; Peterson et al., 2011) are recruited to 
DSBs in mitosis and #-H2AX is normally phosphorylated (Giunta et al., 2010; 
Nelson et al., 2009; van Vugt et al., 2010). A fundamental and important question 
is why do cells block the ‘secondary’ steps of the DSB repair process in mitosis, 
specifically the recruitment of 53BP1 to DNA lesions. Our results with the 53BP1-
AA mutant suggest that allowing 53BP1 to localize to DSBs and chromatin in late 
mitosis counter-intuitively promotes genomic instability, and leads to mitotic 
defects that are manifested in increased number of kinetochore positive 
micronuclei and lagging chromosomes.  The underlying mechanism for this 
observation remains unclear but it is feasible that stress induced telomere de-
protection in mitosis (Hayashi et al., 2012) coupled with the ability of 53BP1 to 
promote end-joining of telomeres by increasing chromatin mobility (Dimitrova et 
al., 2008) may contribute to this striking phenotype. Blocking NHEJ in the 53BP1-
AA expressing cells does resolve the mitotic defects giving some credence to this 
idea.  Another important question is whether other DDR factors have a similar 
regulatory mechanism where dephosphorylation is a pre-requisite for their 
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participation in the DDR.  The evolutionary conservation of the phosphoresidues 
(T1609 and S1618) and the flanking amino acids give some credence to the idea 
that similar ‘dephosphorylation-dependent chromatin recruitment motifs’, maybe 
present in other DNA repair proteins.  Preliminary computational predictions 
support this notion (unpublished results, SD and DC) but significant experimental 
work is necessary to confirm the functional relevance of these predictions. Future 
studies will elucidate the molecular details of how protein phosphatases regulate 
the activity of 53BP1 and DNA repair proteins in the early steps of the DDR. 
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ABSTRACT 
PP4C/R3! phosphatase complex directly interacts with and regulates the 
dephosphorylation of 53BP1, a key mediator of DNA damage signaling. Here we 
characterize the molecular nature of this interaction by identifying a C-terminal region 
in the regulatory subunit that is sufficient for association with 53BP1. This C-terminal 
fragment, termed C5, contains multiple serine/threonine residues that are unique to 
R3! and not found in its closest relative R3". Using MS/MS analysis we identify that 
the C5 residue S840 is phosphorylated during mitosis and that this modification is 
required for both 53BP1- R3! interaction and PP4C/R3!-mediated dephosphorylation 
of 53BP1 at T1609 and S1618. Furthermore, we discover a role for the cyclin 
dependent kinase CDK5 in the phosphorylation of R3! S840 and show that absence 
of CDK5 negatively affects 53BP1 accumulation at DNA breaks. The effect of CDK5 
depletion is partially reversed by ectopic expression of an S840 phospho-mimetic 
mutant, suggesting that the phosphorylation status of S840 governs the 53BP1-related 
function of R3!. Finally, we identify a cancer-relevant mutation in R3!, S840F that 
also fails to interact with 53BP1 and thus highlights the physiological relevance of this 
regulation.  
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INTRODUCTION 
As mentioned before serine/threonine phosphatases such as PP4 have one 
catalytic subunit and multiple regulatory subunits allowing for various catalytic and 
regulatory subunit combinations (Chen et al., 2008; Cohen et al., 2005). Changing the 
regulatory subunit changes the specificity of the phosphatase for a given substrate 
(Lee and Chowdhury, 2011; Zheng et al., 2015). Multiple studies have implicated PP4 
in regulation of the DDR. It has been shown to be involved in the dephosphorylation of 
!"H2AX and phosphor-RPA2, thereby mediating efficient repair of DNA and recovery 
from the G2/M checkpoint (Chowdhury et al., 2008; Lee et al., 2010; Nakada et al., 
2008). 
However, increasing evidence points to a role for phosphatases in the initiation 
and maintenance of DDR proteins in addition to facilitating their restoration to a pre-
damage state (Bennetzen et al., 2010; Bensimon et al., 2010; Lee and Chowdhury, 
2011). Previously, we presented work from our group in support of this idea by 
demonstrating that the PP4C/ R3! phosphatase complex actively dephosphorylates 
53BP1 during the transition from mitosis to G1 thereby allowing it to participate in DSB 
repair in G1 phase (Lee et al., 2014a). The regulatory subunit specific for 53BP1 is 
R3!, while the catalytic subunit that mediates the actual dephosphorylation is PP4C 
(Fig. 2.4C). Interestingly, we have observed that the expression levels of both R3! 
and PP4C do not change in the course of the cell cycle. However, R3! preferentially 
interacts with 53BP1 during mitosis with only low levels of interaction seen in 
interphase cells. Furthermore, although this interaction is detected in stalled mitosis, 
the dephosphorylation occurs only in late mitosis/early G1. Therefore a key question 
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that remains unanswered is how is the R3!-53BP1 regulated. These initial findings 
motivated us to study the R3!-53BP1 interaction in more detail. 
CDKs represent a family of serine/threonine kinases that regulate the cell 
division cycle by associating with cyclins. While most CDKs are involved in facilitating 
efficient cell cycle progression, several new studies indicate that certain CDK family 
members are involved in other processes. An important example of this paradigm is 
CDK5, which has mainly been characterized in development and function of the 
nervous system (Liebl et al., 2011; Tarricone et al., 2001). Interestingly, CDK5 is not 
activated by cyclins. Its activation is dependent on the p35 and p39 proteins that are 
primarily expressed in post-mitotic neurons(Dhavan and Tsai, 2001). Conversion of 
the p35 to p25 results in a hyperactive CDK5 that is associated with pathogenesis of 
neurodegenerative disease (Sun et al., 2008; Zheng et al., 2010).  
CDK5 has also been implicated in DDR in neuronal cells. Studies suggest a 
possible role for CDK5 in mediating the neuronal response to oxidative stress and 
DNA damaging agents such as campothecin and mitomycin C (Lee and Kim, 2007; 
Strocchi et al., 2003; Tian et al., 2009). Here, we identify CDK5 as a potential 
modulator of the R3!-53BP1 interaction and present findings supporting the 
hypothesis that CDK5 mediates a post-translational modification of R3! during mitosis 
that prepares the phosphatase to interact with 53BP1. We show that in stalled mitosis 
CDK5 mediates productive R3!-53BP1 interaction by phosphorylating R3! residue 
S840 and this correlates with the dephosphorylation of 53BP1 at T1609 and S1618 in 
G1. Furthermore, we examine the effect of depleting CDK5 on 53BP1 accumulation at 
DSBs and show that CDK5 mediates its effect on 53BP1 via regulation of R3!. 
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Specific inhibition of CDKs (including CDK5) using small molecule inhibitors has been 
a challenge (Liebl et al., 2011). We propose the use of a novel chemical genetics 
approach to specifically modulate CDK5 activity during mitosis. Finally, by studying a 
cancer-relevant melanoma mutation identified in R3!, we assess the physiological 
significance of R3! phosphorylation.  
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MATERIALS AND METHODS 
Cell Culture, antibodies, and reagents 
U2OS, HeLa, and 293T cells were grown in DMEM supplemented with 10% 
(v/v) FBS. Antibodies used were against R3! (Bethyl), PP4C (Bethyl), Phospho-
histone H3 (Cell Signaling), 53BP1 (BD), 53BP1 (Santa Cruz), #-H2AX (Mouse, 
Millipore), Myc (SantaCruz), and Tubulin (Sigma). Rabbit polyclonal anti-
pT1609/S1618-53BP1 antibody was produced by Antagene (Sunnyvale, CA) with a 
peptide, Cys -NRLREQYGLGPYEAV(p)TPLTKAADI(p)SLDN. Nocodazole 
(microtubule polymerization inhibitor) and RO-3306 (CDK1 inhibitor) were obtained 
from Sigma-Aldrich. Nocodazole was used at 100 ng/ml and RO-3306 was used at 9 
µM final concentration.  
 
siRNAs and plasmid transfection 
siRNA duplexes (Invitrogen) were transfected using RNAiMAX (Invitrogen). We 
used the following siRNAs knockdown expression.  
R3# ORF siRNA: 5’-CCAUCUAUAUUGCGUAGUA-3’;  
R3# 3’UTR siRNA: 5’-CACUUUCUUUGAAUCAUCC-3’;  
CDK5 siRNA 1: 5’-UUGCGGCUAUGACAGAAUC-3’;  
CDK5 siRNA 2: 5’-GAUGUCGAUGACCAGUUGA-3’ 
R3# and phospho-mutants were subcloned into the pcDNA3.1-HisA-6xmyc 
mammalian expression vector. R3# mutants S840A, S840D, and S840F were 
generated using QuickChange II XL site-directed mutagenesis kit (Stratagene) 
according to the manufacturer’s instructions. To replace endogenous R3# with 
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wildtype or phospho-mutants, HeLa and U2OS cells were reverse transfected with 
R3# 3’UTR siRNA by RNAiMAX and after 30 h, transfected with siRNA-resistant R3# 
plasmids using Lipofectamine 2000 (Invitrogen).  
 
Co-immunoprecipitation 
293T cells expressing R3# or phospho-mutants, were lysed in lysis buffer 
containing 50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 5 mM EDTA, 1 % (v/v) NP-40 and 
protease inhibitor cocktail (Roche). Cell lysates were incubated with 53BP1 antibody 
(Santa Cruz) at 4°C for 2h and then incubated Protein A/G Plus Agarose (Santa Cruz) 
for 12-16h. The immunoprecipitates were washed three times with lysis buffer. 
Resulting immunoprecipitated proteins were resolved by SDS-PAGE and analyzed by 
immunoblot. Quantification of fractions for equal loading was done using NanoDrop 
1000 (Thermo Scientific). 
 
Immunoblotting  
Immuoblots were visualized using the Odyssey Infrared Imaging System. After 
primary antibody incubation, blots were incubated with goat anti–mouse IR Dye 
800CW or goat anti–rabbit IR Dye 680 (LI-COR) for 1 h and scanned using the Li-
COR imaging system. Images were visualized by Odyssey V3.0 software 
(http://biosupport.licor.com).  
 
Immunofluorescence 
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U2OS cells were plated on glass slides, harvested at different time points and 
fixed for 15 min with 4% (v/v) paraformaldehyde. Fixed cells were permeabilized for 15 
min with 0.1% (v/v) Triton X-100 in PBS, washed and blocked in blocking solution (2% 
FBS in PBS) for 2 h at room temperature (RT). Next, cells were incubated with primary 
antibodies diluted in blocking solution for 2 h at RT. Following primary antibody 
incubation, cells were washed, incubated with secondary antibody diluted in PBS for 1 
h at RT, and washed before being mounted using DapiFuoromount-G 
(SouthernBiotech). Secondary Alexa Fluor IgG antibodies used were: 488 goat anti-
rabbit, 488 goat anti-mouse, 594 goat anti-rabbit, 594 goat anti-mouse (Invitrogen). 
Stacks of images for each cell were collected with a 100X objective (1.35 N.A.) using 
Olympus FV1000 confocal microscope and presented as maximum intensity 
projections.  
 
Synthesis of selective CDK5 inhibitor 20-223 
The aminopyrazole analog (CP-668863 or 20-223) was reported at the Society 
for Medicines Research Symposium as a selective CKD5 inhibitor (Eli Lilly Research 
Center, Surrey UK, June 2007). The analog was reported to have a Ki = 2.9 nM 
versus CDK5 and was 5.7-fold selective versus CDK2. We synthesized 20-223 in four 
steps from commercially available starting materials with an overall yield of 32%. The 
inhibitor was used at different concentrations to test its efficiency. (Synthesis 
performed in the laboratory of Amarnath Natarajan, University of Nebraska Medical 
Center.)  
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Generation of CRISPR knockout cells 
We cloned the following CDK5-targed guide RNA sequences in the Lenti-
Guide-Puro vector (addgene #52963): 
Guide 1: 5’-TGAAGCCTAGGGCAAAAGAAGGG -3’ 
Guide 2: 5’-GCAGGACGTCATGAAGCCTAGGG-3’ 
Guide 3: 5’-CTGTGACCAGGTGAAAGGCGGGG-3’ 
Lentiviruses expressing the above guide RNAs were generated and used to infect 
U2OS cells expressing Cas9 (maintained in 10 µg/ml blasticidin). Successfully 
infected clones were selected using puromycin (2 µg/ml).  
 
Protein expression and purification 
His-tagged CDK5 and p25 cloned into the pFastBac vector were expressed 
using the Bac-to-Bac baculovirus expression system. Cell pellets of each protein were 
combined and lysed in Tris buffer (pH 8) containing 150mM NaCl and 1% NP-40 and 
batch purified using 100$L of Ni-NTA beads. The wildtype and phospho-resistant 
mutant were expressed in BL21 DE3 E. coli cells. Cells were grown at 37ºC to an 
OD600 of ~0.5 and expression was induced with 500$M IPTG followed by overnight 
growth at room temperature. Frozen pellets were lysed in Tris buffer (pH 8.0) 
containing 500mM NaCl, 10% glycerol, and 1% NP-40 via french press and batch 
purified using 100$L Ni-NTA beads. Protein levels were normalized using coomassie 
staining prior to the kinase assay. 
 
In vitro kinase assay 
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Following purification, CDK5/p25 was washed twice with Tris buffer (pH 8.0) 
containing 10mM Imidazole and twice with 1X kinase Buffer (Tris pH 8.0, 5mM MgCl2). 
Excess buffer was removed (leaving ~150$L bead slurry) and cold ATP and imidazole 
were added to a final concentrations of ~2mM and 25mM respectively. The beads 
were then incubated for 2 hours at RT with shaking. Following incubation the bead 
suspension was diluted with 50mM tris buffer (pH 8.0) so that the final concentration of 
imidazole was <5mM and incubated at 4ºC on an end-over-end rotator for 1 hour. The 
beads were then washed with 1x kinase buffer to remove excess ATP and imidazole. 
It is critical to use the kinase immediately as to not lose activity. The cdk5/p25-loaded 
beads were added to substrate cocktail containing kinase buffer and the reaction was 
initiated with the addition of AT32P. Phosphorylation reactions were carried out for 15 
min at RT with shaking and terminated using 4X SDS buffer. Samples were boiled at 
95ºC for 4 min and separated using a 15% SDS-page gel followed by overnight 
transfer to PVDF membrane. Protein bands were visualized using ponceau staining. 
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RESULTS 
Our previous work has shown that 53BP1 interacts with the PP4 phosphatase 
complex via the R3! regulatory subunit and that this interaction is significantly 
enhanced in stalled mitosis (Lee et al., 2014a). We observed that PP4C/R3! complex 
dephosphorylates 53BP1 in late mitosis/early G1 restoring its function in DDR. 
However, since PP4C/R3! is expressed and active throughout mitosis how the 
dephosphorylation of 53BP1 by this phosphatase complex is restricted to the late 
mitosis/early G1 phase remains unclear. We hypothesized that the key to this question 
is the regulated association of R3! with 53BP1.  In order to identify the regulation of 
R3!-53BP1 interaction, we first asked whether a specific region of the R3! protein is 
required for its interaction with 53BP1. To this end, we performed deletion-based 
mutagenesis of the 849 amino-acid residues in R3! and identified residues 721-849 at 
the C-terminus of R3! (termed C5 fragment) that is sufficient for its interaction with 
53BP1 (Fig. 3.1A and B).   
Interestingly, R3" interacts weakly with 53BP1 (Fig. 3.1B) and R3! and R3" 
share 67% homology differing significantly only at their respective C-termini (Fig. 3.2). 
Thus, differences in the C-terminal sequences of R3" and R3! likely account for the 
difference in their specificity for 53BP1. We hypothesized that a post-translational 
modification at the C-terminus of R3! mediates its interaction with 53BP1. Analysis of 
annotated post-translational modifications of the human SMEK2 (R3!) protein using 
Phosphosite Plus 2014 (Hornbeck et al., 2015) revealed a number of phosphorylated 
residues (Fig. 3.3). 
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Figure 3.1: The C5 fragment of R3# is sufficient for interaction with 53BP1.  
(A) Schematic showing the two closely related regulatory subunits of PP4- R3$     
and R3#. Also shown is the C5 fragment spanning R3# residues 721-849. (B) Myc-
tagged empty vector (Empty), R3$, and various deletion mutants of R3# (1-700, 1-
480, C5) were introduced in 293T cells. After nocodazole (100 ng/ml) treatment for 
8h, cells were harvested and lysates were subjected to endogenous 53BP1 
immunoprecipiration.  
 
 
 
 
 
 
 
 
 
!
1 480 700 721 849
R3`full length
 C5 fragment
1 820
R3_full length
Input IP
 myc-tagged: C5Empty R3_ R3` 1-700 1-480 C5Empty R3_ R3` 1-700 1-480
myc
53BP1
A
B
! 106 
 
 
 
 R3$ NPKLDSMRSILRNHRYRRDARTLEDEEEMWFNTDEDDMEDGEAVVSPSDK 702 
 R3# NQKLNSVPSILRSNRFRRDAKALEEDEEMWFNEDEE--EEGKAVVAPVEK 734 !
 R3$  TKNDDDIMDPISKFMERKKLKESEEKEVLLKTNLSGRQSPSFKLSLSSGT 752 
 R3#  PKPEDDFPDNYEKFMETKKAKESEDKENLPKRTSPGGFKFTFSHSASAAN 784 ! ! ! ! ! ! ! ! !!!!!"#$! !!!! !!!!
 R3$  KTNLTSQSSTTNLPGSPGSPGSPGSPGSPGSVPKNTSQTAAITTKGGLVG 802 
 R3#  GTN--SKSVVAQIPPATSNGSSSKTTNLP---------TSVTATKGSLVG 823 ! ! ! ! ! ! ! ! !
 R3$  LVDYPDDDEDDDEDEDKEDTLPLSKKAKFDS 833 
 R3#  LVDYPDDEEEDEEEESSP-----RKRPRLGS 849 
!!!!$%&!!!
Figure 3.2: Multiple Sequence Alignment of the C-terminus of R3$ and R3#.  
Sequence in bold represents the C5 fragment. Residues highlighted in red show the 
location of two serine residues in R3# that are absent in R3$. 
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Figure 3.3:  Analysis of SMEK2 post-translational modification using 
PhosphoSitePlus 2014.  
Post-translational modifications documented in various studies have been annotated.     
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We examined whether any of the phosphorylated residues detected were 
specific to R3! by comparing C-terminal R3" and R3! sequences. This comparison 
revealed the existence of two unique serine residues in R3! - S768 and S840 (Fig. 
3.2). S840 is phosphorylated in mitosis (Beausoleil et al., 2006; Grosstessner-Hain et 
al., 2011) and we also independently verified phosphorylation of S840 using MS/MS 
analysis of the C5 peptide (Fig. 3.4A).  
In our MS/MS analysis we found that S840 was the only R3! residue 
phosphorylated when cells are arrested in mitosis. We therefore asked whether the 
phosphorylation status of S840 impacts the interaction of R3! with 53BP1.  We 
transfected myc-tagged R3! WT or phospho-null S840A in 293T cells, arrested cells 
in mitosis using the microtubule polymerization inhibitor nocodazole, and 
immunoprecipirated endogenous 53BP1 to visualize R3!-53BP1 interaction. We 
found that in stalled mitosis, mutating S840 to alanine significantly decreased the 
interaction of 53BP1 with R3! (Fig. 3.4B). Furthermore, substituting S840 with the 
phospho-mimetic S840D was sufficient to restore this interaction to wild-type levels. 
These data suggested that the interaction of 53BP1 with R3! is dependent on the 
phosphorylation of R3! S840.  
Depletion of either PP4C or R3! blocks the dephosphorylation of 53BP1 in G1 
cells exhibited by an increase in phospho-T1609 and phospho-S1618 signal (Chapter 
2, Fig. 2.4A). In order to investigate whether the phosphorylation of R3! at S840 in 
turn impacts phosphorylation status of 53BP1 at T1609 and S1618, we depleted 
endogenous R3! in HeLa cells and ectopically expressed myc-tagged, si-resistant 
R3! WT, S840A or S840D mutants. Cells synchronized in mitosis were released into 
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G1 and the kinetics of phosphorylation of 53BP1 T1609 and S1618 was evaluated 
using the p (1609/1618) antibody. Consistent with our previous results, cells treated 
with control siRNA exhibited reduction in 53BP1 phosphorylation by 3h post G1 
release and absence of R3! blocked dephosphorylation even at later time points (Fig. 
3.5). Also as expected, replacing endogenous R3! with the si-resistant wildtype 
version reversed this block in dephosphorylation. Moreover, we found that while cells 
expressing R3! S840D mutant were also able to normally dephosphorylate 53BP1, 
those expressing S840A blocked dephosphorylation similar to R3! depletion. Taken 
together, these data indicates that mutating the R3! S840 residue to S840A 
compromised the function of R3! in dephosphorylating 53BP1 at T1609 and S1618.  
R3! interacts strongly with 53BP1 in stalled mitosis, however 53BP1 
dephosphorylation happens only in late mitosis (Lee et al., 2014a). Therefore, 
investigating the molecular details of dephosphorylation will require understanding of 
the precise timing of this interaction. One limitation of using nocodazole for 
synchronization is that it arrests cells in mitosis at the pro-metaphase stage (Benada 
et al., 2015), which precludes studying molecular interactions in late G2 or early 
mitosis. To circumvent this issue, we used another chemical agent, RO-3306, which is 
a selective CDK1 inhibitor that blocks cells at the G2/M boundary (Vassilev et al., 
2006). We exposed U2OS cells expressing myc-tagged wildtype R3! to RO-3306 for 
12-16h. The resulting late G2 synchronized cells were released from RO-3306 block 
and monitored at time points in mitosis/G1. Cells collected at each time point were 
subjected to endogenous 53BP1 pull-down to study the extent of 53BP1-R3! 
interaction (Fig. 3.6A). Untreated asynchronous cells served as a control. We found 
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Figure 3.4: MS/MS analysis reveals phosphorylation of R3# S840 in mitosis. 
(A) MS/MS spectrum of tryptic peptide from R3# C5 domain. N-terminal and C-
terminal fragment ions are marked in blue and red, respectively. Sequence coverage 
confirms phosphorylation on S840, indicated as the green residue in the amino acid 
sequence. (B) Endogenous 53BP1 pull-down in 293T cells transfected with myc-
tagged R3# wildtype (WT), S840A or S840D mutants. Cells were stalled in mitosis by 
an 8h treatment with nocodazole (100 ng/ml). 
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Figure 3.5: 53BP1 dephosphorylation kinetics in cells expressing R3# mutants.  
HeLa cells were transfected with indicated siRNAs and si-resistant myc-tagged R3# 
mutants. Cells were arrested in mitosis using 8h treatment with nocodazole and 
released into G1. Indicated time points were taken to monitor 53BP1 phosphorylation 
using the p (1609/1618) antibody. The phospho-Histone H3 (phistone H3) antibody 
was used to monitor release from mitosis to G1. Myc and R3# blots present 
expression of myc-tagged R3# mutants and R3# siRNA efficiency, respectively.   
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that while asynchronous cells show minimal 53BP1-R3! interaction, cells released 
from RO-3306 block display increased association starting at ~0.5h post release. The 
peak of this interaction occurs at ~1-2h post release after which the interaction is 
gradually reduced at later time points. The cell cycle status of samples used for 53BP1 
pull-down in Fig. 3.6A was also analyzed in parallel using propidium iodide (PI) 
staining (Fig. 3.6B). This strategy does not allow us to comment on the precise timing 
of 53BP1-R3! interaction, but broadly, we observe that the interaction is enhanced 
during late mitosis. This is consistent with the dephosphorylation of 53BP1 occurring 
during the transition from mitosis to G1.     
In order to identify the kinase responsible for phosphorylating R3! S840, we 
used the MIT Scansite prediction algorithm (Obenauer et al., 2003), that predicts cell 
signaling interactions based on short sequence motifs. Using this algorithm we 
predicted two kinases, namely CDK5 and Cdc2 (CDK1), that potentially phosphorylate 
R3! S840 (Fig. 3.7A). Both proteins belong to the Ser/Thr family of cyclin-dependent 
kinases and have distinct roles during the cell cycle. At steady state, CDK1 activity is 
essential for mitotic progression and its activity is also a key target of the G2/M 
checkpoint response (Li and Zou, 2005; Lukas et al., 2004; Vassilev et al., 2006). 
CDK1 activity during mitosis leads to the phosphorylation of a number of cellular 
substrates including those involved in DDR. For example, it was recently shown that 
RNF8, an E3 ubiquitin ligase necessary for recruitment of 53BP1 to DNA breaks, is 
phosphorylated by CDK1 during mitosis preventing it from interacting with the 
upstream DDR factor MDC1(Orthwein et al., 2014). These observations make CDK1 
an attractive prediction in our analysis. However, we reasoned that modulating CDK1 
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activity to investigate its potential role in R3! phosphorylation would be detrimental to 
cells progressing through mitosis, and therefore decided to first focus on CDK5.  
CDK5 is an unusual kinase that has traditionally been studied in the context of 
neuronal development and proliferation and has been implicated in neuronal 
responses to oxidative stress and DNA damaging agents (Dhavan and Tsai, 2001; 
Lee and Kim, 2007; Liebl et al., 2011; Strocchi et al., 2003; Tian et al., 2009). 
However, so far it has not been studied in DDR in a non-neuronal context. To test 
whether CDK5 phosphorylates R3#, we performed an in vitro kinase assay using 
purified human CDK5 and His-tagged R3# wild-type or S840A mutant C5 fragment 
(Fig. 3.7B). We found that incubating the wildtype C5 fragment with recombinant 
human CDK5 produced a strong autorad signal that was indicative of 
R3# phosphorylation. This signal was completely lost when wildtype C5  in the 
reaction was replaced with the S840A mutant (Fig. 3.7B). Ponceau stained R3# and 
CDK5 were used as loading controls. Based on this result, we reasoned that if CDK5 
was indeed phosphorylating R3! at S840, then absence of CDK5 should be 
phenotypically similar to the S840A mutant (as in Fig. 3.4B). To test this idea, we 
depleted CDK5 using siRNA, introduced myc-tagged R3! WT or S840A mutant in 
293T cells and arrested cells in mitosis using nocodazole. In cells treated with control 
siRNA, wildtype R3! showed strong interaction with 53BP1 and as expected, 
expression of the S840A mutant reduced the R3!-53BP1 interaction. However, in 
cells expressing wildtype R3! that were also depleted of CDK5, we saw a striking 
decrease in R3!-53BP1 interaction (Fig. 3.7C). This decrease was similar in  
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Figure 3.6: Peak of 53BP1-R3# interaction occurs between 1-2 h after release 
from RO-3306 block.  
(A) U2OS cells expressing myc-tagged R3# wildtype (WT) were synchronized at the 
G2/M boundary and released into mitosis. Cells were harvested at different time points 
and subjected to 53BP1 immunoprecipitation to examine extent of 53BP1-R3# 
interaction. (B) Propidium iodide staining of U2OS cells used in (A). Percent cells in 
G1/S/G2M phases are denoted below cell cycle profiles for the indicated time points.  
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Figure 3.7: CDK5 mediates the interaction of 53BP1 and R3# by phosphorylating 
R3# S840.  
(A) ScanSite prediction algorithm results predicting CDK5 and Cdc2 as two potential 
R3# S840 phosphorylating kinases. (B) In vitro kinase assay involving recombinant 
human CDK5 and purified wild-type C5 fragment (WT R3#) or S840A C5 mutant 
(S840A R3#). Ponceau staining was used as a loading control. (C) 53BP1 
immunoprecipiration in 293T cells transfected with R3# wildtype (WT) or S840A 
mutant in the presence or absence of CDK5. Cells were treated with nocodazole for 
mitotic arrest. Input shows efficiency of siRNA-mediated CDK5 depletion. 
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magnitude to that obtained after expression of the S840A mutant suggesting that 
CDK5 likely contributes to the phosphorylation of R3! S840 in mitosis. 
To study R3! phosphorylation by CDK5 in greater detail, we have generated a 
phospho-antibody that recognizes R3! phosphorylated at S840. Myc pull-down 
experiments confirmed that the phospho-antibody is specific to S840 phosphorylation 
since introducing the S840A mutant significantly lowered the antibody signal (Fig. 3.8)  
 As reported here, CDK5-mediated R3! S840 phosphorylation is required for 
R3!-53BP1 interaction and R3!-mediated dephosphorylation of 53BP1 is necessary 
for its recruitment to DSBs (Lee et al., 2014b). Therefore we asked whether CDK5 
impacted 53BP1 recruitment to DSBs in G1 cells. To answer this question, we 
transiently depleted CDK5 in U2OS cells treated with RO-3306, and released them for 
2h before exposure to ionizing radiation (IR, 10 Gy). At 2h after IR, 53BP1 recruitment 
to DSBs was monitored by immunofluorescence. Indeed, we found that CDK5 
knockdown caused a significant reduction in endogenous 53BP1 foci marked by 
!"H2AX (Fig. 3.9), suggesting that CDK5 influences the recruitment of 53BP1 to DSBs 
by regulating the phosphorylation of R3!. Since the reduction in 53BP1 foci number 
after depleting CDK5 was less severe than that obtained by depleting R3!, it is likely 
that other non-CDK5 dependent mechanisms may also impinge upon the 53BP1-
specific function of R3!. 
 If CDK5 indeed regulates 53BP1 recruitment to DSBs by phosphorylating R3! 
S840, then it is conceivable that the phenotype obtained in the absence of CDK5 can 
be reversed by expression of the R3! phosphomimic mutant. Consistent with this 
notion, expression of myc-tagged R3! S840D in U2OS cells transiently depleted of 
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CDK5 restored 53BP1 recruitment to DSBs (Fig. 3.10). In this scenario, expression of 
both R3! WT and R3! S840A were unable to restore 53BP1 recruitment. 
For temporal suppression of CDK5 activity, which is not feasible via siRNA, we 
used a chemical inhibitor. Currently known inhibitors of CDKs affect multiple kinases, 
which complicates the functional analysis of a specific CDK. For example, roscovitine-
mediated inhibition is specific to CDK1, CDK2, and CDK5 (Bach et al., 2005; Bain et 
al., 2007; Liebl et al., 2011). To specifically inhibit CDK5 without inhibiting other CDKs, 
we used a newly synthesized selectiveCDK5 chemical inhibitor 20-223 (Pfizer 
compound, collaboration with Amar Natarajan’s laboratory at the University of 
Nebraska Medical Center) that was found to be 5.7 times more selective for CDK5 
than CDK2 (Fig. 3.11). 
We synchronized U2OS cells at the G2/M boundary and released them into 
mitosis/early G1 for 1.5 hours. At this stage, we inhibited CDK5 by adding inhibitor 20-
223 at different concentrations and measured 53BP1 foci formation using 
immunofluorescence (Fig. 3.12). Cells treated with siRNA against R3# served as a 
positive control. We found that compound 20-223 had a dose-dependent impact on 
53BP1 foci formation with significant inhibition occurring at 2 and 5 µM concentrations.  
Although the result with this CDK5 inhibitor is promising it does not allow us to 
rule out any side-effects on other CDKs. To specifically inhibit CDK5 in cells we will 
utilize a novel chemical genetics approach, developed by Shokat and colleagues 
(Bishop et al., 2001; Bishop et al., 2000; Shah, 2005). This chemical genetics based 
strategy elegantly combines both the temporal control afforded by using small  
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Figure 3.8: R3# S840 specific phospho-antibody detects phosphorylated S840. 
 
Validation of phospho-S840 antibody. U2OS cells were transfected with R3# wildtype 
(WT) or S840A mutant and immunoprecipitated using anti-myc agarose beads. 
Phospho-S840 and myc blots are presented.  
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Figure 3.9: Absence of CDK5 reduces 53BP1 accumulation at DSBs.  
Upper panel: U2OS cells transfected with Control (CTsi), R3# (R3#si), or CDK5 siRNA 
(CDK5si) were released from RO-3306 block for 2h and irradiated at 10 Gy or left 
unirradiated. Cells were harvested following an additional 2h incubation and 53BP1 
IR-induced foci formation was measured by immunofluorescence. #-H2AX was used 
to mark DSBs. Lower panel: Quantitation shows percentage cells with 53BP1 foci in 
G1. More than 100 cells were quantified per condition. Error bars represent SEM; n=3 
experiments.   
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Figure 3.10: Ectopic expression of R3# S840D rescues loss of 53BP1 foci in the 
absence of CDK5. 
Upper panel: U2OS cells transfected with CDK5 siRNA (CDK5si) and myc-tagged R3# 
wildtype (WT), S840A, or S840D mutant were released from RO-3306 block (9 µM) for 
2h and irradiated at 10 Gy. Irradiated and unirradiated cells Figure were harvested 
following a 2h incubation and 53BP1 IR-induced foci formation was measured by 
immunofluorescence. !"H2AX was used to mark DSBs. Lower panel: Quantitation 
shows percentage cells with greater than five 53BP1 foci in G1. More than 100 cells 
were quantified per condition. Error bars represent SEM; n=3 experiments.   
!"#$%&$'()$
*!$ $+$ $,$ $+$ $,$ $+$ $,$
-./012$345$!6+""78$!9:9319$;<=$>?$
@AB7C$'()$ @AB7.$'()$
0"DEF$
GH>CI$
.CE*$
J9=K9$
!"#$%# &'#()#$%#
*
+,
--.
#/
012
#3
4#
#
45
67
&#
8"
+0
#0!
#(
&#
'#
&'#
9'#
5'#
:'#
4'#
;'#
<'#
#=>?@)+# #A:'B?@)+#A:'C?@)+# #=>?@)+# A:'B?@)+##A:'C?@)+#
DCE4.0#
! 121 
molecule inhibitors with the specificity imparted by gene ablation, and can be used to 
generate mono-specific inhibitors of any kinase in the genome.  The residue chosen 
for creating the active-site mutation is generally a ‘gatekeeper’ residue, which typically 
governs inhibitor selectivity among kinases. The gatekeeper residue is generally 
mutated to alanine or glycine, which creates a binding pocket for the analog inhibitor. 
We used this approach to generate an F80G gatekeeper mutation in the active site of 
CDK5 thereby engineering an analog-sensitive version of CDK5 capable of 
responding to the 1-NM-PP1 inhibitor (Fig. 3.13) (Collaboration with Kavita Shah’s 
laboratory, Purdue University).  Shah and colleagues have utilized this method to 
identify novel CDK5 substrates in neurons, and importantly demonstrate that the 
analog sensitive F80G-mutant CDK5 is functionally equivalent to wildtype CDK5.  
We are using the CRISPR (clustered regularly interspaced short palindromic 
repeats)-technology to knockout endogenous CDK5, and replace with F80G-mutant 
CDK5. A schematic for depletion of CDK5 in U2OS cells using different guide RNAs 
and the corresponding knockout efficiency in pools of CRISPR cells are shown in Fig. 
3.14. Since CDK5 has been implicated in both survival and proliferation of neuronal 
and cancer cells and mice deficient in CDK5 die perinatally (Liebl et al., 2011), it is 
plausible that continued loss of CDK5 is likely to be detrimental to cell survival.  
Indeed, we observed a loss of cell viability in CRISPR knockout cell lines 
exhibiting continued depletion of CDK5. Therefore, we are reconstituting our CRISPR 
cells with F80G-mutant CDK5 that is potentially capable of functioning exactly like its 
wildtype counterpart while also being amenable to chemical inhibition by 1-NM-PP1. 
Theoretically, this should allow cells to regain wildtype CDK5 function in the absence  
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Figure 3.11: Synthesis of aminopyrazole analog 20-223, a selective CDK5 
inhibitor. 
The aminopyrazole analog (CP-668863 or 20-223) was reported at the Society for 
Medicines Research Symposium as a selective CKD5 inhibitor (Eli Lilly Research 
Center, Surrey UK, June 2007). The analog was reported to have a Ki = 2.9 nM 
versus CDK5 and was 5.7-fold selective versus CDK2. We synthesized 20-223 in four 
steps from commercially available starting materials with an overall yield of 32%. 
(Synthesis performed in the laboratory of Amarnath Natarajan, University of Nebraska 
Medical Center.)  
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Figure 3.12: Selective inhibition of CDK5 using compound 20-223 reduces 
53BP1 accumulation at DNA breaks.  
U2OS cells were synchronized at the G2/M boundary with RO-3306 (9 µM) for 16 h 
followed by release into mitosis for 1.5h. At the end of mitosis, cells were treated with 
CDK5 inhibitor 20-223 at the indicated concentrations, irradiated (10 Gy) in early G1, 
and harvested at 3 h following damage for immunofluorescence imaging. Percent 
53BP1 foci in G1 were quantified by counting nuclei for each condition (n = 50-100).  
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of the endogenous protein. Single-cell clones are being scored to assess successful 
depletion of endogenous CDK5 and detectable expression of the analog-sensitive 
kinase version. Inhibition of CDK5 F80G in the CRISPR cells using 1-NM-PP1 will 
allow us to truly delineate the role of CDK5 in mediating 53BP1-R3# interaction.    
Finally, to assess the physiological relevance of R3! phosphorylation we mined 
the cBioPortal Cancer Genomics database (Cerami et al., 2012; Gao et al., 2013) and 
found a cancer-relevant R3! S840F mutation in melanoma (Hodis et al., 2012). We 
evaluated the interaction of the R3! S840F mutant with 53BP1 by 
immunoprecipitation and found that, similar to S840A, the S840F mutant abrogated 
53BP1-R3! interaction (Fig. 3.15A). One possibility is that the R3! S840F mutant 
loses its ability to interact with the phosphatase catalytic subunit PP4C. However, 
immunoprecipitating myc-tagged versions of S840 mutants including S840A and 
S840D showed that interaction of R3! with PP4C was not affected (Fig 3.15B). It is 
therefore conceivable that loss of R3! function can contribute to the deregulation of 
DNA repair in cancer cells contributing to the cancer pathogenesis.  
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Figure 3.13:  Schematic describing strategy for orthogonal inhibition of analog-
sensitive CDK5.  
(A) Absence of inhibitor allows CDK5 to phosphorylate its targets by utilizing ATP. (B) 
Small molecule inhibitors (such as roscovitine), afford the ability to block kinase 
activity at a specific time at the cost of specificity. (C) Creating a gatekeeper mutation 
in the active site of CDK5 by mutating the F80 residue to F80G does not affect the 
normal function of CDK5.(D) However, the mutated CDK5 is rendered sensitive to 
specific inhibition by an orthogonal inhibitor such as 1-NM-PP1 allowing highly specific 
depletion of CDK5.  
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Figure 3.14: CRISPR-mediated knockout of CDK5 in U2OS cells. 
 
(A) Schematic of CRISPR-Cas9 mediated genome editing at the CDK5 locus on 
chromosome 7. Guide RNA-mediated knockdown of CDK5 can be performed with 
individual guides or in combination. A strategy to knockdown CDK5 with two guide 
RNA target sequences and adjoining PAM sequences are shown. Exon 4 (green) and 
flanking introns (red). Guide RNA 2 and 3 sequences and corresponding PAM 
sequences (blue underline). Site of Cas9 cleavage (red arrows). (B) CDK5 knockdown 
efficiency in U2OS cells transduced with the indicated guide RNA sequences.  
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Figure 3.15: Cancer relevant R3# S840F mutation abrogates R3# binding with 
53BP1. 
(A) 53BP1 immunoprecipitations were performed in U2OS cells expressing the 
indicated R3#-myc constructs. (B) Expression of the same constructs as in (A) in 
U2OS cells followed by myc immunoprecipitation using anti-myc agarose. Interaction 
of mutants with PP4C is presented.  
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DISCUSSION 
 In this chapter, we investigated the regulation of the PP4 regulatory subunit 
R3!, which has recently been shown to dephosphorylate the DNA damage mediator 
protein 53BP1 during the cell cycle. The observation that R3! preferentially interacts 
with 53BP1 in mitosis and specifically dephosphorylates 53BP1 as cells enter G1, 
motivated us to study the details of the R3!-53BP1 interaction. We report here that 
productive interaction of R3! and 53BP1 requires the phosphorylation of S840, a 
residue at the C-terminal end of R3!. Furthermore, we delineate the timing of this 
interaction and identify CDK5 as the kinase that phosphorylates R3! at S840.  
 The effector stages of the DDR response are suppressed during mitosis as 
mitotic kinases CDK1 and PLK1 phosphorylate targets that inhibit CHK1 and CHK2. 
Recent work on 53BP1 regulation during mitosis shows that 53BP1 is excluded from 
DSBs by a combination of post-translational mechanisms. First, the E3 ubiquitin 
ligases RNF8 and RNF168, whose activity is necessary for 53BP1 recruitment, are 
restricted from localizing to chromatin until late mitosis (Giunta et al., 2010; Giunta and 
Jackson, 2011; Heijink et al., 2013). Second, work from our group and others has 
shown that phosphorylation of the 53BP1 UDR at T1609 and S1618 by mitotic kinases 
inhibits binding of 53BP1 to ubiquitylated nucleosome core particles (Lee et al., 2014a; 
Orthwein et al., 2014). Here, we report yet another regulatory mechanism that limits 
53BP1 recruitment in mitosis by temporally regulating the phosphorylation of R3!. By 
allowing R3! S840 phosphorylation only during mid-to-late mitosis, the cell ensures 
that 53BP1 cannot localize to DSBs until early G1 when activation of effector 
mechanisms can re-establish DNA damage checkpoints. Indeed, ectopic reactivation 
! 129 
of 53BP1 during mitosis was shown to cause chromosomal abnormalities and 
telomere fusions in the above studies validating this hypothesis.   
 We also predicted CDK5 as an essential component of R3!- based regulation 
of 53BP1. Consistent with the catalytic activity of other CDKs, CDK5 is a proline-
directed kinase that phosphorylates residues of the type (S/T)PX(K/H/R) and this 
consensus sequence can be located in a number of identified CDK5 neuronal 
substrates (Smith et al., 2001).  An examination of the predicted CDK5 site on R3! 
confirmed that S840 is a prototypical proline-directed site (Fig. 3.2). Indeed, depletion 
of CDK5 had a negative impact on 53BP1 IR-induced foci similar to depletion of R3! 
or expression of the phosphonull S840A mutant. By rescuing this phenotype using the 
phospho-mimetic mutant we were able to show that the effect of CDK5 on 53BP1 was 
indeed mediated by R3!. Nevertheless, predictions can have a certain level of error 
and CDKs are known to have redundant functions. We therefore performed in vitro 
experiments with purified human CDK5 and purified R3! C5 fragment (wildtype or 
S840A) and found that CDK5 effectively phosphorylated S840 in the kinase reaction 
(collaboration with Kavita Shah’s laboratory, Fig. 3.7B). 
 Future work will focus on developing a clearer understanding of the timing of 
R3!-53BP1 interaction at a single cell level. While biochemical experiments have 
helped define the window (1-2h after RO-3306 release) for this interaction, they 
cannot help us define its precise timing. We therefore intend to focus on studying this 
interaction at single-cell resolution (collaboration with David Pellman’s group). 
Furthermore, our data regarding CDK5 strongly suggests that it phosphorylates R3!. 
However we cannot formally rule out the contribution of other mitotic kinases in also 
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phosphorylating R3!. Notable among these are CDK1 that was also predicted as a 
phosphorylating kinase. Monitoring 53BP1 foci formation in CDK5-deficient CRISPR 
cells complemented with analog-responsive CDK5 will answer this question. We also 
plan to apply this chemical genetics approach to study the contribution of CDK1 in this 
process. 
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ABSTRACT 
Accidental radiation exposure is a threat to human health that 
necessitates effective clinical planning and diagnosis. Minimally invasive 
biomarkers that can predict long-term radiation injury are urgently needed for 
optimal management after a radiation accident. We have identified serum 
microRNA (miRNA) signatures that indicate long-term impact of total body 
irradiation in mice when measured within 24 hours of exposure.  Impact of TBI on 
the hematopoietic system was assessed to determine a correlation of residual 
hematopoietic stem cells with increasing doses of radiation. Serum miRNA 
signatures distinguished untreated mice from animals exposed to radiation and 
correlated with the impact of radiation on HSCs. Mice exposed to sublethal (6.5 
Gy) and lethal (8 Gy) doses of radiation were indistinguishable for 3-4 weeks 
after exposure. A serum miRNA signature detectable 24 hours after radiation 
exposure consistently segregated these two cohorts. Furthermore, using either a 
radio-protective agent prior to, or radiation mitigation after, lethal radiation we 
determined that the serum miRNA signature correlated with the impact of 
radiation on animal health rather than the radiation dose. Lastly, using 
humanized mice that had been engrafted with human CD34+ HSCs, we 
determined that the serum miRNA signature indicated radiation-induced injury to 
the human bone marrow cells. Our data suggest that serum miRNAs can serve 
as functional dosimeters of radiation, representing a potential breakthrough in 
early assessment of radiation-induced hematopoietic damage and timely use of 
medical countermeasures to mitigate the long-term impact of radiation.  
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INTRODUCTION 
Exposure to high doses of radiation in the event of industrial accidents, 
terrorist attacks or use of nuclear weapons in military settings poses a significant 
threat to human life (Chin, 2007; Coleman et al., 2004; Waselenko et al., 2004). 
While substantial advancements in characterizing the effects of radiation on 
different organs and systems have been made, treatment options to exposed 
individuals are still dependent on a slow manifestation of symptoms (Waselenko 
et al., 2004). For example, delayed damage to the hematopoietic system at 
moderately high doses of radiation can take several weeks or months to appear, 
and existing biodosimetry techniques do not effectively predict the severity of 
injury sustained. In such situations, medical intervention is complicated by the 
difficulty in triaging individuals exposed to low, moderate, or high doses of 
radiation.  
The radiation LD50 for untreated humans is about 4 Gy (Christensen et al., 
2014). Low to moderate radiation exposures in humans lead to progressive 
development of acute radiation syndrome (ARS) consisting of dose-dependent 
hematopoietic, gastrointestinal, and cerebrovascular malignancies (Waselenko et 
al., 2004). The hematopoietic system is the most vulnerable tissue to the 
damaging effects of radiation (Mauch et al., 1995). Exposure to low or moderate 
doses of radiation leads to a rapid decrease in blood cell counts, including loss of 
lymphocytes, neutrophils, thrombocytes, and a severe decrease in hematopoietic 
progenitors. Radiation injury is also linked to increased risk of cancer and 
infection. Exposure to high doses of radiation causes severe, non-recoverable 
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bone marrow damage, resulting in pancytopenia owing to complete loss of 
hematopoietic stem cell (HSC) populations eventually leading to death. At 2-6 Gy 
exposure in humans, the hematopoietic component of ARS appears in a few 
weeks to 2 months. At higher doses of 8-12 Gy, lethal gastro-intestinal (GI) as 
well as bone marrow toxicity is observed and death is probable in 1-3 weeks 
(Coleman et al., 2004; Waselenko et al., 2004).  
MicroRNAs (miRNAs) have recently emerged as promising biomarkers for 
different pathological conditions. Deregulation of miRNAs has been implicated in 
the pathogenesis of various conditions ranging from cancer to autoimmune and 
cardiovascular disease (Mendell and Olson, 2012). miRNAs are present in body 
fluids, such as serum and plasma (Cortez et al., 2011; Mendell and Olson, 2012), 
and several studies have correlated levels of specific serum/plasma miRNA with 
various pathological conditions, including after exposure to ionizing radiation (Cui 
et al., 2011; Templin et al., 2011). The inherent stability of serum miRNAs under 
harsh conditions and reproducible levels in individuals of the same species make 
miRNAs attractive candidates for use as noninvasive biomarkers (Mitchell et al., 
2008).  
This study was designed to assess whether changes in serum miRNAs 
immediately after exposure may accurately predict the long-term impact of 
radiation-induced hematopoietic injury in murine models.  We discovered unique 
miRNA signatures that effectively distinguished between control, sub-lethal (low 
dose), sub-lethal (high dose), and lethal total body irradiation (TBI) cohorts within 
24 hours after radiation and correlated these signatures with the radiation-
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induced loss of HSCs.  Importantly, 24 hours after exposure, this serum miRNA 
signature distinguished fatal versus non-fatal hematopoietic injury.  Treatment 
with a radioprotective agent prior to lethal TBI or radiation mitigation by bone 
marrow transplant after lethal radiation exposure produced serum miRNA 
signatures that correlated with the functional impact of radiation. The human 
relevance of the serum miRNA signature was observed using a humanized 
mouse model. The serum miRNA signature indicated radiation-induced injury to 
human bone marrow cells in this model system, suggesting that miRNAs can be 
used to detect radiation-induced hematopoietic injury in affected human 
populations within hours of radiation exposure. 
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MATERIALS AND METHODS 
 
Study design 
This study was designed to investigate whether serum miRNAs can 
predict radiation-induced hematopoietic damage early after radiation exposure. 
Differential expression of miRNAs in response to radiation was investigated in 
two model systems, strongly suggesting the applicability of miRNAs as radiation-
specific markers of latent hematopoietic injury. Animals were also treated with 
radioprotective and radiomitigating agents to correlate levels of specific miRNAs 
with animal survival at 30 days post-irradiation. All animal procedures performed 
were approved by the Institutional Animal Care and Use Committee (IACUC) at 
Dana-Farber Cancer Institute (DFCI). Animals were maintained in the animal 
facility and given ad libitum access to food and water. Body condition scores 
(BCS) as described in (Nunamaker et al., 2013) was used to standardize 
endpoints. A BCS of 3 was regarded as the endpoint for all irradiated animals 
irrespective of treatment group, at which point animals were considered 
moribund and euthanized. Mouse serum samples used for miRNA profiling were 
randomized before analysis and experiments were generally repeated three 
times.  
Power analysis was performed using the Hierarchical Clustering Explorer 
3.5 tool (Seo et al., 2006). The number of samples was estimated to be sufficient 
to provide statistical power of at least 80% needed to obtain a p value of less 
than 0.01 for differentially expressed miRNAs with a fold change 0 >1.5 or <0.67 
in between group comparisons. The p value threshold was lowered from 0.05 to 
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account for multi-group post-hoc testing. A sample size of 10 per group was thus 
calculated to allow us to confirm statistically significant differences for the top 95 
differentially expressed miRNAs with the predetermined effect sizes. 
 
Mice and total body irradiation 
C57BL/6J male mice (10 week old) were obtained from Jackson Labs (Bar 
Harbor, Maine) and acclimated in the Animal Research Facility (ARF) at DFCI 
before irradiation at the age of 12-13 weeks. All procedures performed were 
approved by IACUC at DFCI. Animals were exposed to TBI in an irradiation pie 
cage (Braintree Scientific). Irradiation was performed using a 137Cs source at a 
dose rate of 110 cGy/min using a 137Cs source (Gamma Cell 40 Exactor, Best 
Theratronics). Instrument calibration was performed according to vendor 
instructions in accordance with the DFCI Office of Radiation Safety. After 
irradiation, bone marrow was harvested and cells were counted by flow 
cytometry. 
 
HuCD34+ NOD scid gamma chain deficient (NSG) mice  
HuCD34+ “humanized” NSG mice were obtained from Jackson Labs and 
housed in a BL2/N facility at DFCI. All procedures were approved by IACUC at 
DFCI. During the generation of these mice at Jackson Labs, 3 week old female 
NSG mice were irradiated at 1.4 Gy to deplete their bone marrow and injected 
with CD34+ human HSCs. At 12 weeks after transplant, each mouse was tested 
by FACS for engraftment of human CD45+ and murine CD45+ cells. Animals 
were obtained at DFCI approximately 10 weeks after engraftment confirmation at 
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Jackson Labs. Peripheral blood and bone marrow from animals in the untreated 
control arm was reconfirmed for the presence of human CD45+ cells at DFCI with 
anti-human CD45 FITC (clone 2D1 from BD).  
 
Murine miRNA profiling 
miRCURY LNA Universal RT miRNA PCR Rodent Panel I&II containing 
742 assays was used to profile miRNAs differentially expressed in mouse serum 
from animals exposed to different doses of radiation (Exiqon). Normalization of 
data was performed using the global mean of 170 miRNAs most-commonly 
expressed in all samples. RNA spike-in control (UniSp6) was used to test the 
efficiency of the cDNA synthesis reaction while DNA spike-in control (UniSp3) 
tested the efficiency of qPCR amplification. Spike-in controls were used 
throughout the study for profiling and validation.  In order to negate the possibility 
of hemolysis, !Cp for miR-451 and miR-23a-3p was computed for each sample 
as previously reported (Blondal et al., 2013).      
 
Bone marrow harvest and flow cytometry 
Bone marrow was harvested as per protocols described in (Parmar et al., 
2010). Briefly, animals were dissected to isolate femurs and tibia from mouse 
hind limb. Extracted bones were flushed with a 23 gauge needle using Hank’s 
Balanced Salt Solution (HBSS, Gibco) supplemented with 2% Fetal Bovine 
Serum (FBS) and 1% 10 mM HEPES (Gibco) to obtain bone marrow. Cells were 
then passed through an 18 gauge needle to obtain a single cell suspension. BM-
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MNC count was determined by counting cells using 3% Acetic Acid with 
Methylene Blue Solution (Stem Cell Technologies). For LKS (lineage, cKit, Sca1) 
staining to visualize HPCs and HSCs, whole bone marrow was stained with 
biotinylated anti-lineage cocktail (anti-Mac1, Gr-1, CD3e, B220, and Ter119), 
APC-conjugated anti-cKit (clone 2B8), and PECy7-conjugated anti-Sca1 (clone 
D7) antibodies. Following primary antibody staining, cells were washed and 
incubated in PE-conjugated streptavidin secondary antibody to visualize lineage 
positive cells. All primary and secondary antibodies were obtained from BD 
Biosciences. Samples were acquired using an LSR Fortessa instrument (BD) 
and data was analyzed using FlowJo software (TreeStar).  
 
Complete blood counts  
Blood collection for CBCs (100 µl) was performed by retro-orbital bleeding 
after anesthesia in EDTA-coated tubes (BD Biosciences). CBCs were recorded 
with a Hemavet 950 FS hematology analyzer (Drew Scientific).   
 
Colony assays 
To assess colony-forming ability, whole bone marrow isolated after 
flushing mouse femurs and tibiae were plated in 12-well plates at a density of 
20,000 and 100,000 cells/well in mouse or human methylcellulose medium (Stem 
Cell Technologies). Cells from all samples were plated in triplicates and 
incubated at 37ºC in 5% CO2 for 7 days at which time hematopoietic colonies 
(colony-forming units in culture, CFU-Cs) were scored.  
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HSC and bone marrow transplantation 
Short-term and long-term repopulating ability was assessed by 
transplantation of either sorted HSCs or unfractionated whole bone marrow from 
donor mice (C56BL/6J CD45.2 congenic) into lethally irradiated (10 Gy) 
recipients (B6.SJL-Ptprca Pep3b/BoyJ CD45.1 congenic) as described in (Parmar 
et al., 2010). Donor mice were exposed to 2 and 6.5 Gy TBI and allowed to 
recover for 3 months, at which time animals were sacrificed, bone marrow was 
isolated by flushing, and HSCs were sorted on a FACSAria (BD Biosciences). 
For transplants involving sorted HSCs, a total of 2000 LKS+ cells from CD45.2 
donor mice were mixed with 250,000 support bone marrow cells (CD45.1+) and 
injected IV per lethally irradiated CD45.1 recipient. For transplants involving 
unfractionated bone marrow, a total of 500,000 whole bone marrow cells from 
CD45.2 donor mice were mixed with 250,000 support bone marrow cells 
(CD45.1+) and injected IV per lethally irradiated CD45.1 recipient. Peripheral 
blood samples collected at 1 and 4 months post-transplant were used to assess 
short-term and long-term repopulation, respectively. Donor-cell chimerism in 
recipients was assessed by staining peripheral blood with FITC-conjugated anti-
CD45.2 (clone 104) and PE-conjugated anti-CD45.1 (clone A20) antibodies. To 
measure the extent of multi-lineage reconstitution, the percentage of donor-
derived B cells, T cells, and myeloid cells was calculated by co-staining with PE-
conjugated anti-B220 (clone RA3-6B2), PE-anti-CD3e (clone 145-2C11), and 
PE- anti-Mac1/anti-Gr1 (clones M1/70 and RB6-8C5), respectively. All antibodies 
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were obtained from BD Biosciences. Stained samples were acquired on an LSR 
Fortessa instrument (BD) and analyzed using FlowJo software (TreeStar). 
 
Serum preparation 
Peripheral blood was collected by retro-orbital bleeding after anesthesia. 
Up to 200 µl of blood was collected in DNAse/RNAse- free Eppendorf tubes and 
incubated at room temperature (RT) for 2 h to allow clotting. Blood samples were 
then spun in an Eppendorf 5415C centrifuge at 14,000 rpm (15,996 g) for 5 min 
at RT. The supernatant was collected and re-spun at the above conditions to 
remove any remaining cellular contamination. The resulting supernatant (serum) 
was stored in aliquots at -80ºC. 
 
RNA extraction and cDNA synthesis 
Total RNA was isolated from serum samples by using the miRCURY RNA 
Isolation Kit – Biofluids from 50 µl mouse serum as per manufacturer’s manual. 
Total RNA was eluted in 50 µl of RNAse-free H2O and stored at -80ºC long-term. 
Because only small RNA can be isolated, RNA concentration measurement by 
Nanodrop or spectrophotometry is not reliable. Hence, as per manufacturer’s 
recommendations, input volumes for serum RNA were optimized for the cDNA 
synthesis reaction. cDNA was synthesized in 10-µl reactions using the Universal 
cDNA Synthesis Kit II and was diluted 50-fold in RNAse/DNAse-free H2O for use 
in quantitative PCR. Reagents for RNA extraction and cDNA synthesis obtained 
from Exiqon.  
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Quantitative PCR  
Diluted cDNA was subjected to quantitative PCR analysis in Pick-N-Mix 
plates designed in a 96-well format (Exiqon). SYBR Green qPCR Master Mix was 
mixed 1:1 with diluted cDNA and added to specific wells in pre-designed Pick-N-
Mix plates containing dried-down LNA primers specific for selected miRNAs. The 
Pick-N-Mix plates also contained number of controls including miR-101a and 
miR-19b (normalization controls), UniSp6 (RNA spike-in control) and UniSp3 
(DNA spike-in control). Built-in interplate calibrator (IPC) reactions were used to 
control for inter-plate variability. Pick-N-Mix qPCR plates were run on an Applied 
Biosystems 7500 FAST Real-Time PCR System. Data was generally normalized 
using miR-101a. However, normalization using miR-19b produced similar results. 
miR-451 and miR-23a were used to assess extent of hemolysis. All reagents 
used for quantitative PCR were obtained from Exiqon.  
 
Radioprotection with amifostine 
Amifostine was given to both C57BL/6J and huCD34+ NSG (“humanized”) 
mice intraperitoneally (IP) at 200 mg/kg body weight 1 h prior to TBI.  
 
Bone marrow adherent stromal cell culture and transplantation 
All studies were performed under the guidelines and protocols of the 
Institutional Animal Care and Use Committee (IACUC) of the Albert Einstein 
College of Medicine. The animal use protocol for this study was reviewed and 
approved by IACUC at Albert Einstein. Five- to 6-weeks-old male C57BL/6J 
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(NCI-Fort Dietrich) mice were maintained ad libitum. TBI (10.4 Gy) was 
performed on anesthetized animals (intraperitoneal ketamine and xylazine 7:1 
mg/ml for 100 µl/mouse) using a Shephard 137Cs irradiator at a dose rate of 236 
cGy/min following biosafety guidelines of the Albert Einstein College of Medicine. 
Donor bone marrow cells were harvested using sterile techniques from the long 
bones of C57BL/6J mice and cultured in mesenchymal stem cell (MSC) basal 
medium (Cambrex-Lonza) supplemented with 10% heat-inactivated FBS, 1% 
glutamine, and 1% Penicillin/Streptomycin for 4 days. This was followed by 
collection of adherent bone marrow stromal cells (BMSCs). BMSCs (2"106 
cells/mouse) were injected intravenously via tail vein into C57BL/6J recipients at 
24 and 72 hours after irradiation. 
 
Statistical analysis 
MicroRNA Profiling: Normalization of miRNA serum levels was performed 
using 170 commonly expressed miRNA. Analysis of variance (ANOVA) was used 
to determine which miRNAs differed significantly between groups. To adjust for 
multiple comparisons testing the Benjamini-Hochberg correction was applied. A 
threshold of p<0.05 in ANOVA was selected as the level of statistical 
significance. Tukey’s test was used to determine between-group significance in 
post-hoc comparisons. MiRNAs with p values <0.05 in ANOVA were used in 
hierarchical-clustering analysis to visualize expression patterns. Differentially 
expressed miRNAs were tested in pairwise comparisons with a Benjamini-
Hochberg adjusted Student’s t-test to determine between-group differences. 
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Validation with real-time qPCR: One-way ANOVA was used to confirm global 
significance. Dunnett’s post-hoc testing procedure was used to compare miRNA 
levels in the 8.5 Gy + Saline group against the other three experimental groups. 
Univariate comparisons were performed using the student’s t-test or the student’s 
t-test for paired samples. Pearson’s correlation coefficient was used for 
correlation testing. Survival analysis was performed using the log-rank (Mantel-
Cox) test. 
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RESULTS 
Characterization of hematopoietic injury in mice following exposure to 
different doses of TBI  
To test our hypothesis that serum miRNAs may be used to predict long-
term impact of radiation-induced damage to the hematopoietic system we 
systematically assessed radiation induced hematopoietic injury by exposing 
C57BL/6J mice to different doses of radiation. Consistent with previous reports 
(Cui et al., 2011; Wang et al., 2006), at 2 and 6.5 Gy TBI doses, all animals 
survived, and the 8 Gy dose was lethal for majority (65%) of mice (Fig. 4.1). 
Therefore, 2 and 6.5 Gy were chosen as the sub-lethal low and sub-lethal high 
doses, respectively, and 8 Gy was considered the lethal dose for subsequent 
experiments.  
Complete blood count (CBC) of irradiated animals displayed a reduction in 
white blood cells (WBCs) when compared with un-irradiated controls at days 1, 7, 
and 15 following TBI. By day 30, the 2 and 6.5 Gy cohorts showed a near 
complete recovery in their WBC levels whereas the 8 Gy animals did not survive 
(Fig. 4.2A) Hemoglobin levels plummeted in the 6.5 and 8 Gy animals until day 
15; however, by day 30, these levels returned to normal in the 6.5 Gy cohort (Fig. 
4.2B). Platelet levels followed a similar trend reaching a nadir at day 7 for 6.5 Gy 
and day 15 for 8 Gy animals. By day 30, platelet levels in the 6.5 Gy cohort 
improved and were comparable to the 2 Gy cohort (Fig. 4.2C). Animals exposed 
to 8 Gy succumbed to bone marrow failure by day 30, but there was complete  
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Figure 4.1: Survival curve after exposure to different doses of radiation.  
Establishment of sublethal and lethal dose in C57BL/6J mice. Kaplan-Meier 
survival curves of C57BL/6J male mice exposed to 0 (control), 2, 6.5, or 8 Gy TBI 
(n = 20/group). P-value determined by log-rank (Mantel-Cox) test. 
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Figure 4.2: Analysis of peripheral blood CBC parameters following TBI-
induced hematopoietic damage.  
Total WBC count (A), hemoglobin (B), and platelets (C) at 24 h (day 1), 7, 15, 
and 30 days are shown for mice irradiated with the indicated doses. Data are 
averages ± SEM (n = 5 mice per group). The same mice were used for bone 
marrow analysis in Fig. 4.3; one-way ANOVA followed by Dunnett’s test.  
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recovery in CBC levels in animals exposed to lower doses of irradiation (Fig. 
4.2).  
Decrease in bone-marrow cellularity is an important measure of 
hematopoietic injury. Therefore, we examined kinetics of bone marrow 
mononuclear cell (BM-MNC) depletion after exposure to different doses of TBI 
(2-8 Gy). We observed a dose-dependent reduction in the cellularity at 24 h post 
radiation (Fig. 4.3B).  By days 7 and 15, we observed complete recovery of BM-
MNCs in the hind limbs of mice exposed to 2 Gy, whereas for mice exposed to 
6.5 and 8 Gy, the BM-MNC count remained very low. Mice exposed to 6.5 Gy 
showed significant recovery of BM-MNCs by 1 month, and complete recovery by 
3 months compared to the 15 day time point (P < 0.01, paired t-test) (Fig. 4.3B). 
Following a similar pattern of injury and recovery, by day 15 hematopoietic 
progenitor function post-TBI had significantly decreased for all doses, and the 6.5 
and 8 Gy cohorts were indistinguishable from each other with very low colony-
forming unit-in culture (CFU-C) counts (Fig. 4.3C). At subsequent time-points, 
bone marrow from both 2 and 6.5 Gy groups displayed improved progenitor 
function, but mice in the 8 Gy group failed to recover.   
To further evaluate the bone marrow hematopoietic progenitor population 
in control and irradiated animals we quantified the LKS– (lineage-/c-kit+/Sca-1-) 
population, which is enriched in hematopoietic progenitor cells (HPCs), and the 
LKS+ (lineage-/c-kit+/Sca-1+) population, which is enriched in HSCs. Severe 
reduction in the HPC content was observed at 24 hours after TBI in all irradiated 
animals (Fig. 4.4A). The kinetics of recovery for the HPC population (LKS- cells) 
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in the weeks and months after TBI were consistent with hematopoietic function 
(Fig. 4.3B and C).  Importantly, the numbers of HPCs in the 6.5 and 8 Gy cohorts 
remained comparably low and indistinguishable from each other at day 15 after 
TBI.   
Collectively, our data reveal that dose-dependent hematopoietic injury 
occurs after TBI, but animals exposed to sub-lethal high (6.5 Gy) and lethal (8 
Gy) TBI doses remain largely indistinguishable up to 15 days post TBI. Animals 
exposed to sub-lethal high doses do show substantial recovery, unlike their 8 Gy 
counterparts. 
 
Residual HSCs in sub-lethally irradiated mice retain the capacity to 
repopulate the bone marrow  
Sub-lethal doses of TBI can cause permanent damage to the stem cell 
compartment leading to stem cell senescence and decrease in the engraftment 
potential of HSCs (Shao et al., 2014; Wang et al., 2006). Our hematopoietic 
analysis in Fig. 4.3 and Fig. 4.4A suggested that TBI at sub-lethal doses caused 
a severe reduction but not complete depletion of HPCs in the 2 and 6.5 Gy 
irradiated animals. We observed a similar trend in the HSC population (LKS+ 
cells) with striking ablation until 7 days in all TBI cohorts, and detectable recovery 
at the 15 day time point in the 2 Gy irradiated animals (Fig. 4.4B). By 
comparison, HSC content in 6.5 and 8 Gy irradiated animals 15 days post-TBI 
was significantly lower.  
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Figure 4.3: Analysis of BM-MNCs and CFU-C content in mice exposed to 
TBI.  
(A-C) C57BL/6J mice were exposed to TBI at the indicated doses and allowed to 
recover for up to 3 months (A). At each time point, animals were sacrificed and 
bone marrow was analyzed for number of BM-MNCs (B) and CFU-C content (C). 
Frequency of LKS- HPCs (E) per hind limb. Data are means ± SEM (n = 5/group; 
two independent experiments). *P< 0.05; **P < 0.01; ***P < 0.001; ****P < 
0.0001; n.s., not significant; one-way ANOVA followed by Tukey’s test. 
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Figure 4.4: Analysis of LKS- and LKS+ cells in mice exposed to TBI.  
(A-B) C57BL/6J mice were exposed to TBI as in Fig. 4.3A and allowed to recover 
for up to 3 months. At each time point, animals were sacrificed and bone marrow 
was analyzed for frequency of LKS- HPCs (A) per hind limb and total number of 
HSCs (LKS+ cells) (B) per hind limb post-TBI as measured by FACS. Data are 
individual animals and horizontal bars are means. Data are individual animals 
and horizontal bars are means. *P< 0.05; **P < 0.01; ***P < 0.001; ****P < 
0.0001; n.s., not significant; one-way ANOVA followed by Tukey’s test. 
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To confirm that the recovered residual HSCs from 2 and 6.5 Gy animals 
were indeed functional in their ability to repopulate the hematopoietic system, we 
performed HSC transplantation experiments and measured engraftment by 
peripheral blood chimerism at 1 and 4 months post-transplant (Fig. 4.5A). Bone 
marrow HSCs from TBI-treated mice were taken at 3 months post-irradiation and 
transplanted in unirradiated animals. Representative FACS profiles of control, 2 
Gy, and 6.5 Gy donor bone marrow at 3 months after irradiation are presented in 
Fig. 4.5B. Sorted cells were gated on the LKS+ population. Donor cell 
engraftment (total leukocytes) at 1 and 4 months post-transplant showed an 
approximate 4- and 15-fold decrease in irradiated recipients transplanted with 
sorted HSCs from 2 and 6.5 Gy irradiated animals, respectively, compared to 
control (Fig. 4.5C). When multi-lineage reconstitution of T cells, B cells, and 
myeloid cells was investigated, a similar defect in peripheral blood chimerism 
was observed (Fig. 4.6 and 4.7). Competitive repopulation assays performed with 
unfractionated whole bone marrow showed similar defects in the chimerism of 
total leukocytes (Fig. 4.5C) and lineage-restricted cells in peripheral blood (Fig. 
4.8). These data suggest that, although most of the HSCs in sub-lethally 
irradiated animals are severely impaired in their repopulating potential, rare 
functional HSCs do exist and maintain the hematopoietic system.  
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Figure 4.5: Stem cell transplantation from irradiated mice reveals a defect 
in short-term and long-term repopulating ability.  
(A) Schematic to describe transplantation (Tx) of HSCs or unfractionated whole 
bone marrow (WBM) into lethally irradiated recipients. BM, bone marrow. (B) 
Representative FACS profiles of stained bone marrow from control and irradiated 
donor mice used to sort HSCs for transplant. Individual profiles show total 
scatter, Lineage- (lin-) and LKS+ gates. (C) Donor cell engraftment in peripheral 
blood of recipients transplanted with either HSCs or WBM. Total leukocyte 
engraftment at 1 and 4 months post-transplant is shown. Data are means ± SEM 
(n = 5/group for HSC, n = 4/group for WBM). *P< 0.05; **P < 0.01; ***P < 0.001;  
****P < 0.0001; n.s., not significant; compared to control (0 Gy) mice; one-way 
ANOVA followed by Tukey’s test. 
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Figure 4.6: Repopulation analysis at 1 month after HSC transplant.  
Per the experimental protocol in Fig. 4.5A, donor mice were left unirradiated 
(control, 0 Gy) or exposed to TBI doses of 2 or 6.5 Gy and allowed to recover for 
3 months followed by HSC sorting and transplantation into recipient animals. (A) 
Representative FACS plots of donor-cell chimerism measured at 1 month post-
transplant. Peripheral blood from recipient animals was harvested and stained for 
CD45.1 (recipient marker), CD45.2 (donor marker), CD3e (T cells), B220 (B 
cells), and Mac1/Gr1 (myeloid cells). (B) Multi-lineage reconstitution in recipients 
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Figure 4.6 (Continued): 
transplanted with HSCs (percent donor-derived T, B, and myeloid cells at 1 
month post-transplant). Total leukocyte chimerism at 1 month is shown in Fig. 
4.5C. Data are means ± SEM (n = 5 mice per recipient group); **P < 0.01, ***P < 
0.001 compared to control 0 Gy; one-way ANOVA followed by Tukey’s test.  
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Figure 4.7: Repopulation analysis at 4 months after HSC transplant.  
Following repopulation analysis at 1 month reported in Fig. 4.6, animals were 
reanalyzed at 4 months post- transplant. (A) Representative FACS plots of 
donor-cell chimerism in peripheral blood measured at 4 months post-transplant. 
(B) Multilineage reconstitution in recipients transplanted with HSCs. Percent 
donor-derived T, B, and myeloid cells at 4 months are shown. Total leukocyte 
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Figure 4.7 (Continued): 
chimerism at 4 months is shown in Fig 2D. Data in (B) are means ± SEM (n = 5  
mice per recipient group); **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with 
control (0 Gy); one-way ANOVA followed by Tukey’s test. 
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Figure 4.8: Repopulation analysis following unfractionated whole bone 
marrow transplant.  
The transplant protocol followed outline in Fig. 4.5A. A total of 500,000 CD45.2 
whole bone marrow cells and 250,000 CD45.1 support cells were injected in 
lethally irradiated CD45.1 recipients. Peripheral blood from recipient animals was 
harvested and stained for CD45.1 (recipient), CD45.2 (donor), CD3e (T cells), 
B220 (B cells), and Mac1/Gr1 (myeloid cells). Multi-lineage (T, B, and myeloid 
cell) reconstitution at 1 and 4 months post-transplant is presented, with results of 
total leukocyte chimerism at 1 and 4 months in Fig. 2D. Data are individual 
animals with horizontal and vertical bars representing means ± SEM (n = 4 
animals per recipient group); *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; 
n.s., not significant; one-way ANOVA followed by Tukey’s test. 
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Serum miRNA profiling and identification of radiation dose–specific miRNA 
signatures 
To test whether changes in serum miRNA levels after TBI correlate with 
hematopoietic injury and predict long-term damage, we profiled serum miRNAs in 
mice exposed to 0 (control), 2, 6.5, or 8 Gy TBI 24 hours after radiation (n = 10 
animals per group). The number of miRNAs detected per sample (count) and the 
average amplification threshold (Cp) value for miRNAs were evaluated and 
reproducibility confirmed (Fig. 4.9A and B). Red blood cell contamination was 
ruled out by calculating !Cp of miR-451 (expressed in red blood cells) and miR-
23a-3p (relatively stable in serum) (Blondal et al., 2013) (Fig. 4.9C).  
  Out of 170 miRNAs detected in each sample, 68 were found to be 
significantly altered by radiation (Table 4.1) and were considered dose-
responsive (Fig. 4.11). A heatmap representing the top 8 of the 68 miRNAs that 
effectively separated irradiated from non-irradiated samples is shown in Fig. 
4.10. These miRNAs—namely 150-5p, 142-5p, 142-3p, 136-5p, 33-5p, 320-3p, 
30c-5p, and 126-3p—were the top significant hits in ANOVA analysis consisting 
of all irradiated samples (Table 4.1).  
 We investigated whether serum miRNA expression can distinguish the 0 
versus 2 Gy cohorts 24 hours after exposure, and whether these miRNAs 
correlated with BM-MNC or HPC/HSC counts at the 7 day time point. Based on 
our profiling, five serum miRNAs were effective in segregating the two groups 24 
hours after radiation exposure (Fig. 4.12A). MiR-130a-3p showed an increase,  
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Table 4.1: Fold changes of 68 statistically significant miRNAs at different 
doses of TBI with respect to controls. The table ranks miRNAs based on the 
Benjamini-Hochberg corrected P-value. Of the 224 miRNAs analyzed for 
differential expression, 68 had P < 0.05, and are presented here. 
 
    
 Benjamini- 
Hochberg Fold change (versus 0 Gy)  
miRNA Rank corrected p-value  2Gy   6.5Gy  8Gy  
           
mmu-miR-142-5p 1 6.14552E-10 0.744 0.550 0.468 
mmu-miR-150-5p 2 6.41729E-10 0.335 0.360 0.347 
mmu-miR-320-3p 3 6.83112E-06 0.962 1.188 1.321 
mmu-miR-136-5p 4 8.17096E-06 1.038 0.465 0.412 
mmu-miR-33-5p 5 4.8463E-05 1.006 0.548 0.412 
mmu-miR-142-3p 6 4.8463E-05 0.910 0.579 0.513 
mmu-miR-30c-5p 7 0.000365 1.041 1.124 1.375 
mmu-miR-126-3p 8 0.000365 0.961 1.524 1.398 
mmu-miR-706 9 0.000466 0.399 0.356 0.634 
mmu-miR-375-3p 10 0.000466 1.234 2.136 2.284 
mmu-miR-29a-5p 11 0.000466 0.888 0.965 0.709 
mmu-miR-193a-3p 12 0.000530 1.168 0.649 0.436 
mmu-miR-99b-5p 13 0.000530 0.996 1.344 1.513 
mmu-miR-30a-3p 14 0.001069 0.990 1.062 1.586 
mmu-miR-194-5p 15 0.001069 0.812 0.610 0.446 
mmu-miR-151-3p 16 0.001069 1.130 1.467 1.309 
mmu-let-7d-3p 17 0.001069 0.971 1.221 1.202 
mmu-miR-486-5p 18 0.001407 1.188 1.463 2.066 
mmu-miR-423-5p 19 0.001407 1.049 1.296 1.434 
mmu-miR-30b-5p 20 0.002091 1.039 1.119 1.227 
mmu-miR-191-5p 21 0.002343 1.139 1.432 1.633 
mmu-miR-497-5p 22 0.003355 0.937 0.749 0.620 
mmu-miR-32-5p 23 0.003528 1.080 0.628 0.605 
mmu-miR-214-5p 24 0.003992 0.725 0.703 0.472 
mmu-miR-326-3p 25 0.005364 1.239 0.851 0.796 
mmu-miR-1195 26 0.005478 0.968 1.091 1.829 
mmu-miR-122-5p 27 0.005478 0.933 0.348 0.149 
mmu-miR-1839-3p 28 0.006650 1.317 1.534 2.031 
mmu-miR-500-3p 29 0.007062 0.985 0.799 0.577 
mmu-miR-30e-3p 30 0.008429 0.996 1.118 1.448 
mmu-miR-191-5p 31 0.008476 1.111 1.337 1.549 
mmu-miR-322-3p 32 0.008829 0.848 1.319 1.179 
mmu-miR-709 33 0.012398 1.171 1.284 2.016 
mmu-miR-486-3p 34 0.012398 1.156 1.263 2.007 
mmu-miR-133a-3p 35 0.013008 0.858 1.809 2.389 
mmu-miR-676-3p 36 0.013063 1.025 1.200 1.261 
mmu-miR-744-5p 37 0.013451 1.119 1.206 1.301 
mmu-miR-27a-3p 38 0.013751 0.897 0.908 0.702 
mmu-miR-29a-3p 39 0.014569 0.931 0.847 0.760 
  mmu-miR-1839-5p 40 0.014569 1.087 1.277 1.317 
mmu-miR-30a-5p 41 0.014569 1.055 1.182 1.346 
mmu-miR-199b-5p 42 0.016705 0.864 0.514 0.633 
mmu-miR-125a-5p 43 0.022629 0.959 1.092 1.262 
mmu-miR-133b-3p 44 0.024815 0.872 1.659 2.116 
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Table 4.1 (Continued): 
 
mmu-miR-24-3p 45 0.024815 0.980 1.184 1.119 
mmu-miR-21a-5p 46 0.024815 1.115 0.831 0.790 
mmu-miR-503-5p 47 0.024815 1.171 0.806 0.784 
mmu-miR-328-3p 48 0.024815 1.133 1.308 1.338 
mmu-let-7g-5p 49 0.024815 1.099 1.139 1.417 
mmu-miR-362-3p 50 0.024815 0.888 0.804 0.663 
mmu-miR-199a-5p 51 0.025155 0.904 0.602 0.631 
mmu-miR-342-3p 52 0.027478 0.740 1.132 1.058 
mmu-miR-34b-3p 53 0.028987 0.726 1.610 1.543 
mmu-miR-15a-3p 54 0.028987 1.117 0.720 0.588 
mmu-miR-139-5p 55 0.033183 0.892 1.180 1.070 
mmu-miR-17-3p 56 0.033183 1.205 0.631 0.880 
mmu-miR-130a-3p 57 0.033183 1.230 0.993 0.943 
mmu-miR-149-5p 58 0.033183 0.911 1.294 1.527 
mmu-miR-29b-3p 59 0.033183 1.023 0.816 0.739 
mmu-miR-1a-3p 60 0.035135 0.709 1.330 2.129 
mmu-miR-23b-3p 61 0.036567 0.966 1.179 1.113 
mmu-miR-215-5p 62 0.036567 0.745 0.696 0.475 
mmu-miR-204-5p 63 0.040650 0.856 1.631 1.808 
mmu-miR-187-3p 64 0.041980 0.940 0.938 0.563 
mmu-miR-200b-5p 65 0.041980 1.187 1.538 1.668 
mmu-miR-25-3p 66 0.041980 1.093 1.171 1.537 
mmu-miR-338-3p 67 0.046951 1.095 0.857 0.812 
mmu-miR-196b-5p 68 0.049110 1.316 1.065 0.734 
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Figure 4.9: Serum miRNA profiling. 
C57BL/6J mice were exposed to 0, 2, 6.5, or 8 Gy TBI (n = 10 animals per 
group). Serum collected from these animals 24 h after TBI was subjected to 
miRNA profiling. (A) Number of miRNAs detected per sample (count) and the 
average amplification threshold (Cp) value for miRNAs in each sample. (B) Built-
in RNA (UniSp6) and DNA (UniSp3) spike-in controls used to test technical 
performance of samples. (C) Hemolysis controls to test for red blood cell 
contamination of serum miRNAs. !Cp values consisting of miR-451 (expressed 
in red blood cells) and miR-23a-3p (relatively stable in serum) was used to 
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Figure 4.9 (Continued): 
estimate likelihood of hemolysis (see Materials and Methods). Data in (A to C) 
represent each of the samples used in the original profiling experiment.  
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Figure 4.10: miRNAs significantly altered in all irradiated samples.  
Heat map shows expression changes in levels of eight miRNAs significantly 
altered in all irradiated samples (2, 6.5, and 8 Gy) with respect to un-irradiated 
controls (0 Gy). Hierarchical clustering was performed to depict relationship 
between samples.  
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Figure 4.11: Radiation dose–dependence of select miRNAs. 
Average fold change for each miRNA identified in one of the three signatures is 
presented at the three radiation doses (2, 6.5, and 8 Gy). Profiling data were 
reanalyzed to determine dose-dependence by calculating fold change with 
respect to the same miRNA level in control unirradiated samples. Data are 
averages ± SEM (n = 10 animals per group).  
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Figure 4.12: Serum miRNA profiling and identification of radiation dose–
specific 0 vs 2 Gy miRNA signature.  
C57BL/6J mice were exposed to 0, 2, 6.5, or 8 Gy TBI (n = 10/group). Serum 
collected from these animals 24 h after TBI was subjected to miRNA profiling. 
Three signatures – 0 vs 2 Gy, 2 vs 6.5 Gy, and 6.5 vs 8 Gy - consisting of the 
most highly altered 5 miRNAs in each comparison were generated. The 0 vs. 2 
Gy signature is presented here. (A) Control (0 Gy) versus 2 Gy miRNA signature 
with hierarchical clustering depicting relationship between individual samples. (B) 
Validation of the 0 vs 2 Gy signature in (A) with an independent set of animals. 
(C) miRNA fold changes in 2 Gy irradiated animals compared to 0 Gy controls at 
24 h and 7 days post-TBI. Data in (B and C) are normalized to miR-101a or miR-
19b. Data in (B) are individual animals with means ± SEM (n = 6-10/group, two 
independent experiments). Data in (C) are means ± SEM (n = 4-5/group). *P < 
0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., not significant; paired t test. 
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whereas miR-150-5p, miR-142-5p, miR-706, and miR-342-3p showed significant 
decreases. We validated this signature using an independent set of animals that 
were left untreated or exposed to a TBI dose of 2 Gy and observed that all but 
one miRNA (miR-706) distinguished control and 2 Gy irradiated samples after 24 
hours (Fig. 4.12B).  The serum miRNA pattern continued to distinguish the 0 
versus 2 Gy cohorts at the 7 day post-radiation time point (Fig. 4.12C), and was 
consistent with the diminished numbers of HSCs and HPCs in the 2 Gy cohort 
compared with unirradiated controls (Fig. 4.4A and B). It is noteworthy that, 
unlike the serum miRNA signature, BM-MNC counts 1 week after radiation 
exposure did not differentiate the unirradiated versus 2 Gy cohorts (Fig. 4.3B).  
Next, we asked whether serum miRNAs can be used to distinguish 
between low and high sub-lethal doses of radiation. Such a miRNA signature 
may be useful in distinguishing individuals that incurred mild radiation-related 
toxicity at low sub-lethal doses and more severe (often non-recoverable) bone 
marrow damage at high sub-lethal doses (Greenberger and Epperly, 2009; 
Mauch et al., 1988). To address this question, we revisited our profiling data to 
identify miRNAs differentially expressed in the sera of mice exposed to 2 and 6.5 
Gy TBI. Five miRNAs—miR-136-5p, miR-17-3p, miR-126-3p, miR-322-3p, and 
miR-34b-3p—showed the highest differential expression (Fig. 4.13A). We 
independently confirmed that miR-34b-3p, miR-126-3p, and miR-17-3p 
effectively distinguished between low and high sub-lethal TBI doses at 24 h (Fig. 
4.13B). Interestingly, these three miRNAs continued to separate the two sub-
lethal groups at day 7 (Fig. 4.13C).  
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Serum miRNA signature distinguishes animals exposed to sub-lethal and 
lethal dose 
Similar to the 0 versus 2 Gy scenarios, analysis of hematopoietic damage 
alone was unable to differentiate between animals exposed to high sub-lethal 
(6.5 Gy) and lethal (8 Gy) dose of TBI until 15 days following radiation (Figs. 4.3 
and 4.4).  Although a relatively small difference (1.5 Gy), this increase in 
radiation dose is lethal. We therefore mined our profiling data in search of a set 
of serum miRNAs that were significantly different between 6.5 and 8 Gy 
treatment groups at 24 hours post-radiation. The five differentially expressed 
miRNAs are in Fig. 4.14A; two were higher at 8 Gy (miRs 30a-3p and 30c-5p) 
and three were lower at 8 Gy (187-3p, 194-5p, and 27a-3p). In a separate cohort 
of animals, four of the five miRNAs remained significant (Fig. 4.14B). 
Interestingly, none of the miRNAs that distinguished 0 from 2 Gy, 2 from 6.5 Gy, 
or 6.5 from 8 Gy overlapped. The focus of our study was to identify distinct sets 
of miRNAs with the highest differences between certain TBI comparisons, so our 
signatures represent the most highly altered miRNAs.  However, there may be 
other miRNAs that continue to change with increasing doses (Table 4.1).  
We further characterized the sub-lethal versus lethal serum miRNA 
signature to ask whether the miRNAs differentially expressed between the two 
groups continued to show differences at later time points.  Sera were collected 
from mice at 24 hours, 3 days, and 7 days after TBI doses of 6.5 and 8 Gy.  Only 
miR-30a-3p and miR-30c-5p continued to differentiate 6.5 versus 8 Gy at days 3 
and 7 post-TBI (Fig. 4.14C), suggesting that these miRNAs may allow  
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Figure 4.13: Serum miRNA profiling and identification of radiation dose–
specific 2 vs 6.5 Gy miRNA signature.  
Signature was generated as described in Fig. 4.12. (A) Signature for 2 versus 6.5 
Gy with hierarchical clustering depicting relationship between individual samples. 
(B) Validation of the 2 vs 6.5 Gy signature in (D) with an independent set of 
animals. (C) miRNA fold changes in 6.5 Gy irradiated animals compared to 2 Gy 
at 24 h and 7 days post-TBI.  Data in (B and C) are normalized to miR-101a or 
miR-19b. Data in (B) are individual animals with means ± SEM (n = 6-10/group, 
two independent experiments). Data in (C) are means ± SEM (n = 4-5/group). *P 
< 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., not significant; paired t test. 
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Figure 4.14: The 6.5 vs 8 Gy miRNA signature can differentiate between 
sub-lethal and lethal radiation exposure.  
Signature was generated as described in Fig. 4.12 (A) The 6.5 versus 8 Gy 
miRNA signature presented with hierarchical clustering showing relationship 
between individual samples. (B) Validation of the 6.5 versus 8 Gy signature in (A) 
with an independent set of animals. Data are individual animals with means 
normalized to miR-101a ± SEM (n = 7-9/group, two independent experiments).  
(C) miRNA fold changes in 8 Gy irradiated animals compared to 6.5 Gy at 24 h, 3 
days, and 7 days post-TBI. Data in (C) are means normalized to miR-101a ± 
SEM (n = 4-5/group). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., not 
significant; paired t test. 
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differentiation of sub-lethal versus lethally irradiated samples up to 7 days after 
initial exposure. 
 
Serum miRNAs distinguishing sub-lethal and lethal radiation, not only 
radiation dose, correlates with survival and radioprotection 
Next, we determined whether the sub-lethal versus lethal serum miRNA 
signature correlated only with the radiation dose, or if it was also linked to overall 
survival. To address this question, we used a radioprotective agent amifostine, 
which is known to extend survival in mice and in humans by decreasing 
radiation-related cytotoxicity (Andreassen et al., 2003; Hosseinimehr, 2007). We 
hypothesized that if serum miRNAs are indeed linked to the impact of radiation 
on health, then serum miRNA levels in animals treated with amifostine prior to 
lethal TBI should correlate with the protective effect of this drug.  
Cohorts of mice were treated with saline or amifostine prior to 8.5 Gy TBI 
and sera were collected 24 hours following exposure (Fig. 4.15A). All mice 
exposed to lethal radiation and injected with saline died around day 16, whereas 
100% of animals treated with amifostine survived (Fig. 4.15B). All miRNAs in the 
sublethal versus lethal signature from Fig. 4.14A were significantly altered when 
comparing differences between groups (Table 4.2) and when comparing saline-
treated versus amifostine-treated irradiated animals (Table 4.3). The serum 
miRNA signature only changed in response to amifostine treatment after lethal 
radiation (not after control 0 Gy) (Fig. 4.16A). Remarkably, the serum miRNA 
levels correlated with the radio-protective function of amifostine; that is, the 
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amifostine-treated lethal radiation cohort resembled the control sub-lethal 
radiation cohorts (Fig. 4.16A). This result strongly suggests that a serum miRNA 
signature distinguishing sub-lethal versus lethal radiation correlates with impact 
of radiation rather than dose.  
To further substantiate this point we correlated relative miRNA expression 
for animals irradiated with 8.5 Gy in the radioprotection study (amifostine) with 
relative expression ratios of 8 and 6.5 Gy TBI cohorts in the original profiling 
study (Figs. 4.14A and 4.15A). We hypothesized that, if the serum miRNA 
signature distinguishing sub-lethal versus lethal radiation correlates with viability 
rather than radiation dose, the changes in these miRNAs in the radioprotection 
experiment will statistically correlate with the changes in the 8- and 6.5 Gy TBI 
cohorts. That is, the amifostine-treated lethal radiation cohort will truly represent 
the sub-lethally radiated 6.5 Gy cohort. Consistent with our hypothesis, we 
uncovered a significant correlation (r= 0.97; p = 0.0067, Pearson’s correlation) 
(Fig. 4.16B), suggesting that the five miRNAs (187-3p, 194-5p, 27a-3p, 30a-3p, 
and 30c-5p) may serve as markers of radiation-induced loss of viability in mice.  
We next asked whether this miRNA signature also corresponds to the 
protective effects of radio-mitigating agents introduced post-radiation. 
Transplantation of bone marrow stromal cells (BMSCs) after lethal radiation 
exposure promotes recovery of bone marrow cellularity, HPCs, and HSCs in 
mice (Chute et al., 2007). We therefore transplanted lethally irradiated (10.4 Gy) 
C57Bl/6J mice with two doses of BMSCs after radiation and monitored survival 
for 30 days (Fig. 4.17A). All animals in the TBI group succumbed to lethal  
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Figure 4.15: Radioprotective agent amifostine protects C57BL/6J mice from 
lethal TBI.  
(A) Schematic of experiment with C57BL/6J mice given amifostine or saline 1 h 
before 0 or 8.5 Gy TBI (n = 10/ group). Serum was isolated for miRNA profiling 
24 h later. (B) Kaplan-Meier survival curves of mice.  P-value determined by log-
rank (Mantel-Cox) test. 
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Figure 4.16: The sublethal versus lethal miRNA signature predicts impact 
of radioprotective agents.  
Experiment was performed as per the protocol in Fig 4. 15A. (A) Relative levels 
of indicated miRNAs in the sera of mice. Data are individual animals with means 
normalized to miR-101a ± SEM (n = 5/group; two independent experiments). (B) 
Correlation of relative expression ratios of miRNAs in the 6.5 versus 8 Gy 
signature from two separate experiments: those described in 4.15A and in Fig. 
4.14A (r = 0.97; P = 0.0067, Pearson’s correlation). **P< 0.01; ***P< 0.001; 
****P< 0.0001; n.s., not significant; one-way ANOVA followed by Dunnett’s test. 
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Figure 4.17: The sublethal versus lethal miRNA signature predicts impact of 
radiomitigating agents.  
(A) Survival curve of C57BL/6J mice exposed to 10.4 Gy TBI followed by 
transplantation of BMSCs (n = 5/group). P-value determined by log-rank (Mantel-
Cox) test. (B) Fold change of indicated miRNAs from sera of animals in (A) at 
day 5- post TBI. Data are means normalized to miR-101a ± SEM. *P< 0.05; **P< 
0.01; ***P< 0.001; n.s., not significant; one-way ANOVA followed by Dunnett’s 
test. 
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Table 4.2: Significantly altered miRNAs between 6.5 and 8 Gy irradiation 
and pre-treatment with amifostine. Per the protocol in Fig. 5A, mice were 
treated with amifostine 1 h prior to 8.5 Gy TBI dose to study whether miRNAs in 
the 6.5 versus 8 Gy signature were predictors of animal viability (n = 10 per 
group). Differences in expression values of indicated miRNAs in the four 
treatment groups (CT + Saline, CT + Ami, 8.5 Gy + Saline, 8.5 Gy + Ami) were 
compared by one-way ANOVA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
miRNA P 
miR-187-3p 0.0013 
miR-194-5p 0.0016 
miR-27a-3p 0.0063 
miR-30a-3p <0.0001 
miR-30c-5p 0.0006 
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Table 4.3: MiRNAs in the 6.5 versus 8 Gy signature as indicators of survival 
after TBI. Mice were treated per protocol in Fig. 5A (n = 10 per group). P values 
for comparison of specific miRNA expression changes between the 8.5 Gy + 
Saline group and the other three experimental groups (CT + saline, CT + 
amifostine, 8.5 Gy + Ami) are presented. One-way ANOVA followed by Dunnett’s 
test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
miRNA CT + Saline CT + Ami TBI + Ami 
miR-187-3p      0.0009   0.0046   0.0034 
miR-194-5p      0.0022   0.0013   0.0097 
miR-27a-3p      0.0182   0.0183   0.0038 
miR-30a-3p      0.0002 <0.0001   0.0003 
miR-30c-5p      0.0023   0.0005   0.0018 
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radiation by day 10, but 100% of animals transplanted with BMSCs survived, 
exhibiting the protective effect of BMSC transplantation. 
Furthermore, four out of five miRNAs in the sublethal versus lethal 
signature (not miR-194-5p) indicated radio-mitigation by BMSCs at day 5 post 
exposure (Fig. 4.17B). Decrease in miR-150-5p has emerged as a consistent 
marker of radiation exposure in mice (Cui et al., 2011; Jacob et al., 2013) 
including our 0 versus 2 Gy miRNA signature (Fig. 4.12A). However, as 
anticipated from our data, miR-150-5p did not differ between TBI and TBI with 
BMSC treatment.  
 
Validation of the serum miRNA signature in humanized mice 
To test the relevance and potential applicability in humans, we validated 
miRNA levels in a second, “humanized” model system. We used NOD scid 
gamma (NSG) mice engrafted with human CD34+ HSCs. NSG mice support 
robust long-term engraftment of human HSCs and their multilineage 
differentiation (Pearson et al., 2008). Initial engraftment percentages of human 
CD45+ cells in peripheral blood of mice are in Table 4.4. CD45 staining of bone 
marrow and peripheral blood in animals approximately 12 weeks after initial 
assessment of engraftment showed similar or higher percentages of human cells 
(Fig. 4.18A).  
Four to 4.5 Gy of TBI causes 100% mortality in NSG mice (Shultz et al., 
2005). Therefore, we exposed huCD34+ NSG mice to a lethal dose of 4.5 Gy 
TBI, and considering the reconstitution of the hematopoietic compartment with 
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human cells, we focused on bone marrow injury, peripheral blood counts, and the 
potential for marrow recovery by amifostine. Exposure to lethal radiation showed 
near complete depletion of BM-MNCs in the saline-treated TBI cohort, whereas 
prior treatment with amifostine showed rescue of bone marrow cellularity, and 
moderate recovery of human CD45+ cells and bone marrow CFU-Cs cultured in 
human medium (Fig. 4.18B-D). Peripheral blood counts of moribund animals 
indicated a significant decrease in all blood cell parameters except WBCs, as 
well as a substantial improvement in hemoglobin, RBC levels, and hematocrit 
levels was observed in the amifostine-treated group (Table 4.5). These data 
suggest that huCD34+ NSG mice are sensitive to the effects of radiation and that 
amifostine treatment led to protection of the human cells.  
The sequences of the miRNAs in the sublethal-versus-lethal signature in 
mice are identical to those of humans (Fig. 4.20)(Kiezun et al., 2012). To assess 
whether the effect of lethal radiation with amifostine treatment is reflected in the 
levels of miRNAs in the sublethal-versus-lethal signature, we isolated serum from 
these humanized animals 24 hr after radiation and measured miRNA levels (Fig. 
4.19). Consistent with previous results in C57Bl/6J mice, miR-150-5p and four 
out of five miRNAs in the in the 6.5 vs. 8 Gy signature (miR-27a-3p, miR-187-3p, 
miR-30a-3p, and miR-30c-5p) were altered in response to radiation in huCD34+ 
NSG mice.  Furthermore, amifostine pretreatment rescued levels of three of the 
miRNAs (miR-187-3p, miR-27a-3p, and miR-30a-3p). Together these results 
suggest that serum miRNA signatures may be conserved between mice and 
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humans, and thus have the potential to serve as indicators of radiation injury in 
humans. 
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Figure 4.18: Sublethal versus lethal miRNA signature correlates with the 
protective effect of amifostine in NSG mice engrafted with human CD34+ 
HSCs.  
(A) Representative (n = 5) FACS plots showing percent engraftment of human 
CD45+ cells in the bone marrow and peripheral blood of NSG mice transplanted 
with human CD34+ HSCs. (B to D) Humanized NSG mice were pretreated with 
amifostine or saline and exposed to 4.5 Gy TBI. Control animals received no 
pretreatment and 0 Gy irradiation. Moribund animals were analyzed for total bone 
marrow cellularity (B), number of human CD45+ cells per hind limb (C), and CFU-
Cs measured at 7 days after plating in human methylcellulose media (D). Data 
are individual animals with means ± SEM (n = 5-8/group); paired t-test (B, C, and 
D). 
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Figure 4.19: Sublethal versus lethal miRNA signature correlates with the 
protective effect of amifostine in NSG mice engrafted with human CD34+ 
HSCs.  
Relative miRNA levels in the sera of humanized mice at 24 hr after exposure to 
TBI. Data are individual animals with means normalized to miR-101a ± SEM. *P 
< 0.05; **P < 0.01; ***P < 0.001; n.s., not significant, one-way ANOVA followed 
by Dunnett’s test (E).  
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Fig. 4.20: Identical mature miRNA sequences in human and mouse.  
Genomic sequences of miRNAs in the 6.5 versus 8 Gy signatures were aligned 
using microRNAviewer. Mature sequences are highlighted in blue. Asterisks (*) 
indicate base conservation.  
<http://people.csail.mit.edu/akiezun/microRNAviewer/index.html> 
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Table 4.4: Percent human CD45+ cell engraftment in individual huCD34+ 
NSG (humanized) mice. Vendor provided engraftment percentages analyzed at 
12 weeks after transplantation. Animals were grouped into three groups, namely 
Control untreated (n = 5), TBI + Saline (n = 7), and TBI + Amifostine (n = 8). 
Human CD45+ cell engraftment was reconfirmed at the end of the experiment in 
control untreated animals.  
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Table 4.5: Peripheral blood complete blood count in individual huCD34+ 
NSG (humanized) mice. Peripheral blood was harvested from moribund TBI-
treated animals or unirradiated controls. Average and SEM of CBC parameters 
are calculated per group.  
 
Group Mouse  # 
CBC 
WBC        
(x 103/!l) 
RBC         
(x 106/!l) 
Hb 
(g/dl) 
HCT    
(%) 
PLT  (x 
103/!l) 
TBI + Saline 
2 1.20 0.24 1.90 1.60 20 
5 1.30 0.19 2.80 1.20 4 
7 0.56 1.64 2.80 3.00 88 
Avg 1.02 0.69 2.50 1.93 37.33 
SEM 0.23 0.48 0.30 0.55 25.75 
TBI + 
Amifostine 
8 1.28 2.55 4.80 17.00 213 
9 1.19 1.65 3.20 11.00 44 
13 1.20 2.92 4.80 4.80 56 
Avg 1.22 2.37 4.27 10.93 104.33 
SEM 0.03 0.38 0.53 3.52 54.44 
Control 
16 1.20 4.75 11.00 38.50 345 
17 1.32 5.35 10.50 39.60 609 
18 2.16 5.66 12.40 42.20 686 
19 1.77 5.89 11.60 45.30 645 
20 1.44 5.41 10.70 40.60 577 
Avg 1.58 5.41 11.24 41.24 572.40 
SEM 0.17 0.19 0.34 1.18 59.69 
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Table 4.6: Target sequences of individual miRNAs. MiRNAs in the three 
signatures reported in Fig. 3 and their target sequences detected using Pick-N-
Mix plates are shown. Sequences for miR-101a and miR-19b, identified as stable 
miRNAs in the sera of C57BL/6J mice and used for normalization of miRNA 
validation and expression data, are also listed. UniSp6 and UniSp3 sequences 
are proprietary (Exiqon). !!
  miRNA Target sequence 
Control miRNA mmu-miR-101a-3p UACAGUACUGUGAUAACUGAA 
Control miRNA mmu-miR-19b-3p UGUGCAAAUCCAUGCAAAACUGA 
RNA spike-in UniSp6 Exiqon Proprietary Sequence 
DNA spike-in UniSp3 Exiqon Proprietary Sequence 
0 Gy v. 2 Gy signature 
mmu-miR-130a-3p CAGUGCAAUGUUAAAAGGGCAU 
mmu-miR-142-5p CAUAAAGUAGAAAGCACUACU 
mmu-miR-150-5p UCUCCCAACCCUUGUACCAGUG 
mmu-miR-706 AGAGAAACCCUGUCUCAAAAAA 
mmu-miR-342-3p UCUCACACAGAAAUCGCACCCGU 
2Gy v. 6.5 Gy signature 
mmu-miR-34b-3p AAUCACUAACUCCACUGCCAUC 
mmu-miR-322-3p AAACAUGAAGCGCUGCAACAC 
mmu-miR-126-3p UCGUACCGUGAGUAAUAAUGCG 
mmu-miR-17-3p ACUGCAGUGAGGGCACUUGUAG 
mmu-miR-136-5p ACUCCAUUUGUUUUGAUGAUGG 
6.5 Gy v. 8 Gy signature 
mmu-miR-187-3p UCGUGUCUUGUGUUGCAGCCGG 
mmu-miR-194-5p UGUAACAGCAACUCCAUGUGGA 
mmu-miR-27a-3p UUCACAGUGGCUAAGUUCCGC 
mmu-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA 
mmu-miR-30a-3p CUUUCAGUCGGAUGUUUGCAGC 
mmu-miR-30c-5p UGUAAACAUCCUACACUCUCAGC !
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DISCUSSION 
Current use of diagnostic screening to estimate dose of accidental 
radiation exposure is mainly based on three factors: time to onset of radiation 
sickness, kinetics of lymphocyte depletion, and analysis of chromosomal 
abnormalities (Dainiak et al., 2003; Waselenko et al., 2004). These techniques 
are time-consuming and are often not quantitative enough to draw definite 
conclusions. Serum miRNAs fall under the emerging “omic” biodosimetry assays 
and represent a simple technology that may effectively determine whether an 
individual was exposed to radiation (if so, whether the dose was sublethal or 
lethal), and predict long-term survival of exposed individuals. With current 
progress in miniaturization of quantitative PCR, a miRNA-based assay has the 
potential to become a point-of-care technology that can be performed outside the 
lab. It can allow longer lag time post-exposure before the first sample can be 
taken compared to lymphocyte depletion kinetics and DNA damage assay using 
!"H2AX and provide results within the 12-24 hrs following exposure.  
Here, we successfully profiled and identified novel serum miRNAs that 
were differentially expressed in response to TBI and correlated well with injury at 
sub-lethal and lethal doses. Recent studies (Cui et al., 2011; Jacob et al., 2013; 
Templin et al., 2011) have identified circulating (serum/plasma) miRNAs that are 
altered in response to TBI, and there is partial overlap with some of the candidate 
miRNAs (miR-126-3p, miR-150, miR-342-3p, miR-151-3p, miR-139-3p and miR-
142) that emerged from our analysis.  A possible cause for the differences is the 
miRNA expression profiling platform. Recently a study (Mestdagh et al., 2014) 
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systematically compared 12 different miRNA expression platforms. Specifically 
for serum miRNAs there was a 12-fold difference between the highest and lowest 
number of detected miRNA when identical samples were profiled by different 
platforms. According to this report, the LNA-based platform from Exiqon—which 
we use in our study—had the highest specificity.  
A key issue we addressed in this study is the correlation of serum miRNAs 
with the impact of radiation, specifically with hematopoietic injury and animal 
viability. Working with a narrow dose range, we identified serum miRNAs that 
distinguish between sub-lethal (6.5 Gy) and lethal (8 Gy) exposure. This is of 
paramount importance because during a radiologic emergency, doses sustained 
will almost never be in specific increments and distinction between lethal and 
sub-lethal doses is the key challenge. Moreover this miRNA signature also 
predicted the impact of radiation on animal survival following pre-treatment with 
the radio-protective agent, amifostine or mitigation using BMSC.  Interestingly, 
most of the serum miRNAs (miR-187-3p, miR-27a-3p, miR-30a-3p, and miR-30c-
5p) that correlated with amifostine radioprotection also predicted survival of 
animals transplanted with BMSCs. Finally, our experiments with huCD34+ NSG 
humanized mice suggest that the miRNAs identified in the C57BL/6J mouse 
model may also be relevant in humans. Together, these findings highlight the 
utility of miRNAs in predicting the functional impact of both radio-protective and 
radio-mitigating agents and broadly suggest a potential application of serum 
miRNAs in prognosticating the impact of radiation. Future studies, however, will 
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be needed in human samples to validate these miRNAs or discover new 
signatures that differentiate lethal from sublethal radiation effects. 
Broadly our results provide the first evidence that serum miRNAs may 
effectively predict the impact of radiation on long-term viability of animals.  Our 
work represents an advance in early assessment of radiation damage, which can 
help alleviate hematopoietic symptoms, facilitate timely intervention after 
exposure, and improve overall survival of exposed individuals. 
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Paradigm of DNA Damage Induced Phospho-Signaling and an Emerging 
Role for Phosphatases in DDR 
 In this dissertation we provide new evidence for the involvement of the PP4 
serine/threonine phosphatase in regulating the early steps of DDR. We also 
present this regulation in the context of the cell cycle. The traditional paradigm for 
DNA damage induced phospho-signaling states that sensors of DNA damage 
activate specific kinases. Targets of these kinases (which are mediators and 
effectors of DDR) are then activated and it is the combination of mediators and 
effectors that produce different effector responses (Petrini, 2007)(Fig. 5.1). An 
excellent example of this paradigm is 53BP1, which acts as a DDR mediator. ATM 
phosphorylation and distinct chromatin modifications allow 53BP1 to localize to 
DSBs following DNA damage. After chromatinization 53BP1 acts as a platform for 
localization of other key DDR factors. Recent literature has identified specific 
effectors of 53BP1, namely RIF1 and PTIP that interact with 53BP1 by distinct 
phospho-protein interactions leading to distinct effector responses (Callen et al., 
2013; Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Diaz et al., 2013; 
Zimmermann et al., 2013). 
Our laboratory has asked the broad question of whether phosphatases, 
which reverse the action of kinases, have any role in this process. The traditional 
view has been that phosphatases dissociate the mediator-effector complexes 
formed and restore cells to a pre-DNA damage state. Several examples of this 
important function of phosphatases exist (Chowdhury et al., 2008; Lee et al., 
2010; Nakada et al., 2008). However, recent evidence from our lab suggests that  
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Figure 5.1: Paradigm of DNA Damage Induced Phospho-Signaling 
(Petrini, 2007).  
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in addition to resetting DNA damage, phosphatases play a crucial role during the 
activation of DDR. In this dissertation, we present an example of one such 
regulation mediated by the PP4/R3β phosphatase complex. We report that 53BP1 
is hyperphosphorylated in mitosis at two key residues (T1609 and S1618) located 
in the conserved UDR motif and this correlates with its exclusion from DNA 
breaks. As the cells exit mitosis and enter G1, efficient recruitment of 53BP1 to 
DSBs requires dephosphorylation of the UDR residues, a process dependent on 
the activity of the PP4/R3β complex (Figs. 5.2 and 5.3A). This example brings to 
light a potential role for PP4 and other DDR phosphatases in regulating DDR 
activation.  
 
Cell Cycle Regulation of Other DDR Proteins by Phosphatases 
When examining the cell-cycle regulation of DDR proteins, multiple 
parallels can be drawn with the example of 53BP1 and common themes begin to 
emerge. Like 53BP1, XRCC4 is another NHEJ factor that acts as a recruitment 
platform linking the essential steps of processing and ligation of broken DNA ends 
(Koch et al., 2004; Lieber, 2010; Weterings and Chen, 2008). XRCC4 activity is 
also suppressed during mitosis and correlates with its mitosis specific 
phosphorylation of Ser326 by CDK1/PLK1 (Fig. 5.3B) (Terasawa et al., 2014). 
Activating XRCC4 in mitosis leads to increased occurrence of anaphase bridges, 
which can be suppressed by inhibition of NHEJ. Thus, phosphorylation of XRCC4 
prevents its recruitment to DNA breaks in mitosis thereby avoiding the formation  
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!!
Figure 5.2: Model for regulation of 53BP1 by PP4/R3β.  
53BP1 is hyperphosphorylated in mitosis to disable its recruitment to DSBs. A 
PP4/R3β complex dephosphorylates 53BP1 at T1609 and S1618 during the 
transition from mitosis to G1. The interaction of 53BP1-R3β is regulated by CDK5-
mediated phosphorylation of R3β S840. The action of CDK5 enables temporal 
control of the R3β-53BP1 interaction allowing 53BP1 to relocalize at DSBs in G1 
(Lee et al., 2014 and this dissertation). 
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of mitotic defects. This mode of regulation is very similar to what we observed for 
53BP1 and therefore it is tempting to speculate that a phosphatase complex 
dephosphorylates XRCC4 at Ser326 at the end of mitosis re-allowing it to 
participate in NHEJ in G1. 
 Yet another interesting example of phosphatase-based activation of 
function is that of YEN1 (Yen1 Holiday junction resolvase), which belongs to the 
XPG family of nucleases. YEN1 forms a complex with the MUS81-MMS4 junction-
specific endonucleases that promote formation of crossover products by cleaving 
HR intermediates (Blanco et al., 2010; Ho et al., 2010; Tay and Wu, 2010). Since 
non-crossover products are favored over crossover products in mitotic cells to 
prevent loss of heterozygosity (LOH) (Ira et al., 2003), it is essential to exclude 
YEN1 from participating in the resolution of HR intermediates during mitosis. 
Indeed, CDKs target YEN1 starting as early as S phase, thereby sequestering its 
nuclear localization and inhibiting its participation in HR until the anaphase stage 
(Kosugi et al., 2009; Loog and Morgan, 2005; Ubersax et al., 2003). Interestingly, 
the phosphatase CDC14 was shown to be responsible for countering this 
phosphorylation to allow nuclear relocalization of YEN1 thereby restimulating its 
activity (Fig. 5.3C) (Blanco et al., 2014). The above discussed examples of 
53BP1, XRCC4, and YEN1 suggest that phosphatases ‘prime’ the activity of DDR 
factors in a cell-cycle dependent manner by countering the phosphorylation of 
mitotic kinases.  
 
Cell-cycle Regulation of 53BP1 and PP4 In S/G2 
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53BP1 has been extensively studied during the cell cycle. In the G1 phase, 
when NHEJ is more common, 53BP1 exerts its pro-NHEJ effects by suppressing 
end-resection and inhibiting BRCA1 accumulation at DSBs via RIF1 (Callen et al., 
2013; Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Diaz et al., 2013; 
Zimmermann et al., 2013). As cells enter S/G2, the action of BRCA1 specifically 
excludes 53BP1 from DSBs, thereby promoting end resection, which is a key 
bottleneck for DSB repair by HR (Chapman et al., 2012; Feng Lin, 2015). The 
Chapman study used super-resolution microscopy to show that 53BP1 is capable 
of accumulating at DNA repair foci in G1, S, and G2 phases. However, in S and 
G2 it is removed from core S phase foci in a BRCA1-dependent fashion. 
Furthermore, it was recently shown that BRCA1 excludes 53BP1 and RIF1 from 
DSBs via its interaction with CTIP (Escribano-Diaz et al., 2013; Feng et al., 2013). 
Consistent with this notion of restricting 53BP1 from localizing to DSBs in S 
and G2, we have observed an increase in phosphorylation of 53BP1 T1609 and 
S1618 using the p (1609/1618) antibody as cells enter S and G2 phases (Fig. 
5.4). It is tempting to speculate that the same kinases that phosphorylate these 
residues in mitosis may be responsible for phosphorylating them in late S and G2 
phases. It is also conceivable that a separate pool of 53BP1 is phosphorylated in 
S/G2 and suppressed from DSB localization. While our observations are 
preliminary, they indicate that phosphorylation-based regulation of 53BP1 may not 
be restricted only to mitosis but is likely to occur throughout the cell cycle. Indeed, 
a recent study reported mitosis-specific phosphorylations occurring at the  
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Figure 5.3: Regulation of DDR factors by dephosphorylation during the cell 
cycle. A model for regulation of 53BP1 (A) and XRCC4 (B) by dephosphorylation 
during mitosis/G1. (C) YEN1 regulation by dephosphorylation during S phase and 
mitosis (Zheng et al., 2015). 
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Figure 5.4: Phosphorylation of T1609/S1618 increases as cells enter S/G2. 
Upper panel: Percent HeLa cells in indicated cell cycle phases at each time point 
after release from nocodazole (Noc) treatment. Lower panel: Assessment of 
53BP1 phosphorylation using the p (1609/1618) antibody. Total 53BP1 is shown 
as a loading control.  
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completion of S phase. Specifically, the study reported that PLK1 is active ~5 
hours before mitotic entry (Akopyan et al., 2014). Furthermore, in one of the 
studies mentioned earlier, Escribano-Diaz and colleagues showed that the ability 
of BRCA1-CTIP to inhibit RIF1 foci formation in S/G2 is dependent on CTIP S327 
and S487 phosphorylation. Both these sites are phosphorylated by CDKs 
suggesting that CDKs are active in S phase (Escribano-Diaz et al., 2013). 
It will be interesting to see whether concurrent phosphorylation of 53BP1 
during S/G2 by mitotic kinases regulates 53BP1 exclusion from DSB foci as a 
parallel regulatory mechanism. Experiments involving ectopic expression of 
53BP1-AA mutant (T1609A/S1618A) in Fucci cells can address this question. On 
the other hand, it will also be interesting to see if ectopic expression of 53BP1-ED 
mutant (T1609E/S1618D) allows BRCA1 to accumulate at DSBs in G1. We intend 
to answer these questions in the near future.  
 Similar to 53BP1, we also plan to study whether PP4 is regulated during 
S/G2 phases.  According to our preliminary observations cited above, after PP4-
mediated dephosphorylation of 53BP1 in G1, T1609 and S1618 appear to be re-
phosphorylated in preparation for the next phase of mitosis. In this scenario, it is 
conceivable that PP4C/ R3! is somehow inhibited from accessing 53BP1 and this 
may occur through a few possible mechanisms. First, the localization of PP4 may 
be regulated by multiple post-translational modifications sequestering it from the 
nucleus during S/G2. While an interesting idea, this does not seem likely since the 
role of PP4 in dephosphorylating nuclear proteins, γH2AX and RPA2 during S 
phase has been established (Chowdhury et al., 2008; Lee et al., 2010; Nakada et 
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al., 2008). Second, the association of the R3! regulatory subunit responsible for 
substrate specificity with the catalytic PP4C subunit may be prevented. Thus, 
even though R3! can interact with 53BP1, it cannot dephosphorylate in the 
absence of PP4C. Third, interaction of either 53BP1 or PP4 with an unknown 
factor may impede 53BP1/PP4 interaction. Future studies will focus on testing 
these hypotheses by identifying novel substrates and/or interacting partners of 
PP4. Recent advances in phosphoproteomic technologies offer increasingly 
unbiased approaches to identifying phosphatase substrates and specific 
phosphorylation sites (Zhou et al., 2010). Use of such approaches will develop a 
better understanding of phosphatase-based regulation of DDR.    
We also report here a novel role for CDK5, which by phosphorylating R3β 
at S840 in mitosis regulates the timing of 53BP1-R3β interaction. In our 
experiments, siRNA-mediated depletion of CDK5 and also its inhibition by a new 
small molecule inhibitor reduced the localization of 53BP1 to DSBs. We therefore 
propose a model wherein CDK5-mediated phosphorylation of R3β in 
mitosis  ultimately regulates 53BP1 localization in G1 (Fig. 5.2). Interestingly, in 
neuronal cells, CDK5 plays a role in DDR by directly phosphorylating ATM at 
Ser794 thereby activating ATM and its downstream targets (Tian et al., 2009). 
However, the study we present here is one of the first reports implicating CDK5 in 
the regulation of a DDR factor in cancer cells. Future experiments focusing on the 
regulation of CDK5 during the cell cycle and the identification of regulatory feed-
forward loops similar to CDK5-R3β-53BP1 involving other DDR factors will allow 
us to better understand the role of CDK5 during the repair of DSBs. 
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Biomarkers Indicating the Extent of Hematopoieitic Injury 
A part of this dissertation also focused on the impact of DNA damage at the 
organismal level. Radiation-induced DNA damage caused by industrial accidents, 
terrorist attacks, or the use of nuclear weapons in military settings can have a 
substantial negative impact on human life and limited options exist for both the 
diagnosis and treatment of exposed individuals (Waselenko et al., 2004). In this 
study, we correlated radiation-induced DNA damage in animal models to the 
presence of specific miRNAs in the serum with the goal of identifying miRNA 
signatures that can effectively predict the severity of injury sustained before the 
appearance of symptoms. Our findings, recently published (Acharya et al., 2015), 
identify three different miRNA signatures that can effectively predict extent of 
radiation-induced hematopoietic damage and correlate with the impact of radiation 
on animal survival.  
Existing technologies used to assess the extent of radiation have notable 
limitations. For example, one of the hallmarks of the lymphocyte depletion kinetics 
assay is the fact that it can be performed outside the laboratory, but a drawback is 
that several measurements are needed to get a dose estimate (Goans et al., 
1997; Parker and Parker, 2007). The ideal time frame for DNA damage assays 
using γ-H2AX is 0.5 to 2 hours post-exposure (Andrievski and Wilkins, 2009; 
Riecke et al., 2010; Sullivan et al., 2013), which may not be enough time for 
individuals to report to a medical countermeasures facility. The dicentrics 
chromosome assay is very specific to radiation and is considered the “gold 
standard” for determining the dose, but it has a long processing time, tedious 
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scoring methods, and relatively narrow range for dose determination (Pinto et al., 
2010; Sullivan et al., 2013). Thus, there is a critical need to develop radiation-
specific indicators that are capable of predicting latent damage to various organs 
and systems immediately after radiation exposure. 
Although the miRNAs identified here can forecast the extent of 
hematopoietic injury and predict for survival immediately after exposure, it is 
possible that radiation victims may not report to a medical countermeasures 
facility in the first 24 hours. In such a scenario, biomarkers that persist longer will 
need to be identified. Profiling of serum miRNAs at later time points, such as 5 or 
7 days, will allow detection of more persistent miRNAs that continue to follow a 
specific trend after radiation. As a proof of principle, miR-30a-3p and miR-30c-5p 
in our sub-lethal versus lethal signature continued to display an increase until day 
7.  Future studies should focus on defining the cell of origin of specific serum 
miRNAs and investigate their physiological relevance. This will help determine 
whether serum miRNAs are passive bystanders secreted in the wake of radiation 
injury or act as potential alarm signals communicating a state of distress to 
different parts of the body (Cortez et al., 2011; Mendell and Olson, 2012). Indeed, 
several groups have reported identification of circulating miRNAs found in 
exosomes (Valadi et al., 2007), apoptotic bodies (Zernecke et al., 2009), high-
density lipoprotein (Vickers et al., 2011) and RNA-binding proteins (Arroyo et al., 
2011) as a form of cell-to-cell communication (Cui et al., 2011; Kosaka et al., 
2013) providing a rationale for future experimentation. Validation of serum 
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miRNAs identified here in non-human primates and patient samples will allow the 
application of these signatures in humans. 
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